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ABSTRACT
Nystatin is an antifungal polyene macrolide antibiotic produced by Streptomyces noursei, first 
described in 1950 (Hazen and Brown, 1950). Nystatin is currently being used for treatment of 
superficial fungal infections, and is considered a medically important drug. However, until 
recently, nothing was known about the biosynthesis of this antibiotic in S. noursei. This study 
is the part of the detailed investigation of the genetics and biochemistry of nystatin biosynthesis 
with emphasis on the regulation.  
First, the pleiotropic regulatory gene locus from S.noursei capable of enhancing actinorhodin 
(Act) production in S.lividans was cloned and sequenced. Two genes, designated ssmA and  
ssmB, have been suggested to be responsible for the phenomenon. Putative product of ssmA
showed limited homology to the peptide encoded by afsR2, known as a pleiotropic regulator 
from S.lividans and S. coelicolor. Recombinant S.lividans strains carrying deletion derivatives 
of the locus were tested for Act production. The results of these experiments showed that ssmA 
is required for Act overproduction, while   ssmB is possibly involved in the negative regulation 
of antibiotic production.  Further experiments suggested that ssmA is involved in the carbon 
source-dependent regulation of nystatin production in S.noursei.
Next, the entire nystatin biosynthetic gene cluster from S.noursei was cloned and sequenced, 
putative functions for the biosynthetic genes were implied, and a model for the nystatin 
biosynthesis was suggested. Six genes encoding PKS type I, genes for posttranslational 
modifications of nystatin aglycon, efflux of antibiotic out of the cell, and putative cluster-
specific regulatory genes have been identified in the cluster.  Inactivation of PKS-encoding 
genes in the cluster resulted in nystatin non-producing mutants, confirming their roles in the 
biosynthesis of this antibiotic. Genes presumably encoding nystatin efflux pump were studied 
via gene inactivation and analysis of resulting mutants. It was shown that the efflux is tightly 
linked to C-10 hydroxylation of the nystatin macrolactone ring. Several genes for post-PKS 
modifications have been found in the nystatin cluster, among them three genes for synthesis 
and attachment of mycosamine moiety to the nystatin aglycon. Effect of inactivation of these 
genes on nystatin biosynthesis was studied. Combined, these results have helped to refine the 
model of nystatin biosynthesis. 
The regulatory locus of 6 genes has been found on a right flank of nystatin biosynthetic cluster. 
Four of them were shown by gene inactivation to be directly involved in the regulation of 
nystatin biosynthesis. Promoter-probe studies revealed the main targets of regulation in the 
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nystatin gene cluster, and cross-complementation experiments allowed establishing the 
hierarchy among the regulators. Finally, the model for regulatory cascade was suggested.  
The results of studies described above provided important information needed for rational 
engineering of novel polyene macrolides by manipulation of the nystatin biosynthetic genes. 
Seven analogs of nystatin with altered polyol region and carboxylic group have been obtained 
and subjected to in vitro antifungal and hemolitic activities tests. It was shown that 
combinations of several mutations could be beneficial for the activity-toxicity properties of the 
new compounds. The two most active and less toxic analogs were chosen for in vivo tests in a 
mouse model, where they proved to be considerably less toxic and at least as active as 
amphotericin B, the antifungal antibiotic used for treatment of systemic fungal infections. 
These results indicate that two obtained nystatin analogs can be used for further development 
into antifungal drugs for human therapy, and that genetic engineering is an effective tool for 
obtaining new compounds with improved therapeutic properties. 
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1.   INTRODUCTION 
Antibiotics belong to the large, chemically heterogeneous group of natural products classified 
as secondary metabolites. They are synthesized   by many bacterial, fungal, plant and animal 
species and are not required for normal growth of the producing organisms. By definition, 
antibiotics are secondary metabolites that have the ability to kill or inhibit the growth of other 
microorganisms.  
Discovery of penicillin by Alexander Fleming in 1928 opened the modern history of 
antibiotics. Penicillin is the first antibiotic found in microorganisms, it is synthesized by 
Penicillum notatum, P. chrysogenum and several other fungi. It showed activity against a wide 
range of bacteria, and was soon introduced into medical practice as a successful treatment 
against pneumonia, blood poisoning, strep throat, diphtheria, scarlet fever, syphilis, gonorrhea, 
meningitis, rheumatic fever and many other diseases (Chain et al., 1940). This “wonder” drug 
saved millions of lives during the World War II, and also today, together with its derivatives, it 
is one of the most commonly used antibiotics. Back then, however, nobody could make a 
prediction that the use of penicillin would become limited, because bacteria would develop 
resistance against penicillin. As early as in 1952, about three-fifths of all staphylococcus 
infections were caused by penicillin–resistant bacteria. It became clear that different 
approaches, as for example, changing the chemical structure of antibiotic molecules in order to 
get their new properties, must be considered. The discovery of penicillin also brought about 
the idea that if there is one antibiotic in nature it must be more, and since that time many more 
antibiotics have been found, though only few of them are  fungal in origin. Most of the 
antibiotics known today are derived from bacteria belonging to the order Actinomycetales and 
particularly to the genus Streptomyces.
1.1 Antibiotics produced by Streptomyces bacteria 
Actinomycete bacteria are the source of ca. 60% of all known antibiotics produced by 
microorganisms. As Berdy reports the number of antibiotics produced by soil-inhabiting 
actinomycetes discovered by 2002, estimated as 8700, compared with 4900 from fungi and 
2900 from all other bacteria.   Nearly 80% of actinobacteria-derived antibiotics were found in 
Streptomyces species (Berdy, 2005). It has been estimated that the streptomycetes alone may 
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produce up to 250,000 different biologically active molecules of different classes, including 
some important drugs as anti-cancer, anti-parasitic agents and immunosuppressants (Watbe et 
al., 2001).

Figure 1.1. Origin of antibiotics discovered in 1950-2001. (Adapted from Berdy (2005). 
The Streptomyces bacteria form complex colonies on solid media, which represent a mould-
like system of interconnected hyphae that first grows as a so-called vegetative/substrate 
mycelium and then later, after the nutrient resources become limited, produces aerial 
sporulating hyphae. These features are not typical bacterial, that’s why microbiologists were 
confused about their origin for a long time. From the discovery of the first actinomycetes in 
the 1870s and till as late as 1950s, they were considered as an intermediate between bacteria 
and fungi.  Nevertheless, in early 1950s there were the first pointers on bacterial origin of 
streptomycetes as, for example, the cell-wall composition resembling that of typical Gram-
positive bacteria, and also their sensitivity to anti-bacterial antibiotics. Later, with a help of 
electron microscope, it was shown that S. coelicolor lacks a nuclear membrane, defining 
streptomycetes as bacteria (Hopwood, 1999). Streptomyces can also be distinguished from 
other bacteria by a much higher G+C content in their DNA, often up to  75% compared with 
about 50% for low G+C Gram-positive bacteria like Bacillus or Streptococcus.
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Interest in Streptomyces as a possible source of antibiotics was sparked after the discovery of 
streptomycin, the first known antibiotic from a bacterium, by Selman Waksman in 1943 (Jones 
et al., 1944). This antibiotic was first isolated in the laboratory of Waksman from the strain of 
Streptomyces griseus. It is difficult to overestimate the significance of this bactericidal drug as 
the first effective chemotherapeutic treatment for pulmonary tuberculosis and bubonic plague 
(Singh and Mitchison, 1954). It appeared also to be effective against causative agents of other 
diseases: typhoid fever, cholera, urinary tract infections, etc. In 1952, S.Waksman was 
awarded a Nobel prize for this outstanding discovery. 
Since then, many more useful antibiotics have been discovered in Streptomyces bacteria. Some 
examples of these antibiotics are given in Table 1.1 
Table 1.1.   Useful antibiotics from Streptomyces spp. and their application (Kieser et 
al.,2000).

Antibiotic



Producer

Chemicalclass

Target

Application

Actinomycin

Streptomycesspp.

Peptide

Transcription

Antitumor

Avermectin

S.avemitilis


Macrolide(PK)

Chlorideion
channels

Antiparasitic

Amphotericin


S.nodosus


Polyenemacrolide


Membrane

Antifungal


Bleomycin


S.verticillus

Glycopeptide

DNAstrand
breakage

Antitumor

Candicidin


S.griseus

Polyenemacrolide

Membrane

Antifungal

Daunorubicine

S.peucitius

Anthracycline(PK)

DNA

Antitumor
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intercalation

Kanamycin

S.kanamyceticus

Aminoglycoside

Protein
synthesis

Antibacterial

Tetracycline

S.aureofaciens

Tetracycline(PK)

Protein
synthesis

Antibacterial

Thiostrepton

S.azureus

Thiopeptide

Protein
synthesis

Growth
promotant

Validamycin



S.hygroscopicus

Aminoglycoside

Protein
synthesis

Plantprotectant

Virginiamycin

S.virginiae
Macrocyclic
lactone+macrocyclic
peptidolactone

Protein
synthesis

Growth
promotant
1.2 Genetics and biochemistry of antibiotic biosynthesis in Streptomyces
 1.2.1 The short historical overview of the development of knowledge on the genetics and 
biochemistry of Streptomyces
After the potential of Streptomyces as antibiotic producers was understood, many laboratories 
in different countries began intensive research on genetics and biochemistry of these unique 
organisms. To the most important discoveries of the 1960s belongs the creation of the first 
genetic map of Streptomyces coelicolor chromosome by Hopwood (Hopwood, 1967). After 
this publication, S. coelicolor became a model organism for genetics and molecular biology 
studies.
The identification of A-factor as a diffusible molecule required for activating streptomycin 
production and sporulation in S. griseus by Khokhlov and his collaborators is another 
important finding in Streptomyces physiology (Khokhlov et al., 1967). This hormone-like 
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molecule was characterized as a novel J-butyrolactone by the same research group in 1976
(Kleiner et al., 1976). In later works the discovery of this small signaling molecule was 
significantly developed in S. griseus, S. coelicolor and S. virginiae, and has been among the 
most important features of the modern understanding of regulatory network in biosynthesis of 
antibiotics in Streptomyces (Yamada et al., 1987; Onaka et al., 1998).  
The discovery of the )C31 temperate phage by the group of N. Lomovskaya was another very 
important event in studying Streptomyces biology (Lomovskaya et al., 1970). Approximately 
at the same time, the first Streptomyces plasmid SCP1 was postulated, but all active attempts 
to physically isolate it failed (Hopwood and Wright, 1973). Only in 1987 the group of H. 
Kinashi could identify the reason for that failure. He and his colleagues with a help of newly 
developed pulsed-field gel electrophoresis technology showed that SCP1 is large (350kb) and 
linear DNA molecule (Kinashi and Shimaji, 1987). The significance of this discovery was 
understood when it appeared that linear replicons, including the chromosome, are widely 
spread among Streptomyces.
The first circular Streptomyces plasmid SCP2 was isolated by Schrempf et al. in 1975. 
(Schrempf et al.,1975). This discovery was an important step toward introducing DNA into 
Streptomyces by transformation and finally cloning genes in these organisms. Since then, 
several methods of the gene transfer into Streptomyces have been developed, including 
transformation of protoplasts (Bibb et al., 1978), phage-mediated transduction (Stuttard, 1979), 
and plasmid-mediated conjugation (Mazodier et al., 1989).
Early finding that genes for biosynthesis of antibiotic methylenomycin are localized on a 
plasmid led to the speculations that plasmid determination of antibiotic production genes 
might be typical for Streptomyces (Kirby et al., 1975). However, in the subsequent studies on 
antibiotic actinorhodin in S. coelicolor it was shown that genes for its biosynthesis are 
chromosomally localized and clustered (Wright and Hopwood, 1976). Such organization of 
antibiotic biosynthetic genes appears to be a main rule, even some more examples of plasmid-
located gene clusters have been found (Kinashi et al., 1987).
Cloning of the first genes in S. coelicolor and S. lividans marked the beginning of intensive 
studies on the genetics and biochemistry of antibiotic biosynthesis in these bacteria
(Thompson et al., 1980). In 1983, a complete biosynthetic cluster of antibiotic actinorhodin 
has been cloned for the first time (Malpartida and Hopwood, 1984) – an extremely important 
achievement that had a long-term impact on genetics of Streptomyces bacteria.
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1.2.2. Antibiotic biosynthesis gene clusters from Streptomyces
The powerful tools of molecular biology made it possible not only to clone antibiotic 
biosynthesis gene clusters, but also to determine the functions of genes involved in the 
process. Methylenomycin gene cluster, located on SCP1, was shown to contain biosynthetic, 
regulatory and resistance genes. The first known methylenomycin resistance gene was 
identified and cloned in Streptomyces. It was a part of gene locus that caused the production of 
methylenomycin when introduced into non-producing strain, and overproduction of antibiotic 
when inactivated in the original strain, and it was deduced as a regulatory region. This work 
led to the first demonstration by C. Bruton of what has become a paradigm, the clustering of 
antibiotic biosynthesis, resistance and pathway-specific regulatory genes (Chater and Bruton, 
1985). Further studies revealed the requirement for conjoined actions of enzymes involved in 
assembly of scaffold (chemical skeleton) of antibiotic molecule, and its modification. 
Clustering of genes encoded such proteins seems to be logical as it promotes coordinated 
expression and regulation within a genome of producing organism. As mentioned above, there
are several groups of genes, which have been detected, but not all of them necessarily present 
in every antibiotic biosynthetic cluster.
“Core” of such cluster consists of structural genes encoding enzymes for scaffold biosynthesis, 
as for example, PKS or NRPS. Genes for modification, as methyltransferases, hydroxylases, 
acyltransferases, halogenases, and glycosyltransferases are usually localized in the 
neighborhood of the “core”.
Figure 1.2. Organization of a typical antibiotic biosynthesis gene cluster. (Adapted from 
Zotchev (2009). 
Resistance genes for self-protection against produced antibiotic encode enzymes, which 
inactivate it or modify the antibiotic target in producing organism. The genes for active 
transport of the synthesized product are also can be found in the cluster. The enzymes encoded 
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by these genes are responsible for efflux of antibiotic outside the cell and thus also ensure the 
protection of organism against it. Pathway-specific regulator/s control the expression of 
structural, transport and resistance genes and are the  part  of the antibiotic biosynthesis cluster 
with some rare exceptions. Typical organization of antibiotic biosynthesis gene cluster is 
presented on Figure 1.2 (above).
Cloning and analysis of entire biosynthetic clusters is an important step in understanding of 
antibiotic biosynthesis. The analysis of biosynthetic genes using bioinformatics tools allows 
determining the whole biosynthetic pathways. Hundreds of antibiotic biosynthesis gene 
clusters have now been cloned and analyzed. Some important examples are provided in Table 
1.2 below. 
Table 1.2.   Examples of cloned and characterized antibiotic biosynthesis gene clusters. 

Genecluster

Antibioticclass

Application

Producer

Reference
Erythromycin Macrolide antibacterial Sac.erythraea
Donadio et al.
1991
Penicillin
Nonribosomal
peptide
antibacterial Penicilliumnotatum

Aharonowitzet
al.1992

Vancomycin

Glycopeptide antibacterial
Amycolatopsis
orientalis

Martinetal.
1998


BEͲ14106

Macrolactam cytotoxic Streptomycessp.
Jørgensenetal.
2009

Rapamycin

Macrolide immunosuppressant S.hygroscopicus

Schweke.etal.
1995

Daunorubicin Antracycline cytotoxic S.peucitius
Madduri&
Hutchinson,1995
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Avermectin Macrolide antihelmintic S.avermitilis Ikedaetal.1987
Thiostrepton Thiopeptide antibacterial S.azureus Liaoetal.2009
Validamycin Aminocyclitol antifungal S.hygroscopicus Baietal.2006
Novabiocin Aminocoumarine antibacterial S.spheroides
Steffenskyetal.
2000
In the following section, I will focus on macrolide polyketides synthesized by type I 
polyketide synthase, since this study was dedicated to nystatin, the representative of this class 
of antibiotics. 
1.2.3 Biosynthesis of type I polyketides 
There are three types of polyketide antibiotics: type I, II, and III.  They are synthesized by 
adding small monomer units, such as acetic or malonic acid, to linear oligomer, two atoms at a 
time, by multifunctional enzymes, polyketide synthases (PKS). PKS are responsible for such 
characteristics of molecule as chain length, oxidation state, cyclisation, branching, and 
stereochemistry. Biosynthesis of polyketides occurs by a mechanism reminiscent to fatty acid 
biosynthesis but with some differences (Hopwood and Sherman, 1990).
Type I polyketide antibiotics are often macrolides differing from each other in the size, 
modification and composition of lactone ring. The latter is a common characteristic of all 
macrolide antibiotics. Typical representatives are, for example, erythromycin, rapamycin and 
nystatin (Figure 1.3). The latter is a representative of polyene macrolides with characteristic 
large macrolactone ring featuring conjugated double bonds.
The first details on the type I polyketide biosynthesis were revealed for erythromycin (Ery), 
macrolide antibiotic produced by Saccharopolyspora erythrea, and this remains the model 
system for this class of polyketides (Donadio et al., 1991). Ery molecule is composed of the 
14-membered macrolactone ring, 6-deoxyerythronolide B (6dEB), with two deoxysugars, L-
mycarose and d-desosamine, attached at C-3 and C-5, respectively. The 6dEB core of 
erythromycin is a result of six successive condensations between a propionyl-CoA starter and 
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six (2S)-methylmalonyl-CoA extenders, which are catalyzed by 6-Deoxyerythronolide B 
synthase (DEBS) (Marsden et al., 1994).
Figure 1.3. Chemical structures of macrolide antibiotics assembled by type I PKS. 
Three PKS proteins encoded by eryA genes are organized in 6 modules. Each module contains 
enzymatic functions as separate domains necessary for one of the 6 elongation cycles in the 
synthesis of the polyketide chain. So, the “modular hypothesis” (Donadio et al., 1991) 
proposed that: (1) one module  is used  exclusively for one condensation E-carbonyl
processing step in the synthesis of polyketide; (2)  the order in which modules appear in DEBS 
matches the order of use in the biosynthesis of 6dEB.  There are three enzymatic activities 
which are absolutely required for chain elongation. The so-called minimal PKS include: 
- an acyl transferase (AT) domain to load the correct extender unit onto the ACP enzyme.  
Polyketides are composed of a variety of acyl building blocks. At least three AT domains 
groups according to specificity to extender units can be recognized in macrolide PKS: 
malonyl- transferring AT, methylmalonyl transferring AT, and AT, recognizing acyl residues 
derived from monocarboxylic acid. In DEBS, the AT domains of extender modules are 
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specific for 2-methylmalonyl-CoA. AT domain in the loading module is specific for 
propionyl-CoA.
-  an acyl carrier protein (ACP) is a unit on which the growing carbon chain is tethered;
-  kethosynthase (KS) domain  is responsible  for the Claisen condensation, linking the new 
extender unit with growing  polyketide chain, accompanied by loss of carbon dioxide. 
In addition to the “minimal” PKS domains, other domains with different reductive activities 
may be present. 
In DEBS, after each two-carbon unit condensation, the E-carbon can be retained as a ketone ( 
module 3), or modified by ketoreductase (KR) to hydroxyl as in module 2, to double bond by 
KR + dehydratase (DH) as in module 4, or to saturated bond  by the action of KR, DH and 
enoylreductase (ER), the same module. The growing PKS I carbon chain is assembled and 
modified according to the order of domains, moving along the protein, interacting with 
domains in turn, and undergoing reductive changes, corresponding to the set of domains   
presented in the module. The logic of this model arose from the gene organization of Ery 
cluster, and the idea that the numerous number of analogs could be produced by alteration of 
PKS genes, appeared as a logical supposition (Katz, 1997).  An overview of 6dEB 
biosynthesis  presented on Figure 1.4 below. 
Figure 1.4. Overview of erythromycin biosynthesis – formation of aglycone by type I PKS. 
Adapted from Cane (2010). 
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The two final steps in the biosynthesis of polyketide backbone are the chain release and 
cyclisation into the lactone ring.  Thioestherase (TE) domains are found on the C- terminal of 
PKS. On the end of module 6 in DEBS there is a TE domain, which is defined as type I TE 
(TE-I). The synthesized full-length polyketide chain covalently links to the TE domain, then 
released by hydrolysis resulted in Ery lactone macrocycle. It is not determined yet if Ery TE is 
also responsible for lactone cyclisation or the additional function is needed.  Interestingly, 
some gene clusters for macrolide PKS may contain an additional gene for type II TE, as in 
nystatin and tylosin gene clusters (Brautaset et al., 2000; Cundliffe et al., 2001). Disruption of 
TE-II genes from several PKS gene clusters revealed that TE-II plays an important role in 
keeping the normal levels of antibiotic production. It is also shown that TE-II can perform 
editing function by removing aberrant intermediates appearing in case of incorrect operation 
during chain extension (Heathcote et al., 2001). 
After the lactone ring is released from the PKS, it is usually enzymatically modified in order to 
obtain the biologically active molecule. Common in all macrolactone biosynthetic pathways is 
mono-, di-, or tri-glycosylation. In addition, some other functional groups as methyls, 
hydroxyls and carbonyls may be added (McDaniel et al., 2005). The first step after 6dEB 
synthesis is C-6 hydroxylation resulting in production of erythromycin B. This reaction is 
catalyzed by cytochrome P-450 monooxygenase encoded by eryF (Weber et al., 1991).  
Many macrolides contain deoxysugar(s) and/or deoxyaminosugar(s), attached to the lactone 
ring via glycoside linkage, and can play an important role in the bioactivity of a molecule. 
These deoxysugars are derived from glucose and are from the 6-deoxyhexoses group. The 
genes encoding enzymes for deoxysugar biosynthesis are located in the PKS clusters. 
Glycosyltransferases are responsible for the transfer of individual synthesized sugars into the 
aglycon to form glycoside bond, as for example, TylCV for L-mycarose in tylosin (Merson-
Davies and Cundliffe, 1994) and EryCIII for D-desosamine (Summers et al., 1997). 
1.2.4 Genetic manipulation of PKS genes 
As it was mentioned above, the hypothesis of modular PKS led to the idea that PKS in 
principle can be manipulated by, for example, introduction of mutations into different 
domains. Such changes may result in loss of function, alteration of substrate specificity or 
even in gaining of a new function (Rodriguez and McDaniel, 2001). Theoretically, if we can 
predict all consequences of such changes, then the number of new PKS of varying length and 
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composition created by combining of different domains and modules is enormously high. This 
features of biosynthesis provoked the idea of constructing the libraries of compounds with all 
possible length and combinations of carbon units. The creation of a combinatorial library of 
more than 50 different analogs of erythromycin with up to three mutations in one or more 
domains in antibiotic molecule by Mc Daniel et al. (1999) is a convincing evidence of great 
potential of combinatorial biosynthesis. Once the library of productive mutants has been 
prepared, the introduction of additional multiple mutations lead to dramatic increase of the 
library size, and production of a great diversity of erythromycin analogues. 
Later, the work of Menzella et al. (2005) demonstrated the possibility of complete 
reorganization of PKS and production of functional biosynthetic enzymes. DNA fragments 
encoding parts of modular PKS from seven different polyketide synthases biosynthetic 
pathways of streptomycetes and myxobacteria have been synthesized and assembled   in 154 
bimodular combinations.  About half of the bimodular assemblies yielded   the triketide 
lactone product after introduction in E.coli strain.  The research team from Biotica 
(Cambridge, UK) constructed a direct biosynthetic pathway for Ivermectin, veterinary 
antiparasitic drug.  Ivermectin is usually produced by costly semi-synthesis (Gaisser et al., 
2003). After successful domain exchange in the avermectin PKS it is possible to produce 
Ivermectin-like compounds by direct fermentation of S. avermitilis recombinant strain. 
 However, polyketide synthase systems are much more complicated then they first appeared.  
In order to be able to use the advantages of above mentioned technologies in full we have to 
deal with some potential problems. For example, host cells that would survive after 
introduction of a new PKS pathway, and have to provide all building blocks and enzymes to 
synthesize and activate a new compound.  Some years ago Escherichia coli for production of 
polyketides was successfully engineered (Pfifer and Khosla, 2001), although high yieds of 
polyketides have never been achieved in this system.
Substrate preference might be a serious challenge, as altered PKS domains have to interact 
normally. Once the domain is changed, it must be recognized and correctly processed by 
following functions.  For example, KS domains must interact with any ACP domain and 
accept any building block in chain extension.  Substrates for TE domains are also determined 
by the action of previous modules/domains.  The details about   so-called linkers, sequences in 
size from 20 to over 250 amino acids, which separate domains, as far as details about   protein 
folding in a new PKS, all this information must contribute to the successful creation of the new 
functional PKS molecules.   
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1.3 Regulation of antibiotic biosynthesis
Taking in consideration that streptomycetes live in complicated and changing environment, 
and that the antibiotic biosynthesis is an energy consuming process, it is logical to assume that 
these organisms might have a comprehensive regulatory network allowing switching on the 
antibiotic production only in response to certain environmental signals in order not to waste 
the cells resources unnecessarily.  Such factors as nutrient limitation, change of temperature 
and pH, phage infection, presence of other organisms or organic solvents are known to trigger 
the antibiotic production (Martin and Liras, 2010). The biosynthesis of secondary metabolites, 
including antibiotics, by Streptomyces is growth phase-dependent, and generally coincides 
with the development of aerial hyphae in surface-grown cultures. The fact, that one organism 
has a genetic capacity to produce several secondary metabolites with diverse chemical 
structure and biological activity means that there might exist a competition for the precursor 
supply between the biosynthetic pathways, and the decision should be made on which of the 
pathways should be activated in current circumstances.  
Regulatory proteins that control antibiotic production can be divided in several groups 
according to their role in the above mentioned process. The first includes pleiotropic regulators 
that influence both secondary metabolism and morphological differentiation (e.g. sporulation). 
Example is bldA gene, which encodes the only tRNA translating rare leucin codon UUA in 
Streptomyces (Lawlor et al., 1987). 
The other group consists of pleiotropic regulators, which have little or no effect on 
differentiation, as, for example, absA operon from S. griseus and S. coelicolor encoding a two-
component system that repress antibiotic production in these organisms (Aceti and 
Champness, 1998; Price et al., 1999; Ishizuka et al., 1992). Usually, such pleiotropic 
regulators affect several antibiotic biosynthesis pathways simultaneously. 
Most of the gene clusters for biosynthesis of secondary metabolites contain regulatory genes, 
which directly control structural biosynthetic genes. Such “low level” regulators are usually 
called pathway-specific, and include, for example, actII-ORF4 of the actinorhodin biosynthetic 
cluster (Fernandez-Moreno et al., 1991), cdaR of the calcium–dependent antibiotic cluster 
(Ryding et al., 2002), or redZ and redD genes from undecylprodigiosin cluster, all in S.
coelicolor (White and Bibb, 1997). 
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Several genes involved in the global regulation of antibiotic production have been identified in 
S.coelicolor. One such group of genes is afsK-afsR-afsS,   which globally controls antibiotic 
synthesis under certain conditions. AfsR is a pleiotropic regulator which controls actinorhodin, 
undecylprodigiosin and CDA production, and it shares homology with the SARP                       
(Streptomyces Antibiotic Regulatory Proteins) proteins. Although a member of SARP family 
(details are in the text below), it does not directly control antibiotic biosynthesis genes, but 
activates AfsS, a regulator, which stimulates transcription of the SARP’s redD and actII-ORF4
(Tanaka et al., 2007). 
AfsR also contains a central ATPase domain and a tetratricopeptide repeat (TPR) associated 
with some other Streptomyces regulatory proteins and possibly mediating protein-protein 
interactions (Tanaka et al., 2007; Sekurova et al., 2004). AfsR itself is a subject to 
phosphorylation by the AfsK, a serine/ threonine kinase, which is located on the inner side of 
the cell membrane. Two more serine/threonine kinases, AfsL and PkaG, take part in 
phosphorylation of AfsR. AfsK autophosphorylates in response to unknown signal  
(Matsumoto et al., 1994), and its activity is modulated by KbpA, an AfsK-binding protein, 
which level in cells is enhanced after the onset of antibiotic biosynthesis and its role is 
probably to prevent unlimited antibiotic production (Umeyama and Horinouchi, 2001). 
As a transcriptional activator, AfsR-P (phosphorylated form of AfsR) has greatly enhanced 
DNA-binding activity towards the afsS promoter. afsS gene of S.coelicolor (afsR2 in
S.lividans) is located immediately 3’ to afsR, and encodes  a 63aa “sigma-like” protein, 
containing certain conserved sequences of the domain 3  of sigma-factors (Kim et al., 2006). 
Two AfsR monomers bind to the direct repeats at the afsS promoter and recruit RNAP (RNA 
polymerase). The DNA-AfsR-RNAP complex is formed, allowing binding of RNAP to the 
afsS promoter. In the absence of AfsR this binding doesn’t occur. Activated AfsS in its turn 
stimulates transcription of the SARPs redD and actII-ORF4 in S.coelicolor in as yet unknown 
manner (Vogtli et al., 1994; Floriano and Bibb, 1996; Lee et al., 2002). AfsS-like proteins are 
relatively rare in streptomycetes, and as of today have only been identified in S. coelicolor, S. 
lividans, S. griseus, and S. noursei.
Recently, it has been shown by Lian et al. (2008) that AfsS regulates both antibiotic 
biosynthesis and nutrition starvation response genes in S. coelicolor. Microarray analysis was 
used to analyze the expression profile in the afsS disruption mutant. More than 117 genes were 
perturbed in the mutant strain, and the great majority of them were downregulated, proving 
1.3.1 Pleiotropic regulation
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that AfsS is a pleiotropic transcriptional regulator for many genes.  In the afsS disruption
mutant the phosphate starvation mechanism was shown to be affected, leading to complete 
abolishment of actinorhodin production. In most cases, the effect of AfsS regulation was not 
visible until mid/late stationary phase. In this respect activity of AfsS resembles sigma factors, 
the great number of which is involved in stress response and growth phase adaptation in 
bacteria.
The antibiotic production is a complex process involving several levels of regulation. Earlier 
works have suggested an elegant model of regulatory cascades involving signaling molecules 
Jbutyrolactones, which bind to the receptor proteins, usually repressors, and thus allowing the 
expression of positive regulators. Activators, in their turn, can directly or through pathway-
specific regulators, induce the antibiotic production, and also can be involved in 
morphological differentiation.
A-factor in Stretomyces griseus is so far the most characterized Jbutyrolactone (Horinouchi, 
2002). A-factor acts to induce the transcription of a pleiotropic regulator AdpA, which controls 
antibiotic production (streptomycin and grixazone), and formation of aerial mycelium in S.
griseus (Ohnishi et al., 2005). When the concentration of A-factor, synthesized in a growth-
dependent manner, reaches a certain level, it binds to the protein ArpA, repressor of 
transcription of adpA, the key transcriptional factor for the adpA regulon. ArpA dissociates 
from the adpA promoter, and AdpA activates, among others, strR, pathway-specific regulator
for all streptomycin biosynthesis genes, causing the onset of streptomycin biosynthesis.
A-factor homologs, with a J-butyrolactone-like structure, have been identified in many 
streptomycetes, as, for example, in S. coelicolor A(3)2, S. bikiniensis, S. cyaneofuscatus, S. 
lavendulae, S. viridochromogenes (Takano et al., 2005; Nishida et al., 2007). These strains 
contain genes homologous to afsA and arpA, encoding an A-factor biosynthesis enzyme and   
A-factor receptor, respectively. The latter suggests that these molecules play an important role 
as “bacterial hormones” that switch on certain genes for morphological differentiation and 
antibiotic biosynthesis in streptomycetes, and that the mechanism for regulation by these J-
butyrolactones are similar to the A-factor regulation, where afsA and arpA are involved. 
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Figure 1.5. A-factor regulatory cascase in S. griseus. Adapted from Horinouchi (2002). 
1.3.2 Pathway –specific regulation 
Regulatory proteins encoded by the genes located within the antibiotic biosynthesis gene 
clusters in streptomycetes are referred to as pathway-specific regulators or so-called cluster-
specific regulators (CSR). With very few exceptions, these regulators cotroll exclusively 
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expression of genes in their own cluster. This group of regulators is not uniform, but the most 
studied ones belong to the Streptomyces antibiotic regulatory proteins (SARP), which are 
transcriptional regulators. Representatives of this protein family have a characteristic N-
terminal OmpR-like helix-turn-helix DNA-binding motif, and accompanying bacterial 
transcription activation domain (BTAD). At least some of the SARPs were shown to recognize 
and bind heptameric direct repeats in the promoter regions of genes they regulate (Wietzorrek 
and Bibb, 1997; Tanaka.et al., 2007). 
SARP regulators often control transcription of some or all genes for antibiotic biosynthesis in 
the cluster. The operon organization of genes allows SARP to regulate multiple genes through 
just few promoters. actII-ORF4 and redD from S.coelicolor are represnetatives of the SARP 
regulators family, controlling actinorhodin and undecylprodigiosin production, respectively. 
Both of them are located within the clusters they regulate (Arias et al., 1999; Takano et al., 
1992), and are essential for antibiotic biosynthesis. Microarray analysis revealed that many 
genes for undecylprodigiosin production are activated by RedD (Huang et al., 2005).  As in 
case of actII-ORF4, transcription of redD is also growth-phase dependent, and maximum level 
of transcript must be present to activate undecylprodigiosin biosynthesis genes (Gramajo et al., 
1993). In both cases the overexpression of SARP regulators leads to increased levels of 
antibiotic production. Expression of redD itself is activated by another pathway-specific
regulator, also located in the cluster, the response regulator-like protein RedZ (White and 
Bibb, 1997). 
SARP family regulators have been found in gene clusters for biosynthesis of aromatic 
polyketides, PKS I gene clusters, ribosomally and non-ribosomally synthesized peptides, and 
some other classes of antibiotics. SARP proteins are specific for actinomycetes, and most of 
them have been found in Streptomyces (reviewed in Bibb, 2005).
In contrast to the SARP family regulators common among various classes of antibiotic 
biosynthesis gene clusters, the representatives of LAL (Large ATP- binding regulators of the 
LuxR type ) family of transcriptional regulators have been found  almost exclusively in the 
PKS I   gene  clusters, and some of these clusters contain multiple LAL regulators (Brautaset T 
et al., 2000; Campelo and Gil, 2002; Rascher et al., 2003). Proteins of the LAL family are 
large (872 to 1,159 amino acids) ATP-binding transcriptional regulators characterized by C-
terminal helix-turn-helix DNA-binding motif of LuxR type (De Schrijver and De Mot, 1999). 
They also contain NTP (nucleotide triphosphate) binding domain on the N- terminus 
represented by Walker A and B motifs. When deletion was introduced into the NTP-binding 
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domain in PikD, positive regulator of pikromycin biosynthesis from S.venezuelae, the 
pikromycin production was abolished, suggesting that binding ATP is essential for its activity 
as a regulator (Wilson et al., 2001). However, the exact mode of action of these regulators is 
not yet understood. 
1.3.3 Tylosin biosynthesis in S .fradiae: an example of regulation of macrolide antibiotic 
biosynthesis gene cluster 
Tylosin is an antibacterial macrolide antibiotic produced by S. fradiae. The tylosin 
biosynthetic gene cluster contains multiple regulatory genes, tylP, tylQ, tylS and tylU, 
organized in the “regulatory island” downstream the PKS genes, and one more regulator, tylR,
which is located on the opposite side of PKS genes block (Bate et al., 1999). Tylosin 
biosynthesis was shown to be controlled in a cascade-like manner by these five regulators. tylP
and tylQ  encode homologues of J-butyrolactone- binding proteins, tylS product belongs to 
SARP family, tylR is an ortholog of acyB2, the novel transcriptional activator from S.
thermotolerans (Arisawa et al., 1995). On top of the regulatory cascade is the TylP repressor,
which in the absence of yet unidentified J-butyrolactone represses its own synthesis, thus 
allowing synthesis of another repressor, TylQ, which gene it is otherwise targeting. TylQ 
inhibits expression of tylR, the positive regulator of tylosin biosynthetic genes. 
Figure 1.6. Regulatory cascade controlling biosynthesis of tylosin in S. fradiae. Adapted from 
Cundliffe (2008). 
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TylP also negatively controls expression of tylS. Authors suggested that, when J-butyrolactone
concentration reaches certain level, TylP represses expression of TylQ, and expression of tylR
is activated via interplay of two activators TylS and TylU. So, the derepression of tylP due to 
the tylP-specific J-butyrolactone results in the onset of tylosin production.
Interestingly, there was at first no special interest in the tylU regulatory role until RT-PCR 
experiments, where this gene was shown to be silent together with tylR in the tylS-deficient 
mutant (Stratigopoulous et al., 2004). When tylU gene was inactivated, the production of 
tylosin in the mutant strain was reduced by 80%. It was restored to the WT level by 
overexpression of tylR. Based on these data, tylU was defined as the first “SARP-helper” (Bate
et al., 2006). 
1.3.4 Cross-talk between antibiotic biosynthetic pathways
As described above, the earlier works have suggested a model of regulation, in which 
pleiotropic “higher level” regulators control individual genes from antibiotic biosynthesis 
pathways through cluster-specific “lower level” regulators. However, the question of how the 
coordination between different pathways in an organism producing many secondary 
metabolites is achieved still remains open. New investigations based on microarray data and 
availability of genome sequences of several streptomycetes, and particularly of S.coelicolor,
made it possible to reveal some interesting details about cross-talk between regulators of 
different antibiotic biosynthesis gene clusters.
The absB gene from S.coelicolor encoding an RNase III homologue is a pleiotropic regulator, 
which controls expression of act-ORF4 and redD pathway-specific regulatory genes in Act 
and Red clusters respectively (Aceti and Champness, 1998). Huang et al. (2005) studied the 
effects of cluster-specific regulators (CSRs) on biosynthetic pathways in the wild-type (WT) 
strain, and a mutant deficient in the AbsB regulation. For this purpose, cdaR (CSR for 
calcium- dependent antibiotic), actII-ORF4, redD and redZ pathway-specific regulatory genes 
were individually expressed in the WT and absB-deficient mutant strains. The results obtained 
from these experiments revealed that CSRs can communicate with genes in different antibiotic 
biosynthesis gene clusters. It has been shown that redZ activated expression of red, act and 
cda genes in both the WT and mutant strains. Deletion of redZ abolished expression of red
genes, but also expression of genes for two other antibiotics was delayed.  Remarkably, this 
study revealed that CSRs from one pathway can regulate expression of CSRs in the other 
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cluster(s), and also are able to influence the global regulation. Microarray analysis revealed the 
increased abundance of mRNA for afsR2 (afsS), the pleiotropic regulator, in the strain 
overexpressing redZ. Interestingly, redZ exhibits the growth phase-dependent control over 
afsR2, as the regulatory effects of afsR2 were not observed until 60 h of growth. Authors 
suggested that in addition to AfsR2-mediated control of antibiotic production, other cellular 
factors might be needed for initiation of the CSRs expression. These results demonstrate the 
example of a cross-talk between clusters for different secondary metabolites and reveal that the 
role of CSRs is much more complicated than in common model for the cascade-like regulation 
of secondary metabolites biosynthesis. 
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2. AIMS OF THE STUDY 
Fungal infections represent a serious medical problem for patients with weakened immune 
system. The number of antifungal compounds used in medical treatment of such infections is 
limited. Polyene macrolides are efficient antifungal agents that have been used for over 50 
years to treat fungal infections. However, their use is limited due to serious side effects, such 
as nephrotoxicity. Development of a new polyene macrolide with retained antifungal activity 
and reduced toxicity would provide a substantially improved antifungal antibiotic. Although 
chemical derivatization of polyene macrolides has been extensively tried out for many years, 
no improved polyene macrolide appeared on the market. Genetic engineering of antibiotic 
biosynthesis genes could provide an alternative to medicinal chemistry in changing the 
molecular structure of polyene macrolides and, hopefully, improving their pharmacological 
properties. To use this approach, however, biosynthetic genes for polyene antibiotic must be 
cloned and studied. 
The aim of this study was to clone, analyze and manipulate genes involved in the biosynthesis 
of polyene antifungal antibiotic nystatin produced by a bacterium Streptomyces noursei. Prior 
to this study, nothing was known about the genetics and biochemistry of nystatin biosynthesis. 
Besides cloning of the biosynthetic genes, the aim was also to study the regulation of the 
biosynthesis, both by pleiotropic and pathway-specific regulators. Understanding of the 
regulation could prove useful in improving the yield of antibiotic, thus having direct relevance 
to its industrial production. Another important aim of this research was to produce nystatin 
analogs by manipulation of its biosynthetic genes. The idea was to use knowledge on the 
structure-activity relationship of polyene macrolides and on the biosynthesis of nystatin in 
order to rationally engineer novel analogs with improved properties. 
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4.  SUMMARY OF RESULTS AND DISCUSSION  
4.1.     Pleiotropic regulatory gene locus from S. noursei involved in a regulatory network 
affecting nystatin biosynthesis (Paper I) 
As mentioned in the Introduction, the detailed understanding of the regulatory networks 
influencing biosynthesis of antibiotics is still far from being complete. This is despite the fact 
that a huge amount of information have been obtained nowadays from sequencing and 
analyzing of complete genomes of Streptomyces, as well as metabolomes and transcriptomes 
(Alam et al., 2010; Castro-Melchor et al., 2010).
By the time this study has been initiated, nothing was known about the regulation of antibiotic 
production in S. noursei, but some interesting works on regulatory genes and proteins sensing 
environmental changes, reacting on it, and thus regulating antibiotic production in other 
streptomycetes, have been published (see Introduction). For example, afsR, when 
overexpressed, enhances transcription of pathway-specific regulatory genes from Act and Red 
biosynthetic gene clusters in S. coelicolor. Small gene afsS situated downstream of afsR in
both S. coelicolor and S. lividans, can also stimulate Act and Red production when cloned on a 
multicopy vector. With the initial aim of enhancing nystatin production through similar 
approach, we intended to identify possible positive regulators in S. noursei.
4.1.1 Regulatory gene locus from S. noursei capable of stimulating enhanced actinorhodin 
production in S.lividans
Total DNA from S. noursei was isolated, partially digested with Sau3AI, size-fractionated on 
sucrose gradient, ligated into a multi-copy Escherichia coli-Streptomyces shuttle vector 
pWHM4 (Vara et al.,1989), and introduced into S. lividans. Several transformants producing 
blue pigment (Act) were isolated, and one of them, designated A8, was chosen for further 
analysis. Recombinant plasmid pA8, containing a 4.8kb DNA insert, caused the Act 
overproduction when reintroduced into S. lividans. In addition, pA8 had week, but detectable 
growth inhibition effect on recombinant S. lividans strain.
 The deletion analysis of the A8 fragment in order to determine precisely the location of 
regulatory gene, revealed the 1.8kb fragment, A8d8, which was found to be sufficient for 
eliciting Act overproduction  phenotype in S. lividans.
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The complete sequence of the fragment A8d8 revealed two complete (ORF2 and ORF3) and 
two incomplete (ORF1 and ORF4) open reading frames within it.  An incomplete ORF1 was 
shown to encode a C-terminal part of peptide homologous to the AfsR protein from S.
coelicolor A3 (2). Downstream of ORF1, a small ORF2 (164 nt) was detected, which deduced 
product of 55 aa showed some homology to the C-terminal part of CREA catabolite repressor 
from Aspergillus nidulans (Dowzer and Kelly, 1991). Interestingly, detailed analysis of the 
putative ORF2 product revealed two repeats homologous to those from the peptide encoded by
afsR2 (afsS) from S.lividans. Homology search and analysis of the putative ORF3 product (54 
aa), showed 59% identity of its 27 N-terminal aa to the putative signal peptide of the secretable 
metalloproteinase from S. coelicolor.  Finding of the putative transmembrane helix and the 
AxA conserved motif typical for streptomycete signal peptides (Gilbert et al., 1996) also 
supported the suggestion that ORF3 encodes a secretable peptide. Truncated product of the 
incomplete ORF4 located downstream of ORF3 shows similarity to peptide synthetases or 
acetyl-CoA synthetases from different organisms. 
4.1.2 Individual roles for ORF2 and ORF3 in regulation of Act production in S. lividans. 
It was logical to suggest that ORF2 (designated ssmA) or ORF3 (ssmB), or both of them, take 
part in the regulation of Act production in S. lividans, since ORF1 and ORF4 were incomplete. 
Recombinant S. lividans strains carrying A8d8, A8DO2 (ssmA deletion) and A8DO3 (ssmB
deletion) fragments on either multi-copy vector pWHM4 or pSET152 (introduces one 
additional copy of gene per genome via site-specific integration) were constructed to check 
individual roles of ssmA and ssmB in the regulation of Act biosynthesis. In addition, a 
recombinant strain was made by introduction of pSET152 carrying additional copy of ssmA
under control of the strong constitutive promoter PermE* from Saccharopolyspora erythrea
(fragment PA8DO3). Recombinant S. lividans strains were tested for Act production in liquid 
media.  
 According to the results of the experiments with strains containing abovementioned fragments 
on the multi-copy vector, ssmA was required for Act overproduction, as its deletion leads to 
abrogation of this phenotype.  Deletion of ssmB from the ssmA-containing multicopy plasmid 
resulted in enhancement of Act production, while multiple copies of the ssmB suppressed the 
enhancing effect of ssmA. It seems therefore that ssmB is involved in the negative regulation of 
antibiotic production.
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As for S. lividans strains containing the same fragments cloned into pSET152, the results 
confirmed that ssmA is responsible for overproduction of Act as even its single copy conferred 
this phenotype. No Act overproduction was detected in ssmA deletion mutant (construct pSET-
A8dO2). Strain containing pSET-PA8dO3 produced double amount of Act compared to pSET-
A8d8, as a result of PermE* -driven overexpression of ssmA. The fact that overexpression of 
ssmB in a construct where one additional copy of it was introduced in S. lividans (pSET-
PA8dO3) had a negative effect on Act production further confirms the negative regulatory role 
of ssmB in Act production in S. lividans. 
Figure 4.1. (a) A8 DNA fragment from S.noursei, and its derivative A8d8, carrying genes 
ssmA and ssmB essential for activation of actinorhodin production in S.lividans. (b) Schematic 
representation of the A8d8 DNA fragment deletion derivatives. Deletion regions are indicated 
with dotted line (adapted from Sekurova et al., (1999). 
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4.1.3. SsmA might be a part of a system sensing the carbon source in S. noursei. 
In order to investigate the involvement of ssmA in regulation of nystatin production in S.
noursei, and possible effect of ssmA overexpression on this process, the ssmA deletion mutant  
DO221 and  strain where ssmA was placed under control of PermE* , PA8DO32, have been 
generated.  As demonstrated by Shroff et al. (1996), CREA protein is a catabolite repressor for 
the ethanol regulon in Aspergillus nidulans, and it negatively affects the ethanol utilization 
genes on a glucose-containing media. The fact of homology between SsmA and CREA protein 
let us speculate that the function of SsmA might be also dependent on the carbon source.  
Experiments on nystatin production by the S. noursei WT, DO221, PA8DO32, and WT 
(pSET152) strains in semi-defined media with two different carbon sources were performed. 
Figure 4.2. Analysis of the nystatin production and respiration rate by the S. noursei WT, WT 
(pSET152), DO221, and PA8DO32 strains in SAO-23 (a) and SAO-26 (b) media in 3 l 
fermentors. Average values from two independent experiments are presented (adapted from 
Sekurova et al., (1999) 
No significant differences were observed on glucose-containing medium either for ssmA
deletion or for its overexpression mutants when compared to WT (Fig. 4.2a). However, on 
starch-containing medium, nystatin volumetric yield by the deletion mutant DO221 was 86 % 
lower compared to the WT.  As for the overexpression mutant PA8DO32, we observed very 
significant (250 %) increase in both volumetric and specific nystatin production. There were 
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no differences in growth characteristics between this strain and the one containing empty 
pSET152 vector, strongly suggesting that the increase of nystatin production occurred due to 
more efficient expression of ssmA.
 Interestingly, the fermentations on glucose-containing medium were run for 142 h until all the 
glucose was consumed, and in starch-containing media – until 288 h, because of slow starch 
consumption. ssmA deletion mutant also showed slow starch consumption, and very low 
respiration rate (app. 4, 5 times lower) compared to other strains, which indicates an 
impairment in assimilation of starch as a carbon source by this mutant. 
The obtained results suggest that SsmA might be a part of a system sensing the carbon source, 
and transmitting the signal to the pathway-specific regulators of the nystatin biosynthetic gene 
cluster in S. noursei. As mentioned in the Introduction, in a microarray study of the disruption 
mutant of afsS, the ssmA homologue in S. coelicolor, it was shown that AfsS is a pleiotropic 
regulator, affecting both nutrition starvation response genes and antibiotic biosynthesis. This 
fact, together with our observations further supports the idea about the important pleiotropic 
regulatory role of SsmA in nystatin production. 
4.2. The genetics and biochemistry of nystatin biosynthesis in Streptomyces noursei 
(Paper II)
4.2.1 Cloning of the nystatin biosynthetic gene cluster 
The S. noursei gene library constructed previously (Zotchev et al., 2000) was screened with a 
labeled DNA fragment encoding type I PKS to identify and isolate nystatin biosynthetic genes. 
Probe was produced via PCR reaction using oligonucleotide primers corresponding to 
conserved amino acid sequences in ACP and KS domains in known type I PKSs. PCR product 
was cloned and sequenced in order to confirm that it encodes a part of a PKS type I enzyme. 
To prove the involvement of the cloned gene fragment in nystatin biosynthesis, it was used in 
the construction of a suicide conjugative plasmid, and the latter was introduced into S. noursei. 
The plasmid was integrated into the genome via homologous recombination, and the resulting 
disruption mutant obtained was unable to produce nystatin, thus proving the requirement of the 
identified gene for nystatin biosynthesis. Later, this fragment was shown to be a part of the 
nysC PKS gene. The “chromosome walking” technique allowed to isolate a complete nystatin 
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biosynthetic cluster encompassing ca. 125 kb and containing 20 genes (Figure 4.3, and Table 
4.1). The sequencing and mutational analysis of the cluster was subsequently performed. 
Figure 4.3. Organization of the nystatin biosynthetic gene cluster in S. noursei ATCC 11455. 
PKS genes are in violet, genes for post-PKS modifications are in pink, transporters marked in 
yellow and genes for regulation are in orange. 
4.2.2 Putative genes and their functions in the nystatin biosynthetic gene cluster 
Using the BLAST search and amino acid sequence alignments, six genes encoding PKS type I, 
nysA, nysB, nysC, nysJ, nysI and nysK, were identified. All proteins were shown to have a 
significant homology to rapamycin and rifamycin PKSs and predictions of their functions were 
based on comparisons to the known polypeptides.
The NysA protein apparently represented a loading module for the nystatin PKS, involved in 
the initiation of the nystatin aglycone biosynthesis. AT domain of NysA is acetate-specific, 
according to the comparisons with ATs from different PKSs with known substrate specificity, 
and this correlates well with the nystatin molecular structure. In many PKS I loading module 
utilizes acetyl CoA or malonyl CoA (subsequently decarboxylated) to initiate the antibiotic 
biosynthesis. It has been shown that KS, if present in the loading module, is essential for 
decarboxylation, and contains glutamine residue instead of cysteine in the active site (Bisang 
et al., 1999). Interestingly, KS domain in NysA contains active-site serine residue instead of 
conserved cysteine or typical loading module-type glutamine. Later, NysA was studied more 
closely (Brautaset at al., 2003) in our group. Substitution of serine with either cysteine or 
glutamine had no effect on the nystatin production. Further experiments with hybrid loading 
modules suggested that NysA can utilize both acetyl CoA and malonyl CoA (after 
decarboxylation) to start the nystatin synthesis.  In addition, NysA contains ACP module and a 
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seemingly intact DH domain. The latter seems not to have any function in nystatin 
biosynthesis, and might be an evolutionary remnant. 
Table 4.1. Genes in the nystatin biosynthetic gene cluster of S. noursei and their putative 
functions.
nysF Putativephosphopantetheinetransferase
nysG ABCtransporter
nysH ABCtransporter
nysDIII GDPͲmannosedehydratase
nysI NystatinPKS,modules9Ͳ14
nysJ NystatinPKS,modules15Ͳ17
nysK NystatinPKS,module18+thioesteraseI
nysL P450monooxygenase
nysM Ferredoxin
nysN P450monooxygenase
nysDII Aminotransferase
nysDI Glycosiltransferase
nysA NystatinPKSloadingmodule
nysB NystatinPKSmodules1Ͳ2
nysC NystatinPKSmodules3Ͳ8
nysE ThioesteraseII
nysRI Transcriptionalregulator
nysRII Transcriptionalregulator
nysRIII Transcriptionalregulator
nysRIV Transcriptionalregulator
NysB represents modules 1and 2, and is involved in two first elongation steps in biosynthesis 
of the nystatin aglycone. DHs in both modules are inactive, as they lack the characteristic 
active-site sequence. 
NysC is a gigantic, one of the largest known bacterial polypeptides, representing 6 extension 
modules, and responsible for elongation steps 3 to 8 in the aglycone biosynthesis. 
 31
Interestingly, both rapamycin and amphotericin gene clusters from S. hygroscopicus and S.
nodosus respectively, encode RAPS2 and AmphC PKSs very similar to the NysC protein. All 
three of them are hexamodular large type I PKSs, and the overall number of domains, and their 
positions in the protein sequences are also similar. Nevertheless, both, RAPS2 (Rascher A. et 
al. 2003) and AmphC are shorter then NysC. This difference can be explained by more 
compact structure of domains or interdomain linkers in these proteins. For example, the 
interdomain linker preceding ER5 in AmphC is 45aa shorter than correspondent sequence in 
NysC (Caffrey et al., 2001). ER domains are responsible for the appearance of a saturated C-C 
bond on the antibiotic molecule. Caffrey et al. suggested that shortening of linker can lead to 
some spatial movements restrictions for ER5 domain, and production of both amphotericin A 
(tetraene) and B (heptaene) by S. nodosus, as a result. Taking into consideration all the 
similarities between these three proteins, and that they represent PKSs type I for polyene 
macrolides, it is logical to suggest that all of them might have evolved from a common 
ancestor. 
NysI protein is a hexamodular type I PKS which is responsible for the elongation steps 9-14. 
The DH domains in modules 10, 11, 12, 13 and 14, and KR domain in module 13 are inactive. 
NysJ is a trimodular type I PKS protein. DH domains in modules 16 and 17 appear to be 
inactive. This enzyme is responsible for the elongation steps 15-17 in nystatin aglycone 
biosynthesis.
Unimodular NysK PKS completes the synthesis of the nystatin polyketide chain. It lacks a KR 
domain, and its DH domain is inactive. A TE domain is localized at the C- terminus of the 
protein. The latter suggests that in addition to the last condensation step NysK takes part in the 
release of the mature polyketide chain, and its cyclization. 
In order to confirm the involvement of genes nysA, nysB, nysI, nysJ in nystatin biosynthesis,
disruption mutants inactivating these genes were obtained. All of them appeared to be nystatin 
non-producers, suggesting the essential roles of these genes in the biosynthesis of this 
antibiotic. 
nysE gene located immediately downstream nysC encodes another thioesterase in the same 
cluster. NysE shows high degree of similarity to the TEs type II, which function as “editing” 
enzymes during biosynthesis of polyketides. (Buttler et al., 1994; Kim et al., 2002). We have 
later performed inactivation of nysE, which led to considerable (ca. 65%) decrease in nystatin 
biosynthesis (Master Thesis, Anne S. Mortensen, 2002), which correlated well with the 
suggested editing function for NysE.
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In order to obtain a biologically active molecule, a PKS-assembled macrolactone ring most 
often has to be modified. According to the nystatin chemical structure, and organization of the 
nystatin gene cluster, at least three modifications have to be performed after macrolactone ring 
synthesis is completed. Several genes for post-PKS modifications have been found in the 
nystatin cluster.  nysL and nysN genes encode P450 monooxygenases, and have been 
suggested to be responsible for C10 hydroxylation, and oxidation of a C16 methyl group into a 
carboxyl, respectively (Brautaset et al., 2000). The putative role of NysL as hydroxylase was 
confirmed in later study by Volokhan et al. (2006).   Inactivation of nysL gene in S. noursei
resulted in a recombinant strain producing 10-deoxynystatin as a main polyene macrolide 
product. nysM encodes a ferredoxin, which presumably is a part of one or both P450 
monooxygenase systems, and serves as an electron donor. 
The nysH and nysG genes encode putative ABC-type III transporter proteins, whose role is an 
active efflux of nystatin out of the cell.  Later, nystatin transporters were studied in more 
details in our group. Sletta et al. (2005) have shown that in-frame deletions of either nysH or
nysG had quantitatively the same negative effect on nystatin production in S. noursei, while
both mutants overproduced nystatin analogue identified as 10-deoxynystatin. Transporter 
mutants continued to efficiently efflux both nystatin and 10-deoxynystatin out of the cells, and 
this fact strongly supports the hypothesis on the existence of alternative transport system(s) for 
the nystatin-related antibiotics. nysG and nysH  are transcriptionally coupled, and  probably act 
in a concert as a heterodimer. As already mentioned before, accumulation of 10-deoxynystatin 
was observed also as a result of inactivation of NysL. This observation suggests a possible link 
between the C-10 hydroxylation and active efflux of nystatin out of the cell. Most probably, 
NysH-NysG transporter system provides favorable conditions for NysL-catalyzed 
hydroxylation.
nysDI, nysDII, and nysDIII are three genes in the nystatin biosynthetic cluster presumably
involved in the synthesis and attachment of deoxyaminosugar mycosamine moiety to the 
nystatin aglycon. The glycosyltratransferase NysDI is presumably responsible for the 
attachment of the mycosamine moiety to the nystatin aglycon at C-19. NysDII represents an 
aminotransferase   and is involved in mycosamine biosynthesis, while nysDIII encodes a 
protein similar to GDP-mannose-4, 6-dehydratases and probably takes part in one of the initial 
steps in the biosynthesis of mycosamine. The predicted roles for NysDI and NysDII were 
confirmed in a later study by Nedal et al. (2007). Genes nysDI and nysDII were inactivated 
and expressed in-trans in S. noursei. Analysis of the resulting mutants supported the predicted 
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roles for the both enzymes. NysDIII protein was expressed in Escherichia coli, purified, and 
its in vitro GDP-mannose dehydratase activity was confirmed. The genes for the other 
enzymes involved in deoxysugar formation are missing in the cluster, and can be, in principle, 
recruited from primary metabolism. 
nysF gene, situated downstream of nysG, represents  the 5’ border of the nystatin biosynthetic 
cluster. The product of the gene was identified as a putative 4’-phosphopantheteine 
transferase. Such enzymes are responsible for the post-translational modification of the ACP 
domains on the PKSs (attachment of the phosphopantheteine moiety), and are required for 
their functionality (Kealey et al., 1998). 
In order to test the involvement of nysF in modification of the nystatin PKS, this gene was 
inactivated, and we observed an unexpected increase (approx. 60 %) of nystatin production by 
the mutant strains, suggesting a negative regulatory role of nysF in the nystatin biosynthesis 
(Volokhan et al., 2005). xylE reporter gene was expressed in the nysF deletion mutant under
the control of different promoters from the nystatin cluster.  The obtained results showed an 
enhanced expression of xylE from several regulatory and structural genes thus proving that 
NysF negatively regulates the biosynthesis of nystatin. It has been suggested that regulation of 
nystatin biosynthesis may be mediated by a signaling molecule synthesized via NysF-
dependent pathway involving NysF. 
4.2.3 Model for the nystatin biosynthesis in S. noursei 
Based on the data described above, the following model of nystatin biosynthesis was 
suggested (Figure 4.4). Synthesis of the nystatin macrolactone ring begins with the loading and 
chain initiation by NysA.  NysB catalyses the elongation of the chain via adding two 
propionate extender units to the acetate starter. Elongation is then performed sequentially by 
NysC (6 modules), NysI (6modules), NysJ (3 modules), and NysK, which adds the last acetate 
extender unit, and is responsible for the cyclisation of the mature polyketide chain.  
According to the chemical structure of nystatin and organization of its PKS, it could be 
suggested that at least 3 post-PKS modification steps have to be performed to finish the 
synthesis of completed active nystatin molecule.  These modifications include, as mentioned 
above, oxidation of a C16 methyl group to a carboxyl (NysN), C10 hydroxylation (NysL), and 
formation of a glycosidic bond between the aglycone and mycosamine (NysDI). 
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Two transporters, NysH and NysG, acting most likely, as a heterodimer, provide for the active 
transport of nystatin out of the producing organism.
Figure 4.4. Model for nystatin biosynthesis in S. noursei ATCC11455 (adapted from Fjærvik 
and Zotchev (2005). 
At least four regulators, NysRI-IV, acting in a cascade manner (see paper III), regulate the 
process presumably via initiating transcription of the key structural genes for nystatin
biosynthesis initiation and transport, and also accomplishing the autoregulation of the 
regulatory operon.
4.3    Analysis of the regulatory genes in the nystatin biosynthetic gene cluster of 
Streptomyces noursei (Paper III) 
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A set of 6 regulatory genes was found on the right flank of nystatin biosynthesis gene cluster. 
Genes were designated as nysRI, nysRII, nysRIII, nysRIV, and orf2 and orf3 (Figure 4.5). 
nysRI, nysRII, and nysRIII are organized in an operon-like structure, and located downstream 
of the nysE gene encoding putative thioesterase II. The nysRIII gene’s start codon overlaps by 
11 nt with 3’ end of the nysRII gene. The nysRIV gene is located 404 nt downstream of 
nysRIII, and appears to be transcribed separately. orf3 and orf2 located downstream of nysRIV,
and orf2 is transcribed in the direction opposite to that of all the other putative regulatory 
genes.
Figure 4.5 (A) Organization of the regulatory gene locus associated with the nystatin 
biosynthetic gene cluster in S. noursei ATCC 11455.  (B) Putative functional features 
4.3.1 Regulatory gene locus in the nystatin biosynthetic cluster of S. noursei 
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predicted for the NysRI, NysRII, NysRIII, and NysRIV proteins: WA and WB, Walker A and 
B NTP binding motifs; PAS, PAS-like domain (adapted from Sekurova et al. (2004). 
Analysis of the protein sequences encoded by nysRI, nysRII and nysRIII revealed their 
similarity to each other, and to a number of putative transcriptional activators of the LAL 
subfamily (De Shriever and De Mot, 1999). All three predicted proteins have C termini – 
located HTH DNA-binding motifs of the LuxR type and Walker A and B NTP binding motifs 
at the N termini of NysRI and NysRIII. TPR (tetratricopeptide repeats), which have been 
implicated into protein-protein interactions (D'Andrea and Regan, 2003) have been also found 
in both NysRI and NysRIII polypeptides.  In addition, two putative transmembrane regions 
were predicted in the central part of NysRIII. Proteins similar to NysRI-III are found mostly in 
actinomycetes, and act as transcriptional activators for macrolide antibiotic biosynthesis.  
nysRIV gene encodes a 226 aa protein with high degree identity (63%) to the regulatory 
protein PteR from pentaene macrolide antibiotic gene cluster of Streptomyces avermitilis
(Omyura et al., 2001). It has an N-terminal PAS domain and C-terminal DNA- binding HTH 
motif of the LuxR type.  NysRI, NysRII, NysRIII, and NysRIV orthologs have been found in 
amphotericin, candicidin/FR-008 and pimaricin antibiotic biosynthesis gene clusters. 
orf3 encodes a 233 aa protein similar to transcriptional repressors of the DeoR family, and the 
product of orf2 gene is a 354 aa polypeptide similar to transcriptional regulators of the AsnC 
type.
 4.3.2 Four regulatory genes are essential for efficient nystatin biosynthesis 
 Mutational analysis of all 6 regulatory genes was performed in order to determine their 
individual roles in nystatin biosynthesis. Disruption of nysRI gene has led to elimination of 
nystatin production in the mutant strain. Because of operon-like organization of nysRI, nysRII, 
and nysRIII genes the polar effect of this mutation on downstream genes has to be taken into 
consideration.
In-frame deletion mutants were generated, and mutant strains SR12 ('nysRI), SR34 ('nysRII),
SR56 ('nysRIII) were analyzed for nystatin production (Table 4.2). Only 0, 5 % of the WT 
nystatin biosynthesis level was obtained in SR12. This result confirmed our previous 
conclusion on polar effect of this mutation on downstream genes. Nystatin production in SR34 
and SR56 mutants was also very low: 7 and 9% of WT strain, respectively. 
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Table 4.2. Nystatin production by the recombinant S. noursei strains with inactivated or 
overexpressed regulatory genes. 


Strain/Background

Genotype

Complementation
Nystatin
production,
%ofWT
SR12 'nysRI Ͳ 0.5
SR12 'nysRI pNRE2(ermE*P::nysRI) 59
SR34 'nysRII Ͳ 7
SR34 'nysRII pC3A1(ermE*P::nysRII) 100
SR56 'nysRIII Ͳ 9
SR56 'nysRIII pNRT3(ermE*P::nysRIII) 100
NR4K nysRIV::KmR Ͳ 2
NR4K nysRIV::KmR pNR4ES(ermE*P::nysRIVͲS) 2.5
NR4K nysRIV::KmR pNR4EL(ermE*P::nysRIVͲL) 57
ATCC11455 wildtype pSOK804 100
ATCC11455 wildtype pNRE2(ermE*P::nysRI) 104
ATCC11455 wildtype pC3A1(ermE*P::nysRII) 121
ATCC11455 wildtype pNRT3(ermE*P::nysRIII) 100
ATCC11455 wildtype pNR4EL(ermE*P::nysRIV) 136
Inactivation mutant for nysRIV gene NR4EL was obtained by insertion of the Kmr gene into 
the coding sequence of the gene. Mutant strain produced only ca. 2% nystatin of the WT level. 
As for the inactivation orf2 and orf3, no significant effect of these mutations on nystatin 
biosynthesis was observed. This result suggests that neither orf2 nor orf3 genes are directly 
involved in the regulation of nystatin production under conditions tested. 
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 From the data obtained in these experiments we can conclude that four genes, nysRI, nysRII,
nysRIII, and nysRIV, are essential for efficient nystatin biosynthesis in S. noursei, and probably 
represent transcriptional activators for the structural genes in the cluster. 
4.3.3 Complementation and cross-complementation experiments  
pSOK804, an integrative E. coli-Streptomyces shuttle vector, which is able to integrate site-
specifically into one site in the genome of S.noursei, was constructed. Five expression vectors, 
where regulatory genes were placed into pSOK804 under control of strong ermE*p promoter, 
were obtained, used for the complementation of various nysR mutants, and introduced into WT 
S.noursei. The results of experiments are shown in Table 4.2. 
According to the results obtained, nystatin biosynthesis was partially or fully restored in the 
'nysRI, 'nysRII, 'nysRIII, and 'nysRIV mutants, when the corresponding nysR genes under 
control of ermE*p promoter were introduced into the mutants. In case of introduction of the 
expression nysR vectors into WT S. noursei, we observed no effect on nystatin production with 
nysRI and nysRIII, 21% increase with nysRII, and the strongest effect was observed with 
nysRIV: 36% increase in the nystatin production compared to WT (pSOK804). 
It was interesting to understand the hierarchy among the nysR genes in terms of their 
regulation of nystatin biosynthesis. The idea of cross-complementation experiments was to 
check if regulators, expressed from a constitutive ermE*p promoter, could substitute for each 
other in the nysR mutants.  
Expressed under ermE*p promoter, nysRII, nysRIII, and nysRIV genes could restore nystatin 
production in the 'nysRI mutant to approximately same extent (Table 4.3). No cross-
complementation was observed between nysRII and nysRIII. This fact suggests that these two 
genes could be placed on the same level in hierarchy of regulatory genes. Expression of 
nysRIV restored nystatin production in all regulatory mutants, while none of the other nysR
genes could complement the 'nysRIV mutant. This indicates that nysRIV can be placed on the 
lowest level in the hierarchy, and probably directly controls the expression of structural genes 
in the nystatin biosynthetic cluster. 
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Table 4.3. Restoration of nystatin production in cross-complementation experiments with the 
regulatory mutants (see text for details). 
Nystatinproduction,%WT

Mutant
pNRE2
(ermE*p::nysRI)
pC3A1
(ermE*p::nysRII)
pNRT3
(ermE*p::nysRIII)
pNR4EL
(ermE*p::nysRIV)
SR12
'nysRI) 60 58 68 62
SR34
'nysRII) 5.4 100 5.6 77
SR56
'nysRIII) 8.5 11 98 87
NR4K
(nysRIV::KmR)
2.5 2.0 2.5 60
4.3.4 Promoter activity studies 
To obtain the deeper insight into regulatory machine of the nystatin biosynthesis, particularly 
the individual contributions of nysR genes into the process, and also their target genes, the 
promoter activity studies with regulatory mutants were performed. 
The seven putative promoter regions for regulatory and structural genes (Figure 4.6) were 
fused to the promoterless xylE reporter gene, and the reporter cassettes were cloned into the 
pSOK804 vector. The constructs were introduced into wild-type S.noursei, as well as into the 
nysR mutants, and XylE catechol dioxygenase activity assay was used to measure the 
promoters’ activities (see Paper III for the results of XylE assays).
In the wild-type background, the XylE expression was registered for all promoter-probe 
constructs.
The promoter region for the first three PKS genes  nysA, nysB and nysC is relatively strong, as 
the  level of XylE expression from nysAp appeared to be approximately 35 times higher than 
that for the three last PKS genes  nysI, nysJ, and nysK, and absolutely dependent on each of the 
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four regulators. nysA encodes the loading module for the nystatin PKS, and has the crucial role 
in the initiation of nystatin biosynthesis (Paper II). The mutations in all nysR genes had the 
most significant effect on nysAp among all other studied promoter regions, suggesting that 
initiation of nystatin biosynthesis is a primary target for the regulators. 
Figure 4.6. Promoter regions in the nystatin gene cluster used in this study (adapted from 
Sekurova et al.( 2004). 
As for the nysIp promoter region, its slightly reduced activity in all nysR mutants indicates that 
expression of these genes is less dependent on the pathway-specific regulators.
According to our results, promoters driving expression of the nysDI-nysDII-nysN, and nysDIII
genes, taking part in biosynthesis and attachment mycosamine, and C-16 methyl oxidation are 
only slightly dependent on the nysR regulators.
The promoter for the transporter genes nysH and presumably co-transcribed nysG was 
dependent on NysRI at a very low degree, while its activity was strongly suppressed in nysRII,
nysRIII and nysRIV mutants. This fact suggests that transporter genes are another (after nysAp)
important target for the three last activators. 
The promoter region upstream of the regulatory gene nysRI, nysRIp, seems to be relatively 
strong compared to the other studied promoter regions from the cluster, and stronger then 
nysAp. A complete nysRI-nysRII-nysRIII operon is presumably transcribed from the nysRIp
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promoter, and is autoregulated by NysRI and NysRII, as it is strongly dependent on both of 
these regulators. It also has some low dependence on the NysRIV and NysRIII regulators. 
As mentioned above, nysRIV has its own separate promoter nysRIVp, which provided the
highest level of XylE expression achieved with nys promoters in this study, and is regulated by 
all three other activators NysRI, NysRII, and NysRIII. Interestingly, NysRIV seems to 
moderately autoregulate its own promoter.
The efficiency of the ermE*p in S.noursei was also estimated in the control experiment. For 
this purpose, XylE activity was measured in crude cell extracts from WT strains where xylE 
was expressed from nysAp, and ermE*p promoters. It appeared, that ermE*p is stronger (ca.12 
times) than nysAp, and any other promoters in nystatin cluster.
According to the results obtained from the mutational analysis of the regulators, 
complementation and cross-complementation experiments, and XylE assay, we can conclude 
that NysRIV plays the central role in the control of nystatin biosynthesis. In nysRIV
inactivation mutant the level of nystatin production dropped dramatically, while in 
overexpression mutant we observed the most significant increase (36%) of nystatin production 
level in the wild-type strain. nysRIV can complement all nysR mutants, while none of the other 
3 regulators can complement nysRIV. From promoter probe experiment it is evident that 
nysRIVp is downregulated in all nysR mutants, and is the strongest promoter among all studied 
promoters from the cluster. The fact that even in the nysR mutants its activity is not lower than
that of nysIp and nysDIIIp, suggests that high level of nysRIV transcription is necessary to 
achieve its regulatory function in the nystatin biosynthesis. 
4.3.5 The model of the regulatory cascade for the nystatin biosynthesis in S. noursei 
As a result of our study, the following model of the regulatory cascade for nystatin 
biosynthesis in S. noursei can be suggested (Figure 4.7). 
NysRI presumably responds to some external signal and activates the transcription of the LAL 
regulatory operon. It seems that NysRII is also required for the efficient transcription from 
nysRIp, and it is logical to suggest that NysRI and NysRII function in concert to autoregulate 
the operon nysRI-nyRII-nysRIII.
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Figure 4.7. A model of the regulatory cascade controlling nystatin biosynthesis in S. noursei
ATCC11455.
The products of all three genes are presumably required to activate transcription of nysRIV.
NysRIV, in turn, seems to moderately activate its own promoter, and activates the 
transcription from promoters for the different biosynthetic and transport operons, thus directly 
controlling the nystatin biosynthesis. The structure of NysRIV, in particular the presence of 
PAS domain, suggests that transcriptional activation by NysRIV may also be dependent on 
energy levels within the cell. PAS-like domains are found in many signaling proteins, and 
serve as signal sensor domains (Galperin, 2004). PimM, a transcriptional activator of the LuxR 
type with a PAS sensory domain from pimaricin gene cluster, is an ortholog of NysRIV 
(Anton et al., 2007). Experiments on gene expression of the pimaricin gene cluster showed that 
the main targets for regulation for PimM are genes for initiation and first elongation cycles for 
polyketide biosynthesis. These results suggest that   PimM and NysRIV follow similar pattern 
in their regulatory activity. 
As mentioned above, homologs for nysRI-III regulatory genes are found in different macrolide 
antibiotic biosynthetic clusters. The analogs for all 4 nysR regulators have been found in 
amphotericin gene cluster. The organization of amphRI-RIV genes is identical to that of nysRI-
RIV (Carmody et al., 2004).
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4.4    Engineering of the nystatin biosynthesis genes to produce improved antifungal 
antibiotics (Paper IV) 
 Understanding of antibiotic biosynthesis machinery provides an opportunity for the 
development of new antibiotic analogues with improved properties through biosynthetic 
engineering. However, background knowledge on the structure-activity relationship of target 
antibiotic is often required.  
4.4.1    Engineering of specific changes in the polyol region of nystatin 
The polyol region on the polyene macrolide molecule is a promising target for obtaining a new 
antifungal compounds via genetic engineering. Recent study of Caffrey and colleagues showed 
the importance of this region for antifungal and hemolytic activity of polyene macrolides, in 
particular amphotericin B (AmB), which biosynthesis is almost identical to that of nystatin 
(Power et al., 2008). This group performed the replacement of the C-7 hydroxyl on 
amphotericin B molecule with a keto group via inactivation of a ketoreductase domain in 
module 16, and observed a significant reduction of in vitro hemolytic activity although the 
antifungal activity was also reduced.
The C-1-C-15 polyol region on nystatin molecule is interrupted by a saturated C-9-C-10 bond, 
and KR15, DH15 and ER15 domains of NysJ are involved in the formation of this bond. To 
get a better understanding of structure-activity relationship of nystatin, we performed an 
inactivation of DH15 domain of NysJ by site-specific mutagenesis. The resulting mutant was 
shown to produce a molecule 9-hydroxy-10-deoxy nystatin, denoted as BSG002. Purified 
BSG002 was found to be at least 2-fold less hemolytic compare to nystatin, but at the same 
time, its antifungal activity was reduced at approximately 4-fold.  
We have been working in parallel with a similar strategy for nystatin biosynthesis (Figure 4.8), 
and decided to replace the C-5 and C-7 hydroxyls with keto groups on the S44HP nystatin 
analogue, which was generated in our group earlier (Bruheim et al., 2004). The antifungal 
activity of the   S44HP obtained through inactivation of ER5 domain in NysC is considerably 
higher than that of nystatin and equal to that of AmB. S44HP is ca. 10 times more soluble and 
has a wider therapeutic window (MTD-LD50 dose interval) compared to AmB (Treshalin et al., 
2005).  Because of these improved properties S44HP was considered to be a good candidate 
for further genetic manipulations.  
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Figure 4.8. Genetically engineered nystatin analogues produced via manipulation of nystatin 
PKS and post-PKS modification genes (adapted from Brautaset et al. (2008).  
The KR16 and KR17 mutations were individually introduced into the S44HP-producing 
mutant in order to achieve production of 7-oxo and 5-oxo S44HP analogues, respectively.  
Polyene macrolides produced by these mutants, designated as BSG017 and BSG013, 
respectively, were purified and tested for toxicity and antifungal activity. In both cases the 
antifungal and hemolytic activities, compared to S44HP, were decreased. These data 
corresponded to those obtained for AmB with C-5 and C-7 hydroxyls substituted with keto 
groups.
4.4.2 C-16 carboxyl is important for toxicity of the nystatin and its analogues 
As was described above, S44HP, the nystatin analog with significantly increased antifungal 
activity, is an attractive candidate for further chemical modifications in order to obtain 
molecule with better pharmacological properties. Based on the data on polyene macrolides 
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with modified exocyclic carboxy group, we assumed that replacement of C-16 carboxyl by 
methyl via inactivation of nysN could reduce toxicity of S44HP. The resulting mutant 
produced expected compound 16-decarboxy-16-metyl-28, 29-didehydro nystatin, designated 
BSG005. In vitro assays showed its approx. 20-times and 2-times increased antifungal activity, 
compared to nystatin and S44HP, respectively.  Simultaneously, its hemolytic activity was 
reduced approx. 1, 5-times, compared to S44HP.  
Taking into consideration that C-5 and C-7 keto modifications in polyol region, and also C-16 
modification on nystatin molecule resulted in less toxic molecules, we attempted to combine 
these mutations on one molecule in order to obtain even less toxic analog(s). This time we 
introduced nysN mutation into BSG013-producing mutant (C-5-oxo) and BSG017-producing 
mutant (C-7-oxo). Expected analogues 5-oxo-5-deoxy-16-decarboxy-16-methyl-28, 29-
didehydro nystatin and 7-oxo-7-deoxy-16-decarboxy-16-methyl-28, 29-didehydro nystatin, 
designated BSG020 and BSG031, respectively, were produced by the mutants. Remarkably, 
production of these compounds was not reduced dramatically, which means, that it is possible 
to combine multiple mutations in one molecule, and introduce them into pathway 
simultaneously without significant reduction in the production level.
The results of the in vitro activity test and hemolytic assay revealed reduced toxicity, 
compared with S44HP, and increased antifungal activities, compared to BSG013 and BSG017, 
for both compounds. 
We could then conclude that mutations in the polyol region combined with C-16 modification 
on the S44HP background can lead to the production of compound with the better therapeutic 
properties, compared to S44HP. 
4.4.3 In vivo analysis of three engineered nystatin analogs 
Three nystatin analogs, BSG002, BSG005 and BSG020, which performed best in the in vitro 
tests, have been chosen for in vivo studies on acute toxicity and antifungal activity against 
disseminated candidosis in a mouse model.  
BSG002 was shown to have considerably decreased acute toxicity, compared to nystatin. 
However, in the experiment with animals infected with Candida albicans, BSG002 displayed 
almost complete loss of its antifungal activity. This fact suggests that the stability in vivo and 
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pharmacokinetics of new molecules determine the utility of new compounds for therapeutic 
use.
The results for BSG005 and BSG020 clearly showed that both compounds have considerably 
lower toxicity in vivo. As for the antifungal activity experiments, they correlated well with 
those obtained in the in vitro tests. BSG005 performed slightly better than AmB and S44HP, 
while BSG020 displayed a slightly reduced antifungal activity compared to other compounds. 
Remarkably, the in vivo antifungal activities for BSG005 and BSG020 were observed at doses 
which are much lower (10% of Maximal Tolerated Dose, MTD), than those for AmB and 
S44HP (40% and 94% of MTD doses, respectively).  This fact suggests that both compounds 
might have better then AmB therapeutic properties, and thus can become candidates for further 
development as new antifungal agents. 
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5. CONCLUDING REMARKS
This study is a part of detailed investigation of the nystatin biosynthetic machinery, which was 
started first as an attempt for the strain improvement in order to increase the nystatin 
production in S.noursei ATCC 11455, and ended up as an alternative approach (targeted 
genetic engineering) for generation of improved antifungal polyene macrolides. I have been 
lucky to take a part in the work with such a unique and interesting cluster from the very 
beginning, e.g. cloning and unravelling the genes functions in the biosynthesis of nystatin.
Earlier studies on the regulation of antibiotic biosynthesis in bacteria have revealed a number 
of regulators of different levels, but still the whole picture of regulation of biosynthesis for 
such a complex compounds as polyketides remains unclear. The pleiotropic regulatory locus 
from S.noursei, which is able to activate production of actinorhodin in S.lividans, has been 
identified and characterized during our initial studies on nystatin biosynthesis. ssmA gene from 
this locus was shown to regulate nystatin biosynthesis in S.noursei in carbon source-
dependent manner. Remarkably, ssmA has some homology to afsR2 (afsS in S.coelicolor), the
pleiotropic regulator from S.lividans. Recently, it was shown that afsS/afsR2 affects both 
antibiotic biosynthesis and nutrition starvation response genes in S.coelicolor (see 
Introduction). These facts correlate well with our conclusions that SsmA might be a part of a 
system sensing the carbon source, and transmitting the signal to the pathway-specific 
regulators of the nystatin biosynthetic gene cluster in S. noursei.
This work was shortly followed by the cloning and comprehensive analysis of the nystatin 
biosynthetic gene cluster. It can be mentioned that this was the first ever publication of a 
complete gene cluster for a polyene macrolide antibiotic (Brautaset et al., 2000). Later studies 
on the cluster, where I participated, were focusing on nystatin transport, synthesis and 
attachment of the mycosamine moiety, and regulation of the biosynthesis. The latter works 
have revealed a complex hierarchy among the pathway-specific regulators, regulatory targets 
within the cluster, and allowed to suggest a model for the regulation. It should be noted that it 
was the first publication on such a unique regulatory system with multiple regulatory genes 
acting in a cascade manner in the streptomycetes producing polyene macrolide antibiotics.  
Interestingly, an unexpected role of a cluster-associated gene encoding a PKS modification 
enzyme (phosphopantetheinyl transferase) was revealed. Data obtained suggested that this 
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gene is most likely involved in the biosynthesis of a signaling molecule that negatively 
regulates nystatin biosynthesis. Together, these findings provide a basis for rational 
engineering of S. noursei for the increased production of nystatin and its analogues.
Finally, the work on the nystatin cluster has culminated in biosynthetic engineering of new 
analogues with improved pharmacological properties. It is worth noting that one of these 
analogues is now being further developed in a biotech start-up company as an antifungal drug 
for treatment of systemic fungal infections. Overall, the impact of this work on the field of 
antibiotic biosynthesis and biosynthetic engineering has been considerable, and it was very 
exciting to paricipate in this project. 
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Biosynthesis of the polyene antifungal antibiotic nystatin in
Streptomyces noursei ATCC 11455: analysis of the gene cluster
and deduction of the biosynthetic pathway
Trygve Brautaset1, Olga N Sekurova1, Håvard Sletta2, Trond E Ellingsen2,
Arne R Strøm1, Svein Valla1 and Sergey B Zotchev1
Background: The polyene macrolide antibiotic nystatin produced by
Streptomyces noursei ATCC 11455 is an important antifungal agent. The
nystatin molecule contains a polyketide moiety represented by a 38-membered
macrolactone ring to which the deoxysugar mycosamine is attached. Molecular
cloning and characterization of the genes governing the nystatin biosynthesis is
of considerable interest because this information can be used for the
generation of new antifungal antibiotics. 
Results: A DNA region of 123,580 base pairs from the S. noursei ATCC
11455 genome was isolated, sequenced and shown by gene disruption to be
involved in nystatin biosynthesis. Analysis of the DNA sequence resulted in
identification of six genes encoding a modular polyketide synthase (PKS),
genes for thioesterase, deoxysugar biosynthesis, modification, transport and
regulatory proteins. One of the PKS-encoding genes, nysC, was found to
encode the largest (11,096 amino acids long) modular PKS described to date.
Analysis of the deduced gene products allowed us to propose a model for the
nystatin biosynthetic pathway in S. noursei.
Conclusions: A complete set of genes responsible for the biosynthesis of the
antifungal polyene antibiotic nystatin in S. noursei ATCC 11455 has been
cloned and analyzed. This represents the first example of the complete DNA
sequence analysis of a polyene antibiotic biosynthetic gene cluster.
Manipulation of the genes identified within the cluster may potentially lead
to the generation of novel polyketides and yield improvements in the
production strains.
Introduction
Polyketides are natural products, many of which have
applied potential as pharmaceuticals. Examples of such
polyketides include erythromycin (antibacterial), nys-
tatin (antifungal), avermectin (antiparasitic), rapamycin
(immunosuppressant) and daunorubicin (antitumor).
The Gram-positive bacteria of the genus Streptomyces are
the main producers of polyketides, and the genetics and
biochemistry of polyketide biosynthesis in these organ-
isms are relatively well characterized [1]. Macrolide
polyketide compounds are formed via repeated conden-
sations of simple carboxylic acids by modular (type I)
polyketide synthases (PKSs) in a manner similar to fatty
acid biosynthesis. The modular hypothesis proposed by
Donadio et al. [2] suggested that type I PKSs are orga-
nized into repeated units (modules), each of which is
responsible for one condensation cycle in the synthesis
of a polyketide chain. This was proven to be correct by
manipulations of type I PKS genes resulting in pre-
dictable changes in the chemical structures of macrolides
[3]. Besides condensation of the next carboxylic acid onto
the growing polyketide chain, ensured by the catalytic
activity of a β-ketoacyl synthase (KS) domain, modules of
PKSs type I may contain domains with β-ketoreductase
(KR), dehydratase (DH), and enoyl reductase (ER) activi-
ties, which determine the reduced state of the incorpo-
rated extender unit. The acyltransferase (AT) and acyl
carrier protein (ACP) domains present in each module are
responsible for the choice of extender unit and retention
of the growing polyketide chain on the PKS, respectively.
Upon completion of synthesis, the polyketide chain is
released from the  PKS via the action of a thioesterase
(TE), which is probably also involved in cyclization of the
final product. The type I PKSs therefore represent an
assembly line for polyketide biosynthesis that can be
manipulated by changing the number of modules, their
specificities towards carboxylic acids, or by inactivating or
inserting domains with reductive activities [3]. After the
polyketide moiety is synthesized and cyclized to form a
macrolactone ring, it is usually modified via hydroxylation,
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glycosylation, methylation and/or acylation. These modifi-
cations are believed to be crucially important for the bio-
logical activities of macrolides. 
The genes for macrolide antibiotics biosynthesis in Strep-
tomyces are organized in clusters, making isolation of com-
plete sets of such genes relatively straightforward. Indeed,
exploitation of recombinant DNA technology makes it
possible to isolate complete antibiotic biosynthetic gene
clusters by screening gene libraries with DNA probes
encoding PKS fragments [1]. The molecular cloning and
complete DNA sequencing has been described for several
macrolide antibiotics produced by streptomycetes, includ-
ing those for avermectin, pikromycin and rapamycin [4–6].
The cloning and partial DNA sequencing of the gene
cluster for the polyene macrolide antibiotic pimaricin has
recently been reported [7].
Polyene macrolide antibiotics have 20–44-membered
lactone rings containing three to eight conjugated double
bonds. The latter structural feature most probably con-
tributes to the mode of action of these compounds, deter-
mined to be an interaction with sterols present in the
membranes of fungi [8]. Such an interaction leads to for-
mation of polyene–sterol complexes capable of organizing
themselves into transmembrane channels making the
membrane permeable to water and ions, leading to cell
death. Beside being antifungal agents, some of the
polyene antibiotics have been shown to have antibacterial,
antiviral and immunostimulating activities [9,10]. The
antibiotic nystatin A1 (Figure 1) is produced by the Gram-
positive bacterium Streptomyces noursei ATCC 11455, and
is used as an antifungal agent. The chemical structure of
nystatin suggests involvement of a type I PKS in the
biosynthesis of its macrolactone ring. Furthermore, it can
be predicted that the synthesis of the nystatin polyketide
chain starts with acetyl-CoA, and proceeds through con-
densation of three methylmalonyl-CoA and 15 malonyl-
CoA extender units. In this paper we describe the cloning
and analysis of the complete nystatin biosynthetic gene
cluster of S. noursei.
Results and discussion
Cloning of the nystatin biosynthetic gene cluster
In order to isolate the nystatin biosynthesis genes, we
probed a S. noursei gene library with labelled DNA encod-
ing a PKS. To obtain such a DNA probe, two degenerate
oligonucleotide primers were designed, corresponding to
conserved amino acid regions within KS and ACP domains
of known modular PKSs (see the Materials and methods
section). The polymerase chain reaction (PCR)-assisted
amplification of a DNA fragment from the S. noursei
genome with these primers was performed. Subsequent
cloning and DNA sequence analysis of the resulting
0.7 kb PCR product (see the Materials and methods
section) confirmed that it encodes part of a type I PKS.
This DNA fragment was used for screening the S. noursei
gene library constructed previously [11], and one recombi-
nant phage, designated DASHII-N1, which hybridized to
the probe, was isolated. 
Preliminary DNA sequence analysis of the N1 DNA
insert showed that it encodes a type I PKS. To confirm
the involvement of the cloned DNA in nystatin biosyn-
thesis, a 4.2 kb BamHI DNA fragment from the N1 insert
was used in a gene-disruption experiment as a part of the
suicide conjugative plasmid pKO(4.2)–1 (Table 1). One of
the resulting S. noursei disruption mutants, NCD3, carry-
ing pKO(4.2)–1 integrated into its genome (data not
shown) was unable to produce nystatin, thereby confirm-
ing the requirement of the identified PKS gene for nys-
tatin biosynthesis. This fragment was later shown to be an
internal part of the nysC gene (see below).
In order to clone a larger portion of the nystatin biosyn-
thetic gene cluster, the DNA fragments derived from the
ends of the DNA insert in phage N1, as well as those frag-
ments from overlapping recombinant phages, were used as
probes for screening the gene library. This ‘chromosome
walking’ resulted in isolation of recombinant phages
encompassing ~125 kb of the S. noursei genome (Figure 2).
DNA sequence and mutational analyses of the nystatin
PKS genes 
The complete DNA inserts from recombinant phages
were subcloned in Escherichia coli and sequenced. Com-
puter-assisted analysis of the DNA sequence (123,580 bp)
of the cloned region led to identification of the genes
shown in Figure 2 and listed in Table 2. Six genes, nysA,
nysB, nysC, nysI, nysJ and nysK, encoding a type I PKS were
identified. The amino acid (aa) sequences of the deduced
products encoded by these genes were analysed by com-
paring them to the aa sequences of known type I PKSs.
Because all six proteins were shown to share considerable
homology with rifamycin and rapamycin PKSs [12,13],
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Figure 1
Structure of the nystatin A1 molecule according to Lancelin and
Beau [36].
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presumptive functional analysis of the nystatin PKSs was
based on the comparison to the former polypeptides. The
predicted functional features of the NysA, NysB, NysC,
NysI, NysJ and NysK proteins are shown in Figure 3. 
The NysA protein most probably represents a loading
module involved in the initiation of the nystatin aglycone
biosynthesis. NysA contains a KS domain (KSS) similar to
that found in the presumed loading module of the
pimaricin PKS PIMS0 [7]. Both the NysA and PIMS0 pro-
teins are unusual in a sense that they represent the loading
modules only, whereas in all other type I PKSs character-
ized so far, loading modules are fused to the first condens-
ing module in multimodular polypeptides. The conserved
active-site cysteine residue in both NysA and PIMS0 KS
domains is replaced with a serine residue. In all the other
known inactive KSs (KSQ) in the loading modules of
type I PKSs, the conserved cysteine is replaced by gluta-
mine [14], except for the epothilone PKS loading module
KS, which bears a Cys→Tyr replacement [15]. Because
the aa sequence homology between the KSS domains in
NysA and PIMS0 (62.8%) is not higher than between the
NysA KSS and KS domains from other modular PKSs
(ranging from 49.9% to 64.6%), it seems unlikely that
these proteins have a recent common ancestor. It is tempt-
ing to speculate that the Cys→Ser replacement in the
active sites of KSS domains might have some significance
for NysA and PIMS0 functioning as separate loading
polypeptides. The latter might be related to the decar-
boxylase activity shown for the KSQ domains to be largely
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Table 1
Bacterial strains and plasmids used in this study.
Strain or plasmid Properties Source or reference
E. coli XL-1 Blue MRA(P2) Host for maintaining the gene library Stratagene
E. coli DH5α General cloning host BRL 
E. coli ET12567 Strain for intergeneric conjugation [37]
S. noursei ATCC 11455 Wild type (WT), nystatin producer ATCC
S. noursei NAD1 WT derivative with nysA disrupted by integration of pKNA1, nystatin nonproducer This work
S. noursei NBD2 WT derivative with nysB disrupted by integration of pKNB1, nystatin nonproducer This work
S. noursei NCD3 WT derivative with nysC disrupted by integration of pKO(4.2)–1, nystatin nonproducer This work
S. noursei NID1 WT derivative with nysI disrupted by integration of pKNI1, nystatin nonproducer This work
S. noursei NJD1 WT derivative with nysJ disrupted by integration of pKNJ1, nystatin nonproducer This work
S. noursei NRD2 WT derivative with nysRI disrupted by integration of pNRD2, nystatin nonproducer This work
pGEM3Zf(–) ColEI replicon, ApR, 3.2 kb Promega
pGEM11Zf(–) ColEI replicon, ApR, 3.2 kb Promega
pUZ8002 RK2 derivative, KmR, TcR D.H. Figurski*
pSOK201 pSG5 and ColEI replicons, oriT and AmR, 7.1 kb [11]
pPKS72 0.7 kb PCR product amplified from the S. noursei genome cloned in pUC18 This work
(see the Materials and methods section)
pL76S1.3 1.4 kb SalI fragment of nysA cloned in pGEM3Zf(–) This work
pKNA1 1.4 kb EcoRI–HindIII fragment from pL76S1.3 ligated with This work
the 3.0 kb EcoRI–HindIII fragment from pSOK201
pL76NB2.8 2.8 kb NotI–BamHI fragment of nysB cloned in pGEM11Zf(–) This work
pKNB1 2.8 kb BamHI–HindIII fragment from pL76NB2.8 ligated This work
with the 3.0 kb BamHI–HindIII fragment from pSOK201
pL64EB3.8 3.8 kb BamHI–EcoRI fragment from N64 (internal for nysI) cloned in pGEM3Zf(–) This work
pKNI1 3.8 kb EcoRI–HindIII fragment from pL64EB3.8 ligated This work
with the 3.0 kb BamHI–HindIII fragment from pSOK201
pL20EB3.7 3.7 kb BamHI–EcoRI fragment from N20 (internal for nysJ) cloned in pGEM3Zf(–) This work
pKNJ1 3.7 kb EcoRI–HindIII fragment from pL20EB3.7 ligated This work
with the 3.0 kb BamHI–HindIII fragment from pSOK201
pGEM4.2–1 4.2 kb BamHI fragment of nysC cloned in pGEM11Zf(–) This work
pKO(4.2)–1 4.2 kb EcoRI–HindIII fragment from pGEM4.2-1 ligated This work
with the 3.0 kb EcoRI–HindIII fragment from pSOK201
pNRD1 1.4 kb ApaI fragment of nysRI cloned in pGEM11Zf(–) This work
pNRD2 1.4 kb EcoRI–HindIII fragment from pNRD1 ligated with This work
the 3.0 kb EcoRI–HindIII fragment from pSOK201
Am, apramycin; Ap, ampicillin; Km, kanamycin; Tc, tetracycline. *Personal communication.
dependent on the presence of a glutamine residue in the
active site [14]. It has been suggested that KSQ domains in
the loading modules of modular PKSs might provide the
starter unit through the specific decarboxylation of
enzyme-bound extenders [14]. Because the significance of
the serine residue in the active sites of KSS domains for
their putative decarboxylase activity is not apparent, we
are planning to address this question experimentally.
Comparison of the NysA AT domain with its counterparts
from different PKSs suggested that it is acetate specific,
which correlates well with the structure of the nystatin
molecule. Interestingly, NysA contains an apparently
intact DH domain, which seems to serve no function, and
might just have been retained in this protein in the
process of evolution.
NysB apparently represents modules 1 and 2. The DH
domains in both of these modules lack the conserved
active-site motif H(X3)G(X4)P, due to large internal dele-
tions, and therefore must be inactive. The AT domains
identified within NysB display characteristic features of
the propionate-specific AT domains (mAT) [13,16].
These features of NysB support the assumption about its
involvement in first two elongation steps of the nystatin
polyketide moiety biosynthesis. 
The NysC protein, to our knowledge the largest bacterial
polypeptide discovered to date, is composed of six
modules apparently responsible for elongation steps 3–8 in
the nystatin polyketide chain formation. All AT domains in
NysC modules have features typical of the acetate-specific
ATs (data not shown). This correlates well with the
assumption that NysC incorporates six malonyl-CoA
extenders (C-32 to C-21) into the nystatin aglycone. The
only other protein with an organization similar to NysC,
the RAPS2 PKS of S. hygroscopicus, comprising six modules
and involved in rapamycin biosynthesis, is 873 aa shorter
than NysC. This difference can be explained by the more
compact structure of the RAPS2 domains and interdomain
linkers, because the overall number of modules and
domains, as well as their relevant positions in NysC and
RAPS2 match perfectly. The end-to-end alignment of the
NysC and RAPS2 aa sequences shows 49% identity — an
unusually high number considering the lengths of these
polypeptides. This, and the fact that rapamycin has an
antifungal activity and initially was classified as an atypical
polyene macrolide [17], might indicate that similarities
between NysC and RAPS2 are due to a common ancestor
from which the two proteins have evolved. 
The NysI protein is probably responsible for elongation
steps 9–14 of the nystatin polyketide backbone biosyn-
thesis. The presence of an mAT domain in module 11 is
consistent with incorporation of methylmalonyl-CoA
extender at this elongation step. The DH domains in
modules 10, 11, 12, 13 and 14 seem to be inactive due the
large internal deletions encompassing the active-site
motif (see above). The KR domain in module 13 of NysI
lacks the conserved motif aSRrG, and thus appears to be
inactive. The latter feature, together with inactive DH
domain in module 11, most probably account for the pres-
ence of a six-membered ketalic ring (between C-13 and
C-17) on the nystatin molecule (Figure 1). As judged from
the organization of modules in NysJ, the latter is required
for elongation steps 15–17 in nystatin macrolactone ring
assembly. The DH domain in module 16 contains a large
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Gene organization within the S. noursei ATCC 11455 nystatin
biosynthetic gene cluster. The inserts from the overlapping
recombinant phages encompassing the cloned region are shown
above the physical/genetic map. The nys genes are designated with
capital letters in italics, other ORFs are numbered. Stars above certain
ORFs indicate that these genes were successfully disrupted (see the
text and Table 1 for details).
internal deletion encompassing the active site, and the
conserved histidine residue in the module 17 DH
domain active site H(X3)G(X4)P is replaced with tyro-
sine. The DH domains in modules 16 and 17 within
NysJ therefore appear to be inactive. The ER domain
localized in module 15 is probably responsible for the
reduction of a double bond between C-8 and C-9. The
final 18th module in the nystatin PKS system is repre-
sented by the NysK protein, which contains an appar-
ently intact DH domain whose activity should not be
required at the last condensation step. We note that a
similar observation was made during analysis of the
rifamycin PKS, in which intact DH domains in modules
6 and 7 seem to be nonfunctional in the producing organ-
ism [13]. A TE domain was identified at the carboxyl ter-
minus of NysK, suggesting that in addition to the
condensation of the last extender unit, this protein also
participates in the release of the mature nystatin poly-
ketide chain from the PKS complex.
To confirm the involvement of nysA, nysB, nysI and nysJ
in nystatin biosynthesis, these genes were disrupted in
S. noursei via homologous recombination using the con-
jugative suicide vectors pKNA1, pKNB1, pKNI1, and
pKNJ1 (Table 1). All the disruption mutants obtained
(Table 1) were unable to produce nystatin, suggesting
that the genes mentioned above are essential for nystatin
biosynthesis. Even though the polar effects of the dis-
ruptions mentioned above cannot be ruled out, such
effects would imply that the genes affected are tran-
scribed as part of a polycistronic mRNA together with
the disrupted genes (see Figure 2). It seems highly
unlikely, therefore, that the disrupted genes themselves
have no role in nystatin biosynthesis. 
Immediately downstream of the nysC gene, a coding
sequence (nysE) for a TE was identified, providing yet
another example of two TE activities being localized in
the same antibiotic biosynthetic gene cluster. The 251 aa
NysE protein shows a high degree of homology (45%) to
the TEs encoded by the independent genes in the
pikromycin and tylosin biosynthetic gene clusters of Strep-
tomyces venezuelae and Streptomyces fradiae [6,17]. The NysE
polypeptide, however, does not display substantial homol-
ogy to the TE domains located at the carboxyl termini of
several modular PKSs. The precise role for the putative
TE encoded by nysE in nystatin biosynthesis remains
uncertain. Both the pikromycin and tylosin biosynthetic
gene clusters encode two TE activities, one of them
embedded in the PKS [6,18]. Although the exact func-
tions of these TEs are not clear, it was proposed that one
of them might be a ‘proof-reading’ enzyme, clearing off
certain substrates that would block further extension of
the chain by PKS [19,20]. 
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Table 2
Putative genes identified in the nystatin biosynthetic gene cluster of S. noursei.
Designation Product Putative function
nysA Type I PKS Nystatin PKS (loading module)
nysB Type I PKS Nystatin PKS (modules 1 and 2)
nysC Type I PKS Nystatin PKS (modules 3–8)
nysDI Glycosyltransferase Attachment of mycosamine 
nysDII Aminotransferase Mycosamine biosynthesis
nysDIII GDP-mannose-4,6-dehydratase Mycosamine biosynthesis
nysE Thioesterase Release of polyketide chain from PKS
nysF 4′-Phosphopantheteine transferase Post-translational PKS modification
nysG ABC transporter Efflux of nystatin
nysH ABC transporter Efflux of nystatin
nysI Type I PKS Nystatin PKS (modules 9–14)
nysJ Type I PKS Nystatin PKS (modules 15–17)
nysK Type I PKS Nystatin PKS (module 18 + TE)
nysL P450 monooxygenase Hydroxylation at C-10
nysM Ferredoxin Electron transfer in P450 system
nysN P450 monooxygenase Oxidation of methyl group at C-16
nysRI Transcriptional  activator Regulation of nystatin production
nysRII Transcriptional  activator Regulation of nystatin production
nysRIII Transcriptional  activator Regulation of nystatin production
ORF4 Transcriptional  activator Regulation
ORF3 Transcriptional  repressor Regulation
ORF2 Transcriptional  activator Regulation
Genes in the regulatory region 
The putative regulatory genes nysRI, nysRII and nysRIII
encoding polypeptides of 966 aa, 953 aa and 927 aa,
respectively, were identified downstream of nysE. The
deduced products of these genes are homologous to the
transcriptional regulators found in the vicinity of the
cholesterol oxidase–cytochrome P450 operon of Strepto-
myces sp. SA-COO [21]. To confirm the involvement of
nysRI in nystatin biosynthesis, this gene was disrupted in
S. noursei with the suicide vector pNRD2 (Table 1).
Analysis of the secondary metabolites produced by the
corresponding mutant NRD2 revealed that it cannot
synthesize nystatin. Because the nysRII and nysRIII
genes are located just downstream of nysRI, and are tran-
scribed in the same direction, it is plausible that the
nysRI disruption has a polar effect on transcription of
these genes. 
Downstream of nysRIII, three ORFs (ORFs 2–4) were
identified that might be involved in the regulation of
nystatin biosynthesis. The deduced ORF4 product of
210 aa is similar to the transcriptional activators of
response regulator type, whereas a 253 aa polypeptide
encoded by ORF3 shows considerable homology to the
transcriptional repressors of the DeoR family [22]. ORF2,
located downstream of ORF3, and transcribed in the
opposite direction, encodes a putative polypeptide of
354 aa that is similar to the transcriptional activators of
the AsnC family [23]. Experiments aimed at mutational
analysis of all the regulatory genes associated with the
gene cluster are currently under way, and will provide
the answer as to their involvement in the process of nys-
tatin biosynthesis. 
Sequencing of an additional 5 kb DNA from the phage
N69 insert extending the cloned region to the right from
ORF2 (data not shown) identified several genes
for peptide metabolism (T.B. and S.B.Z., unpublished
observations) for which no role in nystatin biosynthesis
could be assigned. This observation suggests that the
right border of the nystatin biosynthetic gene cluster has
been identified. 
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Figure 3
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Functional organization of the nystatin PKS including the NysA, NysB,
NysC, NysI, NysJ and NysK proteins. KS, ketosynthase;
KSS, ketosynthase with the Cys→Ser substitution in the active site;
AT, acetate-specific acyltransferase; mAT, propionate-specific
acetyltransferase; DH, dehydratase; DHi, inactive dehydratase;
ER, enoyl reductase; KR, ketoreductase; KRi, inactive ketoreductase;
ACP, acyl carrier protein.
Putative mycosamine biosynthesis genes 
Three genes presumably involved in biosynthesis and
attachment of the mycosamine moiety were found in the
cluster (Figure 2; Table 2). The 506 aa-long nysDI
product shows considerable homology to the eukaryotic
UDP-glucuronosyltransferases. The latter enzyme
belongs to the UDP-glycosyltransferase family, and is
involved in eliminating potentially toxic xenobiotics by
the way of their glycosylation [24]. It seems likely that
NysDI represents a glycosyltransferase responsible for
the attachment of the deoxysugar moiety (mycosamine)
to the nystatin aglycone at C-19. The deduced product of
nysDII (352 aa) is highly similar to perosamine syn-
thetases from different bacteria. The latter enzyme cat-
alyzes conversion of GDP-4-keto-6-deoxy-D-mannose to
4-NH2-4,6-dideoxy-D-mannose in the biosynthesis of per-
osamine, which constitutes the backbone structural unit
of the lipopolysaccharide O-antigens in pathogenic bacte-
ria [25]. Because the nystatin deoxysugar moiety
mycosamine contains an amino group, it is plausible that
NysDII represents an aminotransferase involved in
mycosamine biosynthesis. The nysDIII gene encodes a
344 aa protein similar to GDP-mannose-4,6-dehydratases,
and is therefore probably responsible for one of the initial
steps in mycosamine biosynthesis. The fact that NysDIII
more closely resembles the GDP-mannose-4,6-dehy-
dratases than the TDP-glucose-4,6-dehydratases (Gdh)
suggests that the mycosamine biosynthetic pathway in
S. noursei differs from those of other antibiotics’ deoxy-
sugar moieties. This would also explain why our initial
attempt to identify the nystatin gene cluster using a Gdh-
specific DNA probe failed [11]. The presence of only two
deoxysugar biosynthesis genes in the cluster might be
explained by the key roles played by the corresponding
enzymes in mycosamine biosynthesis. All other enzymes
required for this deoxysugar formation can, in principle, be
recruited from different (i.e. primary) metabolic pathways. 
Modification and transport genes
Three genes encoding proteins presumably involved in
modification of the nystatin molecule were identified
between nysK and nysDII (Figure 2). Both the nysL and
nysN genes encode P450 monooxygenases of 394 aa and
398 aa, respectively, that are probably responsible for
hydroxylation of the nystatin polyketide moiety at C-10,
and oxidation of the methyl group at C-16. Which protein
is responsible for which reaction is not clear at the
moment, and additional experiments are required for
exact placement of NysL and NysN in the nystatin
biosynthetic pathway. The nysM gene apparently encodes
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Proposed model for nystatin biosynthesis in S. noursei.
a ferredoxin of 64 aa, which presumably constitutes a part
of one or both P450 monooxygenase systems, and serves
as an electron donor [26].
The nysH and nysG genes localized upstream of nysDIII
encode 584 aa and 605 aa polypeptides, respectively. Both
NysH and NysG display high degrees of similarity to
transporters of the ABC family [27], and thus might be
involved in ATP-dependent efflux of nystatin.
Downstream of nysG, a putative nysF gene was identified
whose 245 aa product is homologous to the 4′-phospho-
pantheteine transferases. The latter enzyme carries out
the post-translational modification of the ACP domains on
the PKSs, which is required for their full functionality
[28]. It seems likely, therefore, that the NysF protein
functions in modification of the nystatin PKS and is
important for the nystatin biosynthesis. DNA sequencing
and analysis of the insert in phage N90, which extends the
characterized region by ~10 kb to the left of nysF, identi-
fied genes for signal peptidase, and other proteins with no
possible role in nystatin biosynthesis (T.B. and S.B.Z.,
unpublished observations). The putative nysF gene there-
fore marks the left border of the nystatin biosynthetic
gene cluster in S. noursei. 
Proposed model for the nystatin biosynthetic pathway of
S. noursei 
Based on the information derived from the analysis of the
genes found in the nystatin biosynthetic gene cluster we
propose a model for synthesis of this antibiotic in the pro-
ducing organism S. noursei (Figure 4). The synthesis starts
with loading of the acetyl-CoA onto the NysA protein, and
proceeds through condensation of three methylmalonyl-
CoA and 15 malonyl-CoA extender units by NysB, NysC,
NysI, NysJ and NysK PKS. After cleavage of the mature
polyketide chain from the PKS complex by the TE domain
of NysK, the chain is cyclized to form the nystatin agly-
cone. The next two steps in the nystatin biosynthesis are
probably accomplished by the NysL and NysN monooxy-
genases, which perform hydroxylation and oxidation of the
macrolactone ring at C-10 and C-16, respectively. 
Biosynthesis of mycosamine presumably starts with
the L-fructose-6-phosphate, which is converted to
GDP-D-mannose through the action of a phosphomannoi-
somerase, phosphomannomutase, and a GDP–mannose
pyrophosphorylase. These enzymes are involved in
primary metabolic pathways for cell-surface lipopolysac-
charide biosynthesis in many bacteria [25], and the genes
for the two former have been located on the chromosome
of S. coelicolor A3(2) during the genome sequencing effort.
It seems likely, therefore, that there is interplay between
the primary and secondary metabolisms in S. noursei
during mycosamine biosynthesis, although it is not appar-
ent how the regulation of such genes is coordinated. The
GDP-D-mannose probably serves as a substrate for the
NysDIII protein, which converts it to the GDP-4-keto-6-
deoxy-D-mannose. A GDP-3-keto-6-deoxy-D-mannose
isomerase must perform the next step in mycosamine
biosynthesis, probably followed by the NysDII-mediated
amidation leading to formation of GDP-mycosamine. The
NysDI protein, a putative glycosyltransferase, presumably
completes the pathway by attaching the mycosamine
moiety to the modified nystatin aglycone.
The model presented above is based on the assumption
that both monooxygenases modify the nystatin macrolac-
tone ring prior to its glycosylation. Whether this is true will
be verified by the ongoing experiments on inactivation of
the nysL and nysN genes, and structural analysis of the nys-
tatin derivatives produced by the corresponding mutants. 
Significance
Analysis of the Streptomyces noursei nystatin biosyn-
thetic gene cluster carried out in this study provides useful
information with regard to the genes governing synthesis
of this important antifungal agent. Functional assign-
ments for the proteins encoded within the cluster suggest
a model for the nystatin biosynthetic pathway, and open
possibilities for genetic manipulations with the aim of pro-
ducing novel nystatin derivatives. Identification of several
putative regulatory genes associated with the cluster,
along with data on inactivation of one potential regulator,
imply that they can be used for enhancing the yield of nys-
tatin (and probably its derivatives) in fermentations. 
Materials and methods 
Bacterial strains, plasmids and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 1.
S. noursei ATCC 11455 and its mutants were grown on solid ISP2
medium (Difco), and in liquid TSB medium (Oxoid). Intergeneric conju-
gation from E. coli ET12567 (pUZ8002) into Streptomyces strains was
done as reported elsewhere [29], but with the ‘heat shock’ time
reduced to 5 min. E. coli strains were grown and transformed as
described by others [30], except for E. coli ET12567 (pUZ8002),
which was maintained on media with 20 μg/ml chloramphenicol and 50
μg/ml kanamycin. Analysis of the nystatin production by S. noursei
strains was performed in SAO-23 liquid medium [31]. 
DNA manipulations
Plasmid, phage and total DNA preparations, endonuclease digestions
and ligations were performed as described previously [30,32]. DNA
fragments were isolated from agarose gels using the QIAGEN Kit
(QIAGEN GmbH, Germany), labelled with the use of the digoxygenin
kit from Boehringer Mannheim, and used for Southern blot analysis
according to the manufacturer’s instructions. Genotypes of all disrup-
tion mutants obtained in the course of this study (Table 1) were verified
by Southern blot analysis (data not shown). DNA sequencing was per-
formed at QIAGEN GmbH, and the data were analyzed with the Frame-
Plot 2.3 online program [33] and GCG software [34]. 
Amplification of a PKS-encoding DNA fragment used for
screening of the S. noursei gene library
Degenerate primers used for amplification of a PKS-encoding DNA
fragment corresponded to the conserved aa motifs in ACP and KS
domains in known type I PKSs, and were designed according to the
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codon usage table for Streptomyces [35]. The ACP oligonucleotide
primer (sense) had the sequence 5′-GAG/C CTG/C GGC/G T/CTG/C
GAC TCC/G CTG/C-3′, and the KS oligonucleotide primer (antisense)
had the sequence 5′-G/CGA G/CGA G/ACA G/CGC C/GGT GTC
G/CAC-3′. The 50 μl PCR mixture contained: 0.1 μg S. noursei ATCC
11455 genomic DNA, 25 pm each ACP and KS oligonucleotide
primers, dNTPs (final concentration 350 μm), 1× PCR buffer from
Expand High Fidelity PCR System (Boehringer Mannheim), and 1.5 U
of the DNA polymerase mixture from the same system. The PCR was
performed on the Perkin Elmer GeneAmp PCR System 2400 with the
following program: 1 cycle of denaturation at 96°C (4 min), 35 cycles of
denaturation/annealing/synthesis at 94°C (45 s) and 70°C (5 min), and
1 cycle of final annealing/extension at 72°C (7 min). The 0.7 kb DNA
fragment obtained with this procedure was cloned in pUC18 with the
use of SureClone Ligation Kit (Pharmacia). One of the resulting recom-
binant plasmids, pPKS72, was subjected to DNA sequence analysis,
and later used for primary screening of the S. noursei gene library. 
Accession numbers
The DNA sequence reported here was deposited in GenBank under
the accession number AF263912.
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In Vivo Analysis of the Regulatory Genes in the Nystatin Biosynthetic
Gene Cluster of Streptomyces noursei ATCC 11455 Reveals Their
Differential Control Over Antibiotic Biosynthesis
Olga N. Sekurova,1 Trygve Brautaset,1 Ha˚vard Sletta,2 Sven E. F. Borgos,1 Øyvind M. Jakobsen,1
Trond E. Ellingsen,2 Arne R. Strøm,1 Svein Valla,1 and Sergey B. Zotchev1*
Department of Biotechnology, Norwegian University of Science and Technology, N-7491 Trondheim,1 and
SINTEF Industrial Biotechnology, SINTEF, N-7034 Trondheim,2 Norway
Received 10 September 2003/Accepted 21 November 2003
Six putative regulatory genes are located at the ﬂank of the nystatin biosynthetic gene cluster in Streptomyces
noursei ATCC 11455. Gene inactivation and complementation experiments revealed that nysRI, nysRII, nysRIII,
and nysRIV are necessary for efﬁcient nystatin production, whereas no signiﬁcant roles could be demonstrated
for the other two regulatory genes. To determine the in vivo targets for the NysR regulators, chromosomal
integration vectors with the xylE reporter gene under the control of seven putative promoter regions upstream
of the nystatin structural and regulatory genes were constructed. Expression analyses of the resulting vectors
in the S. noursei wild-type strain and regulatory mutants revealed that the four regulators differentially affect
certain promoters. According to these analyses, genes responsible for initiation of nystatin biosynthesis and
antibiotic transport were the major targets for regulation. Data from cross-complementation experiments
showed that nysR genes could in some cases substitute for each other, suggesting a functional hierarchy of the
regulators and implying a cascade-like mechanism of regulation of nystatin biosynthesis.
Antibiotic production by Streptomyces bacteria has received
much attention in recent years due to the problems associated
with a constantly increasing incidence of multiresistant micro-
bial pathogens. Considerable efforts are directed toward un-
derstanding the antibiotic biosynthetic pathways in Streptomy-
ces spp. and manipulating the corresponding gene clusters in
order to produce novel compounds with improved properties
(17). In addition, remarkable progress is being made in dis-
secting the functions of the genes that regulate antibiotic pro-
duction in streptomycetes (11). Coupling these two ﬁelds of
research is of great importance both for a fundamental under-
standing of the antibiotic biosynthesis processes and for the
rational engineering of novel antibiotic producers.
Biosynthesis of secondary metabolites, and in particular an-
tibiotics, by Streptomyces bacteria is a complex process involv-
ing several levels of regulation. Many pleiotropic regulatory
genes have been isolated from streptomycetes; in most cases,
these genes affect antibiotic biosynthesis by inﬂuencing the
expression of the pathway-speciﬁc regulatory genes (reviewed
in reference 11). The latter genes are usually found physically
linked to the structural antibiotic biosynthesis genes on the
chromosomes of streptomycetes. Both positive and negative
regulators directly affecting the expression of structural genes
via binding to their promoter regions have been identiﬁed in
antibiotic biosynthetic gene clusters. In some cases, it has been
shown that expression of the pathway-speciﬁc regulatory genes
is controlled by signaling molecules, such as A-factor, through
the action of other regulators encoded by genes located out-
side of the biosynthetic gene clusters (22). Since antibiotic
biosynthesis in Streptomyces spp. is linked to the process of cell
differentiation (10), it is likely that expression of most of the
pathway-speciﬁc regulators depends on some sort of signal
transmitted via a complex network. Analysis of the regulatory
genes in the antibiotic biosynthetic gene clusters is crucial for
understanding the mechanisms of regulation, as well as for
designing strategies for the construction of strains with en-
hanced antibiotic production.
Most of the detailed analyses of pathway-speciﬁc regulators
described in the literature are concerned with the biosynthesis
of nonmacrolide antibiotics such as actinorhodin, undecylpro-
digiosin, and daunorubicin (1, 32, 39). However, several studies
where regulatory genes for macrolide antibiotic biosynthesis
were analyzed have also been reported. At least some of these
regulators must be rather special, since they control the ex-
pression of very large polyketide synthase (PKS)-encoding
genes, which implies synthesis of unusually long mRNAs. The
transcriptional activator SrmR encoded within the spiramycin
biosynthetic gene cluster of Streptomyces ambofaciens has been
shown to be required for the transcription of at least one of the
PKS genes involved in assembly of the spiramycin macrolac-
tone ring (14). The acyB2-encoded regulator of Streptomyces
thermotolerans has been shown to activate the expression of the
acyltransferase gene involved in biosynthesis of the macrolide
antibiotic carbomycin (2). Five regulatory genes associated
with the tylosin biosynthetic gene cluster of Streptomyces fra-
diae have been found (3). Gene inactivation experiments have
conﬁrmed differential roles for two regulators of the SARP
(Streptomyces antibiotic regulatory protein) family, TylS and
TylT, in controlling tylosin production (4). TylS was shown to
control the expression of a global regulator (TylR) for the
tylosin cluster, while TylT appeared not to be essential for
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antibiotic biosynthesis. In a separate report, the transcriptional
repressor TylQ was found to play a central role in controlling
tylosin biosynthesis in S. fradiae (31).
A detailed genetic analysis of PikD, the positive regulator
for the pikromycin biosynthetic gene cluster in Streptomyces
venezuelae, has recently been reported (40). PikD belongs to a
LAL family of transcriptional regulators containing nucleotide
triphosphate (NTP) binding motifs and a C-terminally located
helix-turn-helix (HTH) motif of the LuxR type (12). Presum-
ably, these functional features are responsible for the ability of
LAL regulators to bind DNA and activate the transcription of
target genes upon NTP hydrolysis. It was shown that PikD is
required for pikromycin biosynthesis, and the ability of this
protein to act as a transcriptional activator depends on the
presence of functional NTP binding motifs.
The polyene macrolide antibiotic nystatin produced by
Streptomyces noursei ATCC 11455 is widely used in treatments
of fungal infections. Brautaset et al. have previously cloned and
sequenced the entire nystatin biosynthetic gene cluster and
located six putative regulatory genes within its ﬂanking region
(7). In the present work, we describe a comprehensive in vivo
analysis of these genes by means of their inactivation in S.
noursei, determination of targets by use of the xylE reporter
system, and cross-complementation experiments.
MATERIALS AND METHODS
Bacterial strains, media, and growth conditions. Bacterial strains, plasmids,
and recombinant phages used in this study are listed in Table 1. Some of the
plasmids are described below. S. noursei strains were maintained on ISP2 agar
medium (Difco, Detroit, Mich.) and grown in liquid Trypticase soy broth (TSB)
medium (Oxoid) for DNA isolation. Escherichia coli strains were handled by
standard techniques (26). Conjugation from E. coli ET12567(pUZ8002) to S.
noursei and gene replacement were performed as described previously (13, 28).
Nystatin production was assessed by high-performance liquid chromatography
(25) of the dimethylformamide extracts of cultures from 500-ml shake ﬂask
fermentations in 100 ml of semideﬁned SAO-23 medium (28).
DNA manipulation and sequence analysis. General techniques for DNA ma-
nipulation were used as described elsewhere (16, 26). DNA fragments were
isolated from agarose gels with the QIAEX kit (QIAGEN, Hilden, Germany).
Southern blot analysis was performed with a DIG High Prime labeling kit
(Roche Biochemicals, Mannheim, Germany) according to the manufacturer’s
manual. Oligonucleotide primers were purchased from Amersham Pharmacia
Biotech (Little Chalfont, Buckinghamshire, United Kingdom). Analyses of the
amino acid sequences were performed by using the PSORT Prediction (http:
//psort.nibb.ac.jp/form.html), MEME (http://meme.sdsc.edu/meme/website
/meme.html), Pfam (http://www.sanger.ac.uk/Software/Pfam/search.shtml), and
MOTIF (http://motif.genome.ad.jp/) search engines.
Construction of plasmids for gene inactivation. (i) nysRI in-frame deletion
vector. A 1.37-kb DNA fragment designated SR1, encompassing the region
upstream of nysRI and some of its coding region, was ampliﬁed from the phage
N58 template by using primers SOS1 (5-GCAATGAATTCCGTGGCTCG-3)
and SOS2 (5-GGCTCTAGAGTCAG TAAGCCGGAAGAAC-3) (restriction
enzyme sites are underlined). A 1.50-kb DNA fragment designated SR2, encom-
passing the 3 end of nysRI and the downstream region, was ampliﬁed from the
N58 template by using primers SOS3 (5-GCCTCTAGAGACCAGGACCGCC
ACCTCC-3) and SOS4 (5-GACAAGCTTCGGTGCTG CGGACGAGTTC-
3). The SR1 and SR2 PCR products were digested with the EcoRI/XbaI and
XbaI/HindIII endonucleases, respectively, and ligated together with the 3.0-kb
EcoRI-HindIII fragment from pSOK201, yielding the nysRI replacement vector
pSR12. The in-frame deletion affecting the nysRI gene within the pSR12 plasmid
eliminated the coding sequence for amino acids (aa) 13 to 943 in the NysRI
protein, thus affecting all functional features predicted for this polypeptide.
(ii) nysRII in-frame deletion vector. A 1.43-kb DNA fragment designated SR3,
encompassing the region upstream of nysRII and some of its coding region, was
ampliﬁed from the phage N58 template by using primers SOS5 (5-GCAGAA
TTCGAGTCCGTGCTGCTCATCG-3) and SOS6 (5-GCACTGCAGGTGGT
CGGTTGGTTCC-3). A 1.52-kb DNA fragment designated SR4, encompassing
the 3 end of nysRII and the downstream region, was ampliﬁed from the N58
template by using primers SOS7 (5-GGCCTGCAGAGCTGTACCTGCTCCT
GG-3) and SOS8 (5-GACAAGCTTCCTGCCGCACCAACTCGAC-3). The
SR3 and SR4 PCR products were digested with the EcoRI/PstI and PstI/HindIII
endonucleases, respectively, and ligated together with the 3.0-kb EcoRI-HindIII
fragment from pSOK201, yielding the nysRII replacement vector pSR34. The
in-frame deletion affecting the nysRII gene within the pSR34 construct elimi-
nated the coding sequence for aa 14 to 936 in the NysRII protein, thus affecting
most of this polypeptide, including the C-terminal HTH domain.
(iii) nysRIII in-frame deletion vector. A 1.42-kb DNA fragment designated
SR5, encompassing the region upstream of nysRIII and some of its coding region,
was ampliﬁed from the phage N58 template by using primers SOS9 (5-GACG
AATTCAACTGGTCGCGCTGTTCTG-3) and SOS10 (5-GACCTGCAGTC
AGGAGGAGCGAGGAGTC-3). A 1.50-kb DNA fragment designated SR6,
encompassing the 3 end of nysRIII and the downstream region, was ampliﬁed
from the N58 template by using primers SOS11 (5-GCACTGCAGTGGAGA
AGCACCTCACCAG-3) and SOS12 (5-GAGAAGCTTGAGTATTCGGAG
GCCGCTC-3). The SR5 and SR6 PCR products were digested with the EcoRI/
PstI and PstI/HindIII endonucleases, respectively, and ligated together with the
3.0-kb EcoRI-HindIII fragment from pSOK201, yielding the nysRIII replacement
vector pSR56. The in-frame deletion affecting the nysRIII gene within the pSR56
construct eliminated the coding sequence for aa 29 to 899 in the NysRIII protein,
thus affecting all functional features predicted for this polypeptide.
(iv) nysRIV and orf2 insertional inactivation. The plasmids constructed for
insertional inactivation of nysRIV and orf2 were designated pNR4K and
pLRD6K, respectively (see Table 1 for details).
(v) orf3 “frameshift” deletion. A 1.3-kb DNA fragment from the S. noursei
genome encompassing the 3 ends of orf3 and orf2 was ampliﬁed by PCR with
primers NR5D1 (5-GCGAGCGGCCGCTTCACCCCGCAACTCA-3) and
NR5D2 (5-CGCGAAGCTTGGCCGACTGCTCGACGTC-3). The PCR
product was digested with NotI and HindIII and then ligated with a 1.7-kb
EcoRI-NotI DNA fragment from phage N58 (encompassing nysRIV and the
N-terminal part of orf3) and a 3.0-kb EcoRI-HindIII fragment from pSOK201.
The resulting plasmid, pNR5D, contained the S. noursei DNA fragment with a
43-bp deletion in the coding region of orf3. This deletion creates a frameshift
mutation within the ORF3 coding region, subsequently leading to truncation of
its product. As a result of this truncation, 165 C-terminal amino acid residues of
orf3 were eliminated and replaced with 14 aa encoded by another reading frame
(and thus unrelated to orf3).
Construction of plasmids for expression of regulatory genes from the ermEp
promoter. (i) nysRI expression vector. A 0.6-kb DNA fragment representing a
promoterless 5 end of nysRI was PCR ampliﬁed from the phage N1 template by
using primers NR1.1 (5-CGCCGCATGCTGTTCTCACCCCACGT-3) and
NR1.2 (5-GGCGCGACCGGTTCGGCCT-3). The PCR product was digested
with SphI/AgeI and then ligated together with a 2.8-kb AgeI-EcoRI DNA frag-
ment from phage N1 into the pGEM7Zf() vector digested with SphI/EcoRI.
From the resulting construct, a 3.4-kb SphI-HindIII fragment was isolated and
ligated together with a 0.3-kb EcoRI-SphI fragment from pGEM7ZfErmEli,
containing the ermEp promoter, into the EcoRI/HindIII-digested pSOK804
vector (for details, see Results, Table 1, and Fig. 2), resulting in the pNRE2
construct.
(ii) nysRII expression vector. A 2.2-kb SalI-BclI fragment from phage N58
(representing the 3 end of nysRII) was cloned into SalI/BamHI-digested
pGEM11Zf(). A 0.8-kb fragment representing the 5 end of the nysRII gene
was PCR ampliﬁed from the phage N58 template with primers NSR2.1 (5-GC
CGGCATGCGACGAACAGGACGAGAGGT-3) and NSR2.3 (5-GCCGTG
GTCGACGAAGG-3). The PCR fragment was digested with SphI/SalI and then
ligated, together with a 2.2-kb SalI-HindIII fragment from the pGEM11Zf()-
based construct, into the SphI-HindIII-digested pGEM3Zf() vector. From the
latter, a 3.0-kb SphI-HindIII fragment was isolated and ligated, together with the
0.3-kb EcoRI-SphI ermEp promoter fragment, into the EcoRI/HindIII-digested
pSOK804 vector, resulting in the pC3A1 construct.
(iii) nysRIII expression vector. A 2.8-kb SacI-NruI fragment from phage N58,
encompassing 89 nucleotides (nt) upstream of the nysRIII start codon and a large
portion of the coding region, was ligated together with a 0.5-kb NruI-EcoRI
fragment from the same phage, representing the 3 end of this gene, into
pGEM3Zf(). The nysRIII gene was excised from this construct as a 3.2-kb
SphI-EcoRI fragment and ligated into pGEM7Zf(). From the pGEM7Zf()-
based construct the nysRIII gene was excised as a 3.2-kb SphI-HindIII fragment
and ligated together with the 0.3-kb EcoRI-SphI ermEp promoter fragment into
the EcoRI/HindIII-digested pSOK804 vector, resulting in the pNTE3 construct.
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(iv) nysRIV expression vectors. The long (L) and short (S) versions of the
nysRIV gene were PCR ampliﬁed from N58 recombinant phage DNA with
primers NR4P3 (5-CTCAGCATGCCGAAAGGATGGCG-3) and NR4P5
(5-AGGCAAGCTTCGGCGACACGGGCGT-3) or primers NR4P4 (5-C
TCAGCATGCGTACGACCGGCGGG-3) and NR4P5, respectively. The
corresponding PCR products of 0.78 (NR4L) and 0.73 (NR4S) kb were
digested with SphI and HindIII and then ligated, together with the 0.3-kb
EcoRI-SphI fragment containing the ermEp promoter, with the EcoRI-
TABLE 1. Bacterial strains, plasmids, and phages used in this study
Strain, plasmid, or phage Characteristics Reference or sourcea
Strains
S. noursei
ATCC 11455 WT strain, nystatin producer ATCC
SR12 WT with in-frame deletion in nysRI This work
SR34 WT with in-frame deletion in nysRII This work
SR56 WT with in-frame deletion in nysRIII This work
NR4K WT with Kmr insertion in nysRIV This work
NR5D WT with deletion in orf3 This work
DNR609 WT with Kmr insertion in orf2 This work
E. coli
DH5 General cloning host BRL
JM110 dam dcm strain Promega
ET12567 (pUZ8002) Strain for intergeneric conjugation 13
DASHII phage vector
derivatives
N1 Recombinant phage (nystatin gene cluster) 7
N40 Recombinant phage (nystatin gene cluster) 7
N58 Recombinant phage (nystatin gene cluster) 7
N69 Recombinant phage (nystatin gene cluster) 7
N76 Recombinant phage (nystatin gene cluster) 7
Recombinant plasmids
pGEM3Zf() Cloning vector Promega
pGEM7Zf() Cloning vector Promega
pGEM11Zf() Cloning vector Promega
pGEM7ZfErmE*li pGEM7Zf() vector with ermE*p promoter C. R. Hutchinson
pKTO2 VWB-based Streptomyces integrative vector 37
pSET152 E. coli-Streptomyces conjugative vector 6
pSOK101 E. coli-Streptomyces conjugative vector 41
pSOK201 E. coli-Streptomyces conjugative vector 41
pSOK804 2.3-kb SphI-HindIII fragment from pKTO2 ligated with a 3.0-kb SphI-HindIII
fragment from pSET152
This work
pSR12 Vector for nysRI in-frame deletion This work
pSR34 Vector for nysRII in-frame deletion This work
pSR56 Vector for nysRIII in-frame deletion This work
pL58KX5 5.0-kb KpnI-XbaI fragment from phage N58 cloned into pGEM3Zf() This work
pNR4Km 1.3-kb Kmr marker inserted into the ClaI site within the nysRIV gene in
pL58KX5 after Klenow ﬁll-in
This work
pNR4D 6.3-kb KpnI-SphI fragment from pNR4Km ligated with a 3.0-kb KpnI-SphI
fragment from pSOK101
This work
pNR5D Vector for orf3 inactivation This work
pNR6 3.7-kb XmnI-FspI fragment from phage N69 with orf2 cloned into the SmaI
site of pGEM3Zf()
This work
pNR6K 1.3-kb Kmr marker inserted into the MluI site within orf2 in pNR6 after
Klenow ﬁll-in
This work
pLDR6K 5.0-kb EcoRI-XbaI fragment from pNR6K ligated with a 3.0-kb EcoRI-XbaI
fragment from pSOK804
This work
pNRE2 Vector for nysRI expression This work
pC3A1 Vector for nysRII expression This work
pNR3T Vector for nysRIII expression This work
pNR4EL Vector for expression of a 226-aa version of NysRIV This work
pNR4ES Vector for expression of a 210-aa version of NysRIV This work
pIJ4081 Vector with promoterless xylE gene J. White
pGEM-XylE1 pGEM3Zf()-based vector with promoterless xylE gene This work
pAML8 pSOK804-based vector with xylE under the control of nysHp This work
pAML9 pSOK804-based vector with xylE under the control of nysAp This work
pAML10 pSOK804-based vector with xylE under the control of nysDIIIp This work
pAML11 pSOK804-based vector with xylE under the control of nysRIp This work
pAML12 pSOK804-based vector with xylE under the control of nysIp This work
pAML13 pSOK804-based vector with xylE under the control of nysDIp This work
pAML14 pSOK804-based vector with xylE under the control of nysRIVp This work
a ATCC, American Type Culture Collection; BRL, Bethesda Research Laboratories.
VOL. 186, 2004 REGULATION OF NYSTATIN BIOSYNTHESIS 1347
HindIII-digested pSOK804 vector, yielding vectors pNR4EL and pNR4ES,
respectively.
PCR ampliﬁcation of putative promoter regions. Seven intergenic regions
from the nystatin biosynthetic cluster that might contain promoters have been
ampliﬁed by PCR (see Fig. 4). A 315-bp DNA fragment designated nysHp and
containing the region between the nysH and nysDIII genes was ampliﬁed from
the N40 template by using primers NHP1 (5-GCAGTCTAGAGAGGAACAC
CCCGGTTGAC-3) and NHP2 (5-GCAGAAGCTTGGCAAACCCTTCTCG
AACAC-3). In PCR a 315-bp intergenic fragment designated nysDIIIp was
ampliﬁed from the N40 template by using primers ND31 (5-GCAGTCTAGA
GGCAA ACCCTTC TCGAACAC-3) and ND32 (5-GCAGAAGCTTGAGG
AACACCCCGGTTGAC-3). A 202-bp fragment encompassing the region be-
tween the nysDIII and nysI genes and designated nysIp was ampliﬁed from the
same template with the help of primers NIP1 (5-GCCAACTGGTAG CAGTT
CTCAAGCTTTCG-3) and NIP2 (5-GCGGTCTAGACTCAACTCAACCCA
TCTCG-3). The primers for nysAp, the intergenic region upstream of the nysA
gene, were NSAP1 (5-GCAGAAGCTTCGGTTACTTGGTCTCATGC-3) and
NSAP2 (5-GCAGTCTAGAGCCTTGCTCACCCCTGCGG-3); the 212-bp
PCR product was ampliﬁed from the N76 template. A 212-bp fragment encom-
passing the region upstream of the nysDI gene and designated nysDIp was
ampliﬁed from the N76 template by using primers ND11 (5-GCAGTCTAGA
CGGTTACTTGGTCTCA TGC-3) and ND12 (5-GCAGAAGCTTGCCTTG
CTCACCCCTGCGG-3). The 351-bp nysRIp and nysRIVp DNA fragments up-
stream of the nysRI and nysRIV genes, respectively, were ampliﬁed from the N58
template by using primers NR11 (5-GCAGAAGCTTGAGACGGCACCATG
CCAC-3) and NR12 (5-GCAGTCTAGACACGCGTTCCTCCACGTG-3)
for the nysRIp fragment and primers NR41 (5-GCAGAAGCTTGTCGTACG
CCCGTCCGG-3) and NR42 (5-GCAGTCCAGAGAGACGCGCATCCTTT
CGG-3) for the nysRIVp fragment.
Construction of xylE-based promoter probe vectors. PCR-ampliﬁed fragments
of intergenic regions were digested with the HindIII and XbaI endonucleases and
ligated into the pGEM3Zf() vector. The 1.5-kb XbaI-BglII fragment with the
promoterless xylE gene was excised from the pIJ4081 vector and subcloned into
XbaI/BamHI-digested pGEM3Zf(), resulting in pGEM-XylE1. The HindIII-
XbaI promoter-containing fragments from constructs based on pGEM3Zf()
were ligated, together with the 1.5-kb XbaI-EcoRI fragment containing the
reporter gene xylE from pGEM-XylE1, into the HindIII/EcoRI-digested integra-
tive vector pSOK804, resulting in seven constructs (Table 1). Each of the
pSOK804-based constructs contains one of the seven intergenic regions up-
stream of the reporter gene xylE.
The resulting promoter-probe constructs were introduced by conjugation into
the nysRI, nysRII, nysRIII, and nysRIV mutants for the XylE assay experiments.
Assay for XylE activity. For quantitative enzymatic assays, protein extracts
from S. noursei cultures were prepared. For the precultures, 20 ml of liquid TSB
medium in 250-ml shake-ﬂasks containing 3 g of 3-mm-diameter glass beads was
inoculated with spore suspensions and incubated overnight at 30°C with shaking at
250 rpm. On the next day, 50 ml of MP5 medium (containing, per liter, 25 g of
glycerol, 3 g of yeast extract, 2 g of NaCl, 0.2 g of K2HPO4, 0.2 g of MgSO4, and
0.02 g of FeSO4 [pH 7.2]) was inoculated with 1.5 ml of precultures and incubated
at 30°C for 24 or 48 h with shaking at 250 rpm. Cells were harvested by centrifugation
for 10 min at 5,000 rpm (Sorvall), washed with 10 ml of 20 mM phosphate buffer (pH
7.2), and resuspended in 10 ml of sample buffer (100 mM phosphate buffer [pH
7.5]–10% acetone [vol/vol]–20 mM EDTA [pH 8.0]). A 3-ml volume of cell suspen-
sion was sonicated for 2 min, and 10 l of 10% Triton-100 was added per ml of
extract. Extracts were placed on ice for 15 min and then centrifuged for 10 min at
15,000 rpm, and cell supernatants were used for XylE assays.
The reaction mixture for measurement of catechol dioxygenase activity con-
sisted of 1.9 ml of assay buffer (100 mM phosphate buffer [pH 7.5], 0.2 mM
catechol) preincubated at 37°C for 1 min and 100 ml of cell extract. The optical
density at 375 nm was measured over 6 min.
Protein concentrations in extracts were measured according to the Bio-Rad
Protein Assay method, by using bovine serum albumin as the standard. The
catechol dioxygenase activity was calculated as the rate of change in optical
density at 375 nm per minute per milligram of protein.
RESULTS
In silico analysis of putative regulatory genes and their
deduced gene products. Three genes, designated nysRI, nysRII,
and nysRIII, are located downstream of the nysE gene, encod-
ing putative thioesterase, in the nystatin biosynthetic gene clus-
ter of S. noursei ATCC 11455 (7) (Fig. 1A). The nysRIII gene’s
putative start codon overlaps by 11 nt with the 3 end of the
nysRII gene, suggesting that these two genes might be transla-
tionally coupled. Analysis of the deduced primary sequences of
the proteins encoded by the nysRI, nysRII, and nysRIII genes
revealed their signiﬁcant similarity to each other and to a
number of putative transcriptional activators of the LAL fam-
ily (12) (data not shown). Several functional features were
predicted for the NysRI, NysRII, and NysRIII polypeptides
(Fig. 1B). Those include HTH DNA binding motifs of the
LuxR type (15) located at the C termini of all three proteins
(Fig. 2B) and Walker A and B NTP binding motifs (38) at the
N termini of NysRI and NysRIII (Fig. 2A). In addition, two
putative transmembrane regions were predicted in the central
part of NysRIII, while tetratricopeptide repeats (TPR) (20)
were detected in both the NysRI and NysRIII polypeptides
(see Discussion).
The nysRIV gene, previously designated orf4 (7), is located
404 nt downstream of nysRIII. The start codon for nysRIV has
been reassigned, according to a better match of an upstream
FIG. 1. (A) Organization of the regulatory gene locus associated
with the nystatin biosynthetic gene cluster in S. noursei ATCC 11455
(GenBank accession number AF263912). The only restriction enzyme
sites indicated are those used for vector construction as described in
Materials and Methods and Table 1. Heavy solid lines represent DNA
fragments used in gene replacement experiments. (B) Putative func-
tional features predicted for the NysRI, NysRII, NysRIII, and NysRIV
proteins. WA and WB, Walker A and B NTP binding motifs; PAS,
PAS-like domain.
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sequence (AGGA) to the consensus Shine-Dalgarno sequence
(30), and is likely to be located 48 nt upstream of the start
codon originally proposed (7). Thus, nysRIV presumably en-
codes a 226-aa rather than a 210-aa protein (see below). A
database search showed a high degree of NysRIV sequence
identity (63%) to the regulatory protein PteR encoded within
the pentaene macrolide antibiotic gene cluster of Streptomyces
avermitilis (23). Detailed sequence analysis revealed the pres-
ence of a PAS-like domain at the N terminus of NysRIV (33)
and a putative C-terminal HTH motif of the LuxR type (Fig.
1B and 2B).
orf3, located downstream of nysRIV, encodes a protein of
253 aa similar to transcriptional repressors of the DeoR family
(36). orf2, which is transcribed in the direction opposite that of
all the other putative regulatory genes, encodes a 354-aa
polypeptide similar to transcriptional regulators of the AsnC
type (19).
Inactivations of the regulatory genes and their effects on
nystatin biosynthesis. Disruption of the nysRI gene, described
previously, has led to complete elimination of nystatin biosyn-
thesis in the S. noursei mutant NRD2 (7). However, judging
from the operon-like organization of the nysRI, nysRII, and
nysRIII genes (Fig. 1A), this mutation very likely had a polar
effect. In order to determine the individual roles of these three
genes in the regulation of nystatin biosynthesis, we constructed
in-frame deletion mutants. The deletions were generated via
selection of a second crossover event after integration of the
pSR12, pSR34, and pSR56 gene replacement vectors (see Ma-
terials and Methods) into the genome of the S. noursei wild-
type (WT) strain. The resulting mutant strains, SR12, SR34,
and SR56 (see Fig. 1A for genotypes), were analyzed for nys-
tatin production.
Mutant SR12 (nysRI) produced nystatin at a severely re-
duced level, i.e., 0.5% of that in the WT (Table 2). This result
conﬁrmed the assumed polar effect of the nysRI disruption in
the NDR2 mutant, since not even traces of nystatin could be
detected upon fermentation of the latter (7). Nystatin produc-
tion in mutants SR34 (nysRII) and SR56 (nysRIII) was re-
duced by 93 and 91%, respectively, compared to that in the WT
strain (Table 2).
The nysRIV gene was inactivated by insertion of the Kmr
gene into its coding sequence via a gene replacement proce-
dure using plasmid pNR4D (Table 1; Fig. 1A). The resulting
NR4K mutant produced nystatin at a level of ca. 2% of WT
production (Table 2).
orf3 and orf2 were inactivated by deletion and disruption
FIG. 2. Amino acid sequence alignment. (A) Walker A and B NTP
binding motifs in the N termini of LAL-family regulators. (B) LuxR-
type HTH DNA binding motifs at the C termini of LAL-family regu-
lators.
TABLE 2. Nystatin production by recombinant S. noursei strains with inactivated or overexpressed regulatory genes
Strain or background
(genotype) Complementation
Nystatin production
(% of WT)a
SR12 (nysRI) 0.5
pNRE2 (ermE*p::nysRI) 59
SR34 (nysRII) 7
pC3A1 (ermE*p::nysRII) 100
SR56 (nysRIII) 9
pNRT3 (ermE*p::nysRIII) 100
NR4K (nysRIV::Kmr) 2
pNR4ES (ermE*p::nysRIV-S) 2.5
pNR4EL (ermE*p::nysRIV-L) 57
ATCC 11455 (WT) pSOK804 100
pNRE2 (ermE*p::nysRI) 104
pC3A1 (ermE*p::nysRII) 121
pNRT3 (ermE*p::nysRIII) 100
pNR4EL (ermE*p::nysRIV) 136
a Values are means from three independent experiments. In general, variations were within 7% of the mean.
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with the Kmr cassette by using plasmids pNR5D and pLDR6K,
respectively, creating frameshift mutations (see Materials and
Methods) (Table 1). Neither the orf3 nor the orf2 mutation had
a signiﬁcant effect on nystatin biosynthesis, suggesting that
these genes are not directly involved in the regulation of ny-
statin biosynthesis, at least under the conditions tested (data
not shown).
Complementation of the nysRI, nysRII, nysRIII, and nysRIV
mutants by expression of the regulatory genes from the
ermEp promoter. The pSOK804 plasmid vector, containing
an integration function (an integrase gene and AttP) from the
streptomycete temperate phage VWB (37) and part of the
pSET152 vector (6), was constructed (Table 1). Plasmid
pSOK804 was able to integrate site-speciﬁcally into one site in
the genome of S. noursei (data not shown), at a frequency
about 2 orders of magnitude higher than that for the pSET152
vector previously used for gene expression in S. noursei (41).
pSOK804-based integration vectors were assembled for the
expression of the nysRI, nysRII, nysRIII, and nysRIV genes in S.
noursei (see Materials and Methods and Table 1). To circum-
vent potential problems related to self-regulation of these
genes’ endogenous promoters, we chose to use the constitutive
ermEp promoter (5) for their expression. Five integrative
expression vectors were constructed (see Materials and Meth-
ods and Table 1) and used for complementation of the corre-
sponding S. noursei mutants. The results of these experiments
are summarized in Table 2. Nystatin synthesis was either partly
or fully restored in the SR12, SR34, SR56, and NR4K mutants
upon introduction of the vectors expressing the respective reg-
ulatory genes, suggesting that the mutations did not have polar
effects. Only vector pNR4EL, expressing the longer, 226-aa
version of NysRIV, was able to complement NR4K, thus cor-
roborating the new assignment of the nysRIV start codon (see
above).
The vectors used in complementation experiments were also
introduced into WT S. noursei in order to test whether poten-
tial overexpression of the regulators might increase nystatin
production. Interestingly, while no effect was observed with
nysRI and nysRIII, additional expression of nysRII from
ermEp provided for a 21% increase in nystatin production
(Table 2). Expression of nysRIV from the pNR4EL vector in
the WT S. noursei strain had the strongest positive effect on
nystatin synthesis: the resulting recombinant strain produced
nystatin at a level 36% above that of the WT (pSOK804)
(Table 2).
Promoter activity studies with the regulatory mutants. Al-
though deﬁnitive roles in controlling nystatin biosynthesis were
established for LAL-family regulators and NysRIV by the ex-
periments described above, their individual contributions to
the process, as well as the target genes, remained unknown. To
address these questions, seven putative promoter regions for
the structural and regulatory genes from the nystatin cluster
(Fig. 3) were cloned upstream of a promoterless xylE reporter
gene (see Materials and Methods). Since we deduced that the
nysH-nysDIII and nysDI-nysA intergenic regions contain diver-
gent promoters, these regions were cloned in two alternative
orientations to allow the assessment of both promoters. The
reporter cassettes were cloned into the pSOK804 integrative
vector, and the resulting plasmids were introduced into the S.
noursei WT strain and the regulatory mutants. XylE activity
assays of crude extracts prepared from the recombinant strains
were used to monitor relative expression levels from the vari-
ous promoters (Fig. 4).
In the WT background, XylE activity could be detected for
all promoter-probe vectors. Data from the XylE assay (Fig. 4)
showed that expression from the promoter for the putative
mycosamine transferase gene nysDI (and probably for the co-
transcribed nysDII and nysN genes) was 2 times higher in the
FIG. 3. Putative promoter regions in the nystatin biosynthesis gene cluster used in these studies.
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SR56 and NR4K mutants than in the WT background at the
24-h time point. Interestingly, this pattern was changed after
48 h: XylE activity in the SR56 mutant was reduced to ca. 30%
of that in the WT, while that in the NR4K mutant continued to
increase. nysDIIIp, the promoter for a putative GDP-mannose
dehydratase gene, depended only weakly on the regulators: the
XylE activity measured for the nysDIIIp::xylE construct in the
regulatory mutants was ca. 20 to 50% lower than that in the
WT. This difference was most visible at the 24-h time point and
was less profound after 48 h.
Expression from the nysAp promoter for the PKS loading
module gene nysA (and presumably for the cotranscribed nysB
and nysC genes) was very strongly dependent on all four reg-
ulators. Essentially no XylE activity was observed in the cor-
responding protein extracts except for the SR34 mutant, where
only very low XylE activity (ca. 3% of the WT level) was
detected. Compared to the promoters for mycosamine biosyn-
thesis and attachment genes, nysAp provided for ca. 30-times-
higher XylE expression in the WT.
nysIp, the promoter presumably driving the expression of the
NysI, NysJ, and NysK PKS proteins, responsible for further
elongation and termination of synthesis of the nystatin
polyketide chain, showed limited dependence on the presence
of the regulators. The strongest effects observed were those in
the SR34 and NR4K mutants at 24 h, where XylE activity due
to expression from nysIp was ca. 60 to 70% lower than that in
the WT background. Interestingly, nysIp seemed to be depen-
dent on the NysRIII regulator at 48 h, while no such trend
could be observed when XylE activity in the protein extract
from the 24-h culture was measured (Fig. 4). Also, the XylE
activity in the NR4K mutant almost reached the level of that in
the WT at 48 h.
According to the XylE assay, the promoter for the trans-
porter gene nysH (and presumably for the cotranscribed nysG
gene) was essentially independent of NysRI, while its activity
was greatly diminished in the nysRII, nysRIII, and nysRIV mu-
tants (see Discussion and Fig. 4).
nysRIp (the promoter region upstream of the regulatory
gene nysRI) showed only moderate dependence on the Nys-
RIII and NysRIV regulators, since the XylE activities in the
corresponding mutants were diminished by ca. 50 to 60% from
that in the WT. At the same time, nysRIp was strongly depen-
dent on NysRI and NysRII (Fig. 4). This result suggested that
NysRI regulates its own expression and that NysRII is involved
in this process as well. The nysRIp promoter seemed to be very
strong and was superseded only by nysRIVp, which provided
the highest level of XylE expression demonstrated in these
experiments. The activity of the nysRIVp promoter was greatly
affected in all three LAL regulatory mutants, while NysRIV
seemed to be moderately autoregulating its own expression, as
XylE activity in the NR4K mutant was diminished by ca. 60%.
In order to gain more insight into the results of the comple-
mentation experiments described in the preceding section, a
control experiment designed to assess the efﬁciency of the
ermEp promoter in S. noursei was performed. In this experi-
ment, XylE activity was measured in protein extracts from the
WT strain expressing xylE from the nysAp and ermEp pro-
moters. Apparently, ermEp provided for a much more efﬁ-
FIG. 4. XylE activities in the protein extracts of WT S. noursei and regulatory mutants expressing xylE from different promoters. The last
diagram shows a comparative analysis of xylE expression from the nysAp and ermEp promoters in S. noursei ATCC 11455. Variations from the
mean in each data series are represented by error bars.
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cient (ca. 12-times-higher) expression of xylE than nysAp (Fig.
4). ermEp appears to be the strongest of the promoters in-
vestigated in this study.
Cross-complementation experiments. The xylE promoter fu-
sion experiments provided important clues on the target genes
controlled by the four NysR regulators in the nystatin gene
cluster. However, the possible hierarchy of the regulators re-
mained obscure. In order to gain deeper insight into the mech-
anism of regulation of nystatin biosynthesis, cross-complemen-
tation experiments were carried out. The idea behind these
studies was to test which of the regulatory genes, when ex-
pressed from the heterologous ermEp promoter, could sub-
stitute for each other in the regulatory mutants.
Accordingly, pSOK804-based expression vectors containing
four pathway-speciﬁc regulatory genes were introduced into
the SR12, SR34, SR56, and NR4K mutants, and nystatin pro-
duction by recombinant strains was assessed (Table 3). Nysta-
tin production in the SR12 mutant could be restored to the
same extent (ca. 60% of the WT level) by introduction of any
of the four regulatory genes. Interestingly, both nysRII and
nysRIII were able to complement the SR12 mutant, while no
cross-complementation was observed between the nysRII and
nysRIII genes, suggesting that these regulatory genes can be
placed on the same hierarchy level (see Discussion). nysRIV
was able to restore nystatin biosynthesis to a signiﬁcant level
(60 to 87% of the WT) in all regulatory mutants.
DISCUSSION
The results obtained in the gene inactivation experiments
clearly show that at least four regulatory genes control nystatin
production in S. noursei. The nysRI, nysRII, nysRIII, and nys-
RIV genes are required for efﬁcient nystatin biosynthesis and
probably represent transcriptional activators for the gene clus-
ter. Clearly, nysRII and nysRIII are not as important in this
respect as nysRI, since their inactivation has less profound
effects on antibiotic production. This notion is exempliﬁed by
the fact that, according to the xylE fusion experiments, NysRI
regulates an endogenous promoter for its own gene, which is
also likely to drive the expression of nysRII and nysRIII. The
operon-like structure of nysRI-nysRII-nysRIII and the apparent
polar effect of nysRI disruption imply that these three genes
might be transcribed from the same promoter located up-
stream of nysRI. nysRIp is the second strongest (after nysRIVp)
of the nys promoters and remains at least partially active in all
regulatory mutants. Both nysRIp and nysRIVp seem to be
weaker than the ermeEp promoter when used for the expres-
sion of xylE in WT S. noursei (Fig. 4). This fact, along with the
results from the complementation experiments (Table 2), sug-
gests that a high level of expression of the regulatory genes
alone does not ensure a high level of nystatin production, since
only partial complementation was observed when nysRI and
nysRIV were expressed from ermEp. It seems plausible, there-
fore, that the mechanism governing gene expression in the
nystatin biosynthetic cluster requires coordinated expression of
the regulatory genes, which is provided through the intrinsic
regulatory genes’ promoters.
Remarkably, XylE expression from the nysRIp promoter is
strongly reduced only in nysRI and nysRII mutants, suggest-
ing that transcription of the nysRI-nysRII-nysRIII genes is au-
toregulated. Taking the above into consideration, it is conceiv-
able that in both of these mutants, neither of the regulators is
efﬁciently expressed. It seems, however, that the basal level of
expression of NysRII and NysRIII in the nysRI mutant is
sufﬁcient to activate the nysHp promoter (Fig. 4). The latter
appears to be strongly dependent on the availability of the
NysRII, NysRIII, and NysRIV regulators.
The NysRI, NysRII, and NysRIII proteins seem to derive
from a common ancestor, since they contain homologous re-
gions and their domain organization, especially for NysRI and
NysRIII, is similar (Fig. 1B). Proteins with signiﬁcant similarity
to NysRI, NysRII, and NysRIII are found mostly in actinomy-
cetes and are proposed to be transcriptional activators for
antibiotic biosynthesis, lipase, and cholesterol oxidase genes
(18, 21, 27, 29). Genes encoding proteins similar to NysRI to
-III are also located in the biosynthetic gene cluster for the
polyene antibiotic candicidin (9). Most of these proteins might
be considered members of the LAL subfamily of transcrip-
tional regulators proposed by De Schrijver and De Mot (12),
on the basis of their size and the presence of the N-terminal
NTP binding and C-terminal LuxR HTH motifs. The NTP
binding motifs in the transcriptional regulator PikD have been
shown to be required for its activity (40). Therefore, it seems
likely that NysRI and NysRIII also require NTP binding and
hydrolysis for their function. The presence of the TPRs, which
are implicated in protein-protein interactions (35), in NysRI
and NysRIII suggests that these proteins might interact with
other proteins. It is well documented that protein-protein in-
teractions play an important role in transcriptional control in
bacteria (34).
All experimental data obtained for the nysRIV gene (see
below) point to its central role in controlling nystatin biosyn-
thesis. Indeed, very little nystatin is produced by the nysRIV
disruption mutant, while expression of nysRIV from the
ermEp promoter results in signiﬁcant stimulation of nystatin
TABLE 3. Restoration of nystatin production in cross-complementation experiments with the regulatory mutantsa
Mutant
Nystatin production (% of WT)b with complementation by:
pNRE2
(ermE*p::nysRI)
pC3A1
(ermE*p::nysRII)
pNRT3
(ermE*p::nysRIII)
pNR4EL
(ermE*p::nysRIV)
SR12 (nysRI) 60 58 68 62
SR34 (nysRII) 5.4 100 5.6 77
SR56 (nysRIII) 8.5 11 98 87
NR4K (nysRIV::Kmr) 2.5 2.0 2.5 60
a See the text for details.
b Values are means from two independent experiments. Variations were within 11% of the mean.
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production in the WT strain. Also, nysRIV can complement all
nysR regulatory mutants. Detection of a PAS-like domain
within NysRIV suggests that this protein might respond to the
energy levels in the cell. PAS domains are found in many
signaling proteins, where they serve as signal sensor domains
(24). Promoter probe studies clearly demonstrate that nysRIVp
is strongly downregulated in all three LAL regulator mutants.
However, the nysRIVp promoter appears to be the strongest of
the seven nys promoters studied, and even in the absence of
LAL regulators, its activity is at the level of the nysDIIIp and
nysIp promoters. The latter fact suggests that a relatively high
level of nysRIV transcription is required for this gene’s product
to exert a positive effect on nystatin biosynthesis.
The xylE fusion experiments with the promoters for the
nystatin structural genes provided the ﬁrst clues on the regu-
latory mechanism controlling nystatin biosynthesis in S. nour-
sei. Apparently, promoters driving the expression of nysDIII
and nysDI-nysDII-nysN (presumably cotranscribed) are only
weakly dependent on the NysR regulators.
Regulation of the promoters driving the expression of PKS
genes, nysIp and nysAp, is strikingly different. First, the level of
XylE expression from the nysAp promoter in the WT strain
seems to be at least 35 times higher than that from nysIp. This
is not surprising, since nysA encodes the loading module of the
nystatin PKS, expression of which is pivotal for initiation of
biosynthesis (8). The mutations in the nysR regulatory genes
have much stronger effects on nysAp than on nysIp (see Fig. 4),
suggesting that initiation of nystatin biosynthesis promoted by
the nysA gene product is the primary target for the regulators.
Cross-complementation experiments helped to establish a
hierarchy among the four NysR regulators of the nystatin gene
cluster. Differences in the degree of complementation ob-
served in these experiments could most probably be attributed
to the expression of the genes in trans from the heterologous
promoter. The ability of nysRII and nysRIII to complement the
nysRI mutant implies that NysRII and NysRIII can each
substitute for NysRI and that expression of these proteins in
the SR12 mutant is severely affected. It is not clear, however,
why both nysRII and nysRIII can complement the nysRI mu-
tant, since deletion of either of these genes has a detrimental
effect on nystatin biosynthesis, and these genes cannot substi-
tute for each other in cross-complementation experiments (Ta-
ble 3). The answer to this question probably lies in the plau-
sibility of concerted action of the regulators or might be that
such complementation is due to the use of a nonnatural con-
stitutive promoter, ermEp, in the complementation experi-
ments.
Based on the data from promoter analysis and cross-comple-
mentation experiments, the following tentative model can be
suggested. Expression of the LAL regulatory operon would
start with NysRI, which positively regulates its own promoter.
However, it seems that NysRII is required for efﬁcient tran-
scription from nysRIp, while NysRIII is not essential (Fig. 4). It
is thus logical to assume that NysRI and NysRII function in
concert as autoregulators of the LAL operon, ensuring its
efﬁcient transcription. NysRII seems to play a pivotal role here,
as expression of this protein can alleviate the effect of nysRI
mutation. Since no cross-complementation is observed in the
case of nysRII and nysRIII, it seems likely that their products
are both required for efﬁcient nysRIV expression. Since nysRIV
can complement all regulatory mutants, but none of the other
regulators can complement NR4K, nysRIV most probably di-
rectly controls the expression of nystatin biosynthetic genes.
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SUMMARY
Seven polyene macrolides with alterations in the
polyol region and exocyclic carboxy group were
obtained via genetic engineering of the nystatin bio-
synthesis genes in Streptomyces noursei. In vitro
analyses of the compounds for antifungal and hemo-
lytic activities indicated that combinations of several
mutations caused additive improvements in their
activity-toxicity properties. The two best analogs
selected on the basis of in vitro data were tested for
acute toxicity and antifungal activity in a mouse
model. Both analogs were shown to be effective
against disseminated candidosis, while being con-
siderably less toxic than amphotericin B. To our
knowledge, this is the ﬁrst report on polyene macro-
lides with improved in vivo pharmacological proper-
ties obtained by genetic engineering. These results
indicate that the engineered nystatin analogs can be
further developed into antifungal drugs for human
use.
INTRODUCTION
Systemic fungal infections represent a serious problem in medi-
cal care, as they usually affect patients whose immune systems
have been compromised as a result of HIV infection, anticancer
therapy, or immunosuppressive therapy after organ transplanta-
tion (Sims et al., 2005; Maschmeyer et al., 2007; Silveira and Hu-
sain, 2007). The number of antifungal agents that can be used to
treat such infections is currently limited to azoles (e.g., voricona-
zole), echinocandins (e.g., caspofungin), and polyenemacrolides
(e.g., amphotericin B). All the above-mentioned antifungals have
their own therapeutic limitations because of drug-drug interac-
tions, development of resistance, narrow spectrum of activity,
and toxicity (Scott and Simpson, 2007; Perlin, 2007; Spanakis
et al., 2006; Zotchev, 2003). The polyene macrolide amphoteri-
cin B (AmB) has been used for treatment of systemic fungal infec-
tions for several decades, showing excellent efﬁcacy against
a number of fungal pathogens. At the same time, severe side
effects, such as nephrotoxicity, and suboptimal pharmacokinet-
ics, undermine therapeutic value of this antibiotic. A number of
AmB analogs, both semisynthetic and genetically engineered,
have been generated over the last 20 years in an attempt to re-
duce its toxicity and improve solubility (Falk et al., 1999; Paquet
and Carreira, 2006; Seco et al., 2005; Carmody et al., 2005). De-
spite that, no new AmB-based antifungal has appeared on the
market, except for the lipid and liposomal formulations. However,
studies of theAmBanalogshavegenerated important data on the
structure-activity relationship of polyene macrolides that may
also be at least partially applicable to other scaffolds belonging
to the same type of compounds. According to these studies,
the exocyclic carboxyl and the amino group of mycosamine
seem tobeparticularly important for selective toxicity andactivity
(Mazerski et al., 1995; Borowski, 2000). Moreover, Power et al.
(2008) have recently generated a mutant of Streptomyces nodo-
sus with inactivated ketoreductase (KR) domain in module 16 of
the AmB polyketide synthase (PKS) that was shown to produce
7-deoxy-7-oxy AmB. The latter compound has been shown to
retain antifungal activity, while having reduced hemolytic activity,
compared with that of AmB. To our knowledge, none of these
AmB analogs has been tested in vivo.
Polyene macrolides are mostly produced by Streptomyces
bacteria and exert their fungicidal action via interaction with
membrane sterols, resulting in the formation of highly organized
hydrophilic channels, through which small molecules and ions
can leak out (Omura and Tanaka, 1984; Teerlink et al., 1980;
Baginski et al., 2006). These antibiotics appear to have a higher
afﬁnity toward membranes containing ergosterol (e.g., in fungi
and some parasites), compared with cholesterol-containing
membranes (mammalian cells) (Gagos et al., 2005). Still, polyene
macrolides bind to the cholesterol-containing membranes to
some extent, thus causing lysis of particularly vulnerable cells
(e.g., in kidneys) and subsequent organ damage.
The polyene macrolide antibiotic nystatin produced by Strep-
tomyces noursei ATCC 11455 is an important antifungal agent
used in human therapy for treatment of superﬁcial mycoses. Its
use for treatment of systemic mycoses is precluded by toxicity,
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solubility problems, and lower antifungal activity, compared with
that of AmB (Hamilton-Miller, 1973). The nystatin biosynthetic
pathway has been established after cloning of the entire biosyn-
thetic gene cluster (Brautaset et al., 2000). It comprises assembly
of the 38-member macrolactone ring, followed by oxidation of
a C-16 methyl group, attachment of deoxysugar mycosamine
at C-19, and hydroxylation at C-10 (Fjærvik and Zotchev, 2005)
(Figure 1).
Using genetic engineering, we have recently obtained a
heptaene nystatin analog S44HP with antifungal activity consid-
erably higher than that of nystatin and equal to that of AmB
(Bruheim et al., 2004). S44HP is structurally similar to AmB but
has signiﬁcantly different properties. For example, S44HP was
found to be 10 times more soluble than AmB and, despite
having a lower maximal tolerated dose (MTD) value compared
with the latter, seems to have a wider therapeutic window
(MTD-LD50 dose interval) (Treshchalin et al., 2005). We hypothe-
sized that further derivatization of S44HP might yield new poly-
ene macrolides with improved pharmacological properties,
which can be useful for development of safer antifungals. In
the present work, we report the generation of new nystatin and
S44HP analogs by means of manipulation of the nystatin biosyn-
thetic genes and their biological characterization. Two of these
analogs tested in vivo displayed high efﬁcacy and considerably
lower acute toxicity, compared with AmB, suggesting that they
can become lead compounds for development of new antifungal
drugs for human use.
RESULTS AND DISCUSSION
Speciﬁc Change in the C-9–C-10 Polyol Region
of Nystatin Leads to a Signiﬁcant Reduction
of Hemolytic Activity
The polyol region on the polyene macrolide molecule has re-
cently become a potentially interesting target for modiﬁcation
through biosynthetic engineering. Caffrey and co-workers have
demonstrated that replacement of the C-7 hydroxyl group on
the AmBmolecule with a keto group leads to over 10-fold reduc-
tion of in vitro hemolytic activity and4-fold reduction of antifun-
gal activity (Power et al., 2008). On the nystatin A1 molecule, the
C-1–C-15 polyol region is interrupted by a saturated C-9–C-10
bond formed as a result of the activity of KR, dehydratase
(DH), and enoyl reductase (ER) domains in the module 15 of
the nystatin PKS NysJ (Figure 1). To gain a better insight into
structure-activity relationship of nystatin, we inactivated DH15
domain of NysJ by site-speciﬁc mutagenesis of the active site
His followed by gene replacement in S. noursei NDA59, yielding
mutant NJDH15 (see Table S1 available online). The host strain
NDA59 has a nysA deletion, and nystatin production can be
restored to almost 100% by complementation with nysA gene
(Brautaset et al., 2003).
Mutant NJDH15 was complemented with the nysA gene, cul-
tivated in the fermentor, and DMSO extracts were assayed for
polyene production by liquid chromatography (LC)-diode array
detector (DAD)-time of ﬂight (TOF). The analysis unraveled the
Figure 1. Proposed Nystatin Biosynthesis in Streptomyces noursei
Only reductive domains in the nystatin PKS modules are shown.
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production of an analog with a mass (m/z) corresponding to the
stoichiometric formula of nystatin (less than 2 ppm difference
from the theoretical mass) in both ESI+ (positive ionization) and
ESI (negative ionization) modes (Figure S1). The volumetric
production yield of this analog, denoted BSG002 (0.88 ±
0.04 g/l) was about 30%of the nystatin production level obtained
in the wild-type strain under the same conditions (Table S2).
Since the expected change shall affect the C-9–C-10 region,
we hypothesized that the NysL hydroxylase (Volokhan et al.,
2006) might not recognize the altered C-9–C-11 region on the
new molecule, thus failing to perform C-10 hydroxylation. Thus,
a new analog with a molecular weight identical to that of nystatin
can be explained if this compound has acquired a C-9 hydroxyl,
but lacks C-10 hydroxyl group. To verify this hypothesis, the
major compound produced by the NJDH15 mutant was puriﬁed
using preparative high-pressure liquid chromatography (HPLC),
and the concomitant nuclear magnetic resonance (NMR) analy-
sis (see Supplemental Text and Figure S2) clearly supported our
hypothesis that BSG002 indeed represents 9-hydroxy-10-deoxy
nystatin (Figure 2).
Puriﬁed BSG002 (purity >95% and concentration of active
principle adjusted according to the purity) was then subjected
to the in vitro tests for antifungal and hemolytic activities (see Ex-
perimental Procedures). BSG002 was found to be at least 2-fold
less hemolytic, compared with nystatin. However, its antifungal
activity was simultaneously reduced 4-fold (Table 1). Accord-
ing to the model of the channel formed by polyene macrolides,
the hydroxyl groups in the polyol region create a hydrophilic
Figure 2. Genetically Engineered Polyene Macrolides
(A) Molecular structures of nystatin and its analogs generated by biosynthetic engineering.
(B) Molecular structures of amphotericin B analogs produced via manipulation of biosynthetic genes (Carmody et al., 2005; Power et al., 2008).
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environment allowing for leakage of ions from the affected cells.
One could expect that the addition of a hydroxyl group at C-9
might increase the conductance of the channel, and hence in-
crease antifungal activity, while removal of C-10 hydroxyl should
have no effect, as suggested by the data on 10-deoxy nystatin
(Volokhan et al., 2006).
Replacement of the C-16 Carboxyl on the Nystatin
Molecule with a Methyl Group Reduces Hemolytic
Activity Without Affecting the Antifungal Activity
Replacement of a C-16 carboxyl with amethyl group on the AmB
molecule by means of inactivation of the methyl oxidase AmphN
yielded a less hemolytic analog with retained antifungal activity
(Carmody et al., 2005). The S. noursei nystatin gene cluster con-
tains a nysN gene encoding a putative P450 monooxygenase
earlier implicated in oxidation of the C-16 methyl to afford a car-
boxyl group on the mature antibiotic molecule (Brautaset et al.,
2000). Accordingly,S. nourseimutantCL346AS, carrying amuta-
tion in the nysN gene replacing the conserved Cys residue
(Cys346) of NysN presumed to be responsible for heme binding
with Ala, was constructed (Table S1). This mutation was pre-
dicted to abolish activity of NysN on the basis of the data re-
ported for another P450 monooxygenase (Vatsis et al., 2002).
Mutant strain CL346AS was cultivated in the fermentor and ana-
lyzed for production of polyene macrolides, as described above.
The expected mass corresponding to the stoichiometric formula
of 16-decarboxy-16-methyl nystatin (C47H77NO15) was identiﬁed
(<3 ppm difference from the theoretical mass) in both ESI+ and
ESI modes in the culture extract (Figure S3). The production
level of 16-decarboxy-16-methyl nystatin (16-DecNys) was
very low (0.06 ± 0.01 g/l) and represented less than 2%, com-
pared with the nystatin production in the wild-type strain (Table
S2). Similarly low production yield of 16-decarboxy-16-methyl
AmB analog has been observed in S. nodosus upon inactivation
of the amphN gene (Carmody et al., 2005). Since we did not
observe any abnormal growth for the CL346AS mutant, it seems
unlikely that 16-DecNys is toxic to the producing organism. Po-
tentially, accumulation of the latter analog may cause feedback
inhibition of the nystatin biosynthetic pathway by an unknown
mechanism (see below).
In vitro hemolytic assay of the puriﬁed 16-DecNys (purity 75%
and concentration of active principle adjusted according to the
purity) revealed about 2-fold increased HC50 value for this com-
pound, compared with the parental antibiotic nystatin (Table 1).
At the same time, its antifungal activity remained unchanged, as
judged from the MIC50/MIC90 values forCandida albicans, which
were 1.2 ± 0.2/2.0 ± 0.3 mg/ml and 1.3 ± 0.4/1.8 ± 0.5 mg/ml for
nystatin and 16-DecNys, respectively (Table 1). Combined,
these data imply that replacement of the C-16 carboxyl with
a methyl group reduces the toxicity of nystatin, while having no
effect on its antifungal activity. These data are in good agree-
ment with the analogous result previously documented for
16-decarboxy-16-methyl AmB (Carmody et al., 2005). Because
of the low yield, we were unable to produce 16-DecNys in quan-
tity and purity sufﬁcient for NMR analysis of the structure and
in vivo animal experiments.
C-16 Modiﬁcation of the Heptaene Nystatin Analog
S44HP Yields Less Hemolytic and More Active
Polyene Macrolide
Encouraged by the in vitro data obtained for 16-DecNys (see
above), we introduced identical C-16 modiﬁcation on the mole-
cule of the heptaene nystatin analog S44HP, which was shown
to have 6-fold higher in vitro antifungal activity than nystatin
(Bruheim et al., 2004). The CL346AS mutation in the nysN gene
was introduced into the S44HP-producing mutant S. noursei
GG5073SP (Borgos et al., 2006a), generating mutant BSM1
(Table S1). BSM1was cultivated in the fermentor and assayed for
polyene macrolides by LC-DAD-TOF. The expected mass corre-
sponding to the stoichiometric formula of 16-decarboxy-16-
methyl-28,29-didehydro nystatin (C47H75NO15), was identiﬁed
in the culture extract (<1.5 ppm difference from the theoretical
mass) in the ESI mode (Figure S4), and this compound was
designated BSG005 (Figure 2). Interestingly, the BSG005
production level by BSM1 in the fermentor (0.53 ± 0.01 g/l)
was about 40%, compared with the S44HP production level by
parental strain GG5073SP (Table S2). This was20 times higher
than the relative production level of 16-DecNys by the analogous
nysNmutant CL346AS constructed on thewild-type background
(see above), and the biological reason for this discrepancy is un-
known. It is possible that the C28-29 double bond in BSG005
somehow negatively affects its ability to inhibit the nystatin bio-
synthetic pathway, whereas 16-DecNys, which has a saturated
C28-C29 bond, has much higher potential for inhibiting the path-
way. Chemical structure of the expected BSG005 analog, 16-
decarboxy-16-methyl-28,29-didehydro nystatin, was conﬁrmed
by NMR experiments on puriﬁed compound (Figures S5 and S6).
In vitro assay for the puriﬁed BSG005 (purity >95%) revealed
its 2-fold and 20-fold increased antifungal activity, compared
with S44HP and nystatin, respectively (Table 1; Figure S7). At the
same time, its hemolytic activity was reduced 1.5-fold, com-
pared with S44HP (Table 1). Together, these data imply that
replacement of the C16-carboxyl group on S44HP with a methyl
has a positive effect on the pharmacological properties of this
compound under the conditions tested. These results are in
agreement with the similar data reported for noncarboxylated
analogs of both AmB and rimocidin (Seco et al., 2005; Carmody
Table 1. In Vitro Determined Antifungal and Hemolytic Activities
of the Genetically Engineered Nystatin Analogs
Compound MIC50 (mg/ml)
a MIC90 (mg/ml)
a HC50 (mg/ml)
b
Nystatin 1.2 ± 0.2 2.0 ± 0.3 85
BSG002 4.8 ± 0.4 10.5 ± 3.5 180
16-DecNys 1.3 ± 0.4 1.8 ± 0.5 175
AmB 0.12 ± 0.03 0.19 ± 0.03 2.6
S44HP 0.12 ± 0.03 0.20 ± 0.03 2.5
BSG005 0.07 ± 0.02 0.12 ± 0.03 4.0
BSG013 0.25 ± 0.07 0.43 ± 0.07 3.0
BSG017 0.47 ± 0.15 0.92 ± 0.03 3.3
BSG020 0.15 ± 0.03 0.19 ± 0.03 9.0
BSG031 0.18 ± 0.06 0.37 ± 0.07 3.8
The ± values represent maximum deviation from the mean.
a Tested as described in Nedal et al., (2007) usingCandida albicans ATCC
10231 as a test organism.
b Tested by using horse blood erythrocytes and antibiotic concentrations
ranging between 0 and 200 mg/ml.
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et al., 2005; Palacios et al., 2007), although theMIC values for the
latter two compounds have not been reported.
C-5 and C-7 Keto Modiﬁcations in the S44HP Polyol
Region Yield Analogs with Reduced Antifungal
and Hemolytic Activities
According to the current model, the polyol regions of antibiotic
molecules with multiple hydroxyl groups outline the inner part
of the channel piercing the target cell membrane (Baginski
et al., 2002). The hydrophilic properties of the channel are most
likely affected by the number and position of the hydroxyls, and
thus variation of these properties might theoretically affect the
channel’s ion selectivity and conductivity. Power et al. (2008)
have reported biosynthetic engineering of the 7-oxo-AmBanalog
with reduced hemolytic activity. We decided to generate S44HP
analogs, where either C-5 or C-7 hydroxyls in the polyol region
were replaced with keto groups, and to compare their biological
properties. The KR17 domain of the nystatin PKS NysJ protein is
responsible for catalyzing the reduction the C-5 keto group to
afford the C-5 hydroxyl during the biosynthesis of the nystatin
macrolactone ring (Brautaset et al., 2000) (Figure 1). To generate
anS44HPanalogwith retainedC5-keto group,we introduced the
double mutation TA5145FE affecting the proposed KR17 active
site Tyr residue in the nystatin PKS NysJ. The KR16 domain of
the NysJ PKS is responsible for catalyzing the reduction the
C-7 keto group to afford the C-7 hydroxyl on the nystatin mole-
cule. To generate an S44HP analog with retained C7-keto group,
we introduced thedoublemutationYA3404FEaffecting theKR16
active site Tyr3404 residue in NysJ. The KR17 and KR16 muta-
tions were individually introduced to the S. noursei mutant
GG5073SP, generating mutants BSM2 and BSM4, respectively
(Table S1).
The two latter strains were cultivated in the fermentor and
assayed for polyene macrolides by LC-DAD-TOF. Accurate
masses, which correlatedwell with the expected 5-oxo-5-deoxy-
28,29-didehydro nystatin and 7-oxo-7-deoxy-28,29-didehydro
nystatin (both with stoichiometric formula C47H71NO17) were
found in ESI and ESI/ESI+ modes, respectively, (<5 ppm
difference from the theoretical mass, Figures S8 and S9). The
compounds produced by the BSM2 and BSM4 mutants were
designated BSG013 and BSG017, respectively (Figure 2). The
volumetric production yields of BSG013 (0.73 ± 0.01 g/l) and
BSG017 (0.63 ± 0.07 g/l) correspond to about 56% and 49%, re-
spectively, of the S44HP production yield obtained for the paren-
tal strain GG5073SP (Table S2). Chemical structure of BSG013
wasalsoconﬁrmedbyNMRexperiments (FigureS5). Structurally,
BSG013 and BSG017 seem to be identical to the previously
reported polyene macrolides mycoheptin (Borowski et al., 1978)
and candidin (Volpon and Lancelin, 2002), respectively.
Next, puriﬁed BSG013 and BSG017 (purity >95%) were tested
in vitro for hemolytic and antifungal activities, as described
above. Compared to S44HP, BSG013 showed 2-fold reduced
antifungal activity with concomitantly 1.2-fold increased HC50
value (Table 1; Figure S7). BSG017 showed a 4-fold reduced
antifungal activity and 1.3-fold increased HC50 value compared
to S44HP (Table 1; Figure S7). These data indicated that substi-
tutions of C-5 or C-7 hydroxyls with keto groups reduce both
antifungal and hemolytic activities of the S44HP analogs. These
data were consistent with those reported for 7-oxo AmB analog,
where reduction of both antifungal and hemolytic activities have
been observed (Power et al., 2008). However, reduction of hemo-
lytic activity upon replacement ofC-5andC-7hydroxylswith keto
groups on S44HP was not as dramatic as in the case of 7-oxo
AmB.
Combination of C-16 with C-5 or C-7 Keto Modiﬁcations
on S44HP Results in Analogs with Further Reduced
Hemolytic Activity and High Antifungal Activity
Considering that BSG005, BSG013, and BSG017 were all less
hemolytic than S44HP in vitro, we decided to combine the corre-
sponding modiﬁcations on these molecules in an attempt to
obtain an analog with further reduced toxicity. The CL346AS
nysN mutation that was used to construct mutant BSM1 was
introduced into the BSG013- and BSG017-producing mutants
BSM2 and BSM4, yielding recombinant strains BSM3 and
BSM5, respectively (Table S1). The two latter strains were culti-
vated in the fermentor, and production of polyene macrolides
was assessed by LC-DAD-TOF. Accurate masses which corre-
lated well with the 5-oxo-5-deoxy-16-decarboxy-16-methyl-
28,29-didehydro nystatin and 7-oxo-7-deoxy-16-decarboxy-
16-methyl-28,29-didehydro nystatin (both with stoichiometric
formula C47H73NO15), were found in ESI and ESI+ modes (all
with <3 ppm difference from the theoretical masses, Figures
S10 and S11). The analogs identiﬁed were designated BSG020
and BSG031, respectively (Figure 2). In addition, tandem mass
spectrometer (MS)-MS data were used to conﬁrm the chemical
structure of BSG020 (Figure S12). The volumetric production
yields of BSG020 (0.26 ± 0.02 g/l) and BSG031 (0.37 ± 0.04 g/l)
corresponded to20% and 29%, respectively, of that of S44HP
produced by the parental strain GG5073SP (Table S2). These
data demonstrate that several alterations can simultaneously
be introduced into the nystatin biosynthetic pathway without
dramatically affecting production yields of new analogs.
The puriﬁed compounds BSG020 andBSG031 (93%and 80%
pure, respectively) were subjected to in vitro activity and toxicity
assays as described above. The data from these experiments
showed that BSG020 and BSG031 had 3.5- and 1.5-fold
increased HC50 values, comparedwith S44HP, respectively, and
that their antifungal activities were improved compared to those
of their parental oxo-analogs. (Table 1 and Figure S7). Together,
these data indicate that the combination of the oxo substitutions
in the polyol region and C-16 methyl group can potentially be
beneﬁcial for improvement of therapeutic index of S44HP. It
should be noted that AmB analogs with combined C-15-oxo
and C-16-methyl modiﬁcations have been obtained by Power
et al. (2008). Unfortunately, yields of these analogs had appar-
ently been too low for puriﬁcation of substantial amounts of
materials, although crude samples clearly exhibited antifungal
activity. We have failed to generate a mutant producing C-15-
oxo analog of S44HP in detectable amounts, although two
alternative mutations for KR12 inactivation in the nystatin PKS
NysI were attempted (data not shown).
BSG005 and BSG020 Have Considerably Reduced
Toxicity, and BSG005 also Displays Improved Antifungal
Activity, Compared with AmB In Vivo
On the basis of all the accumulated in vitro data (see above), one
nystatin analog (BSG002) and two S44HP analogs (BSG005 and
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BSG020) were chosen for in vivo studies on acute toxicity and
antifungal activity against disseminated candidosis in a mouse
model. First, BSG002 was investigated and compared to its
parental compound nystatin. Preparations containing different
antibiotic concentrations were administered intravenously, and
median lethal and maximum tolerated doses (LD50 and MTD
values, respectively) were calculated from the experimental
data. BSG002 was shown to have considerably lower acute tox-
icity than nystatin in these experiments; the MTD/LD50 values for
BSG002 and nystatin were 53.7/61.7 mg/kg and 7.1/8.5 mg/kg,
respectively (Table 2). These data were in good agreement with
the corresponding in vitro data (Table 1). BSG002 and nystatin
were then used in a mouse candidosis model in order to assess
their antifungal activity in vivo (see Experimental Procedures).
The fungal load in the kidneys of C. albicans infected animals
treated with antibiotics was determined and compared with
that of the untreated animals. In this experiment, nystatin
demonstrated in vivo antifungal activity (reduction of Candida
colony-forming units [CFU] in kidneys by a factor of >10) at doses
equal or higher than 4 mg/kg, whereas no activity was shown for
BSG002 at doses up to 32mg/kg (Table 2). The fact that BSG002
lacks activity in a mouse model of candidosis, while having
reduced but still signiﬁcant activity in vitro, suggests that such
factors as stability in vivo and pharmacokinetics might play a
decisive role for therapeutic usefulness of polyene macrolides.
Next, BSG005andBSG020were tested in similar experiments,
and the data obtained for both analogs clearly demonstrated
higher MTD and LD50 values, compared with those for both
S44HP and AmB, suggesting that they have considerably lower
toxicity in vivo (Table 2). Compared with S44HP, the MTD value
was increased 13-fold for both BSG005 and BSG020, indicat-
ing signiﬁcant reduction of toxicity. These data were in some
agreement with the in vitro data on hemolytic activities of these
compounds, whereas the effects in vivo were much more pro-
found (Table 1). When assessed for efﬁcacy in a mouse candido-
sis model, the effective doses for AmB, S44HP, BSG005, and
BSG020 (Table 2) were considerably lower than that for nystatin
and correlated well with the in vitro data for antifungal activity
as presented in Table 1. BSG005 displayed in vivo antifungal
activity slightly higher than those of both AmB and S44HP,
whereas the antifungal activity of BSG020 was somewhat
reduced compared to these control compounds. Again, these
data were in agreement with the in vitro antifungal activity tests
showing that BSG020 displays a lower antifungal activity than
doesBSG005 (Table 1).Most importantly, these in vivo antifungal
activitieswere observed at doses corresponding to only10%of
MTD for both BSG005 and BSG020. At the same time, 40% and
94% MTD doses for AmB and S44HP, respectively, had to be
used to achieve the same efﬁcacy in reducing fungal kidney
load. The latter data conﬁrm that both BSG005 and BSG020
have favorable activity/toxicity properties, compared with AmB,
under these conditions and suggest that theymaybecomeprom-
ising lead compounds for further development as antifungal
agents.
Structure-Activity-Toxicity Relationship
of Engineered Nystatin Analogs
The impact of modiﬁcations introduced into three different
regions of the nystatin molecule on its antifungal activity and tox-
icity has been investigated both in vitro and in vivo in this study.
In particular, the polyene region (C-28–C-29), the exocyclic
carboxyl group (C-16), and the polyol region (C-5, C-7, C-9,
and C-10) were targeted for modiﬁcations. The data obtained
for S44HP supports our previous observation (Bruheim et al.,
2004) that modiﬁcation of the polyene region resulting in the
appearance of seven instead of four conjugated double bonds
increases both antifungal activity and toxicity. This result is con-
sistent with signiﬁcantly higher antifungal activity and toxicity
reported for the heptaene polyene macrolide AmB, compared
with that of nystatin. The data obtained for C-16 methyl
substituted S44HP analog demonstrated that this modiﬁcation
leads to increased antifungal activity and reduced toxicity,
whereas the analogous modiﬁcation reported for AmB caused
reduced toxicity while leaving antifungal activity presumably
unchanged (Carmody et al., 2005). Modiﬁcations in the polyol
region of nystatin (C-5, C-7, and C9+C10) yielded compounds
with both reduced antifungal activity and toxicity, whereas the
effect varied among these modiﬁcations. Interestingly, the C-7
modiﬁcation in AmB (Power et al., 2008) had no effect on antifun-
gal activity, while causing reduced toxicity, thus further conﬁrm-
ing differences between AmB and S44HP in terms of structure-
activity relationship. Taken together, our data suggest that the
polyol and polyene region, as well as C-16 exocyclic, are all
important for the antifungal activity and toxicity of nystatin and
S44HP. Moreover, our data obtained for the analogs combining
different modiﬁcations indicate that simultaneous introduction of
C-16 methyl and C-5 keto group on S44HPmay be beneﬁcial for
the activity/toxicity proﬁle. Although some of these results could
potentially have been expected on the basis of the data available
for the genetically engineered AmB analogs (Carmody et al.,
2005; Power et al., 2008), certain modiﬁcations in the polyol
region of nystatin, such as at C-7 and C-9/C-10, had a signiﬁcant
negative effect on antifungal activity, while contributing little to
the reduction of toxicity.
SIGNIFICANCE
There is an urgent need for efﬁcient and safe antifungal
agents because of the growing number of life-threatening
systemic fungal infections. Polyene macrolide antibiotics
Table 2. In Vivo Acute Toxicity and Antifungal Activity of
Engineered Nystatin Analogs Tested in a Mouse Model of
Disseminated Candidosis
Compound MTD mg/kg LD50 mg/kg
Candida kidney load,
CFU/g (% MTD)a,b
Control NA NA 6.5 3 104
Nystatin 7.1 8.5 3.4 3 103 (56%)
BSG002c 53.7 61.7 6.3 3 104
S44HP 0.6 2.1 4.2 3 103 (94%)
BSG005 7.8 15.4 2.9 3 103 (10%)
BSG020 7.9 10.5 6.5 3 103 (10%)
AmB 2.0 2.8 4.0 3 103 (40%)
aAfter 4 days of single dose administration of 0.8 mg/kg, except for
nystatin (4 mg/kg), BSG002 (32 mg/kg) and S44HP (0.6 mg/kg).
b Average data for 3 animals.
cNo activity demonstrated for doses up to 32 mg/kg.
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are potent fungicidal agents, but their medical usefulness is
hampered by considerable toxicity. A series of new analogs
of the polyene macrolide antibiotic nystatin was generated
by means of biosynthetic engineering. Testing of these ana-
logs in vitro for antifungal and hemolytic activities provided
important new data on structure-activity-toxicity relation-
ship and allowed selection of the most active and least toxic
analogs. In vivo experiments in amousemodel revealed that
two new nystatin analogs, BSG005 and BSG020, are at least
as efﬁcient as AmB, the only polyene macrolide currently
used for treatment of systemic fungal infections, against
disseminated candidosis, while being considerably less
toxic. The two analogs might therefore represent promising
lead compounds for further development of antifungal drugs
for human therapy.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Media, and Growth Conditions
Plasmids, phages, and bacterial strains used in the present study are described
in Table S1. S. noursei and Escherichia coli strains were maintained and genet-
ically manipulated as described elsewhere (Sekurova et al., 1999; Sambrook
et al., 1989).CultivationsofS. noursei strains for productionof analogswereper-
formed in fed-batch fermentation essentially as described elsewhere (Borgos
et al., 2006a), except for the use of SAO-50 medium, which contained double
amounts of all nutrients, compared to SAO-40 (Borgos et al., 2006a). Analysis
of polyene macrolides produced was done as reported elsewhere (Bruheim
et al., 2004). The gene replacements were performed through conjugation of
thecorrespondingvectors (seebelow) into theS.noursei,veriﬁcationofchromo-
somal integration, and selection for double homologous recombination, as de-
scribed elsewhere (Sekurova et al., 1999). Gene replacements were performed
in nysA-deﬁcient mutants NDA59 (Brautaset et al., 2003) and GG5073SP (Bor-
gos et al., 2006a), and the resulting recombinant strains were complemented
with the nysA gene to restore the polyene macrolide biosynthesis.
DNA Manipulation, Sequencing, and PCR
GeneralDNAmanipulationswereperformedasdescribedelsewhere (Sambrook
et al., 1989). DNA fragments from agarose gels were puriﬁed using QIAEX II kit
(QIAGEN, Germany). Southern blot analyses were performed with the digoxige-
nin-11-dUTPHigh Prime labeling kit (RocheMolecular Biochemicals) according
to themanufacturer’s instruction. Oligonucleotide primerswere purchased from
MWGBiotech (Germany). ThePCRswereperformedwith theGCRichPCRSys-
tem (Roche Molecular Biochemicals) on Eppendorf Mastercycler (Eppendorf,
Germany), using conditions described elsewhere (Brautaset et al., 2003). DNA
sequencing was performed at MWG Biotech (Germany).
Construction of Gene Replacement Vectors
Inactivation of NysJ DH15
The 3.33 kb BclI/SphI fragment of recombinant phage N20 (Table S1) was
ligated into the BamHI/SphI sites of pGEM-11zf+. From the resulting plasmid,
the 3.34 kb EcoRI/HindIII fragment was isolated and ligated into the corre-
sponding sites of plasmid pGEM-3zf+, yielding pDH15-B. The latter plasmid
was used as a template for site-directed mutagenesis to introduce the DH15
mutation H966F using the mutagenic oligonucleotides Mut-DH15-1: 50-CACC
CCTGGCTCGCCGACTTCGTCGTCGGCGGCATGGTC30 (sense) and Mut-
DH15-2: 50-GACCATGCCGCCGACGACGAAGTCGGCGAGCCAGGGGTG30
(antisense). Altered nucleotides are indicated in bold, and the introducedmuta-
tion eliminated the originally present BrtI recognition site (not shown). Mutation
was ﬁrst conﬁrmed by BrtI restriction digestion and then veriﬁed by DNA
sequencing. The plasmid-containing mutation was designated pDH15-mut.
The 1.6 kb EcoRI/SacI fragment of pDH15-B, the 1.1 kb HindIII/BglII fragment
of pDH15-B, and the mutated 0.64 kb SacI/BglII fragment from pDH15-mut
were isolated and ligated together with the 3.1 kb EcoRI/HindIII fragment of
pSOK201 (Zotchev et al., 2000) (Table S1), yielding DH15 inactivation vector
pSH15-123.
Inactivation of nysN
The4.1 kbNcoI/XbaI fragment from the recombinant phageN95 (Table S1)was
cloned into the corresponding sites of the plasmid pLITMUS28. From the re-
sulting construct, the entire 4.1 kb insert was excised with EcoRI/HindIII and
cloned into the corresponding sites of pGEM11-zf+. From the resulting plas-
mid, pGEM11nysN4.1, the 1.5 kb region including the nysN active site was
PCR-ampliﬁed with primers conA-1F: 50-TTTTGAATTCTTCAAGCCGATGAGC
C-30 and conA-1R: 50-TTTTAAGCTTGGTCGAAC AGGTCCGG-30, introducing
EcoRIandHindIII sites (underlined) into thePCRproduct. Thesesiteswereused
toclone thePCR fragment intopGEM11-zf+, yieldingplasmidpGEM11nysN1.5.
The latter plasmid was used as a template for site-directed mutagenesis
(QuickChange kit, Stratagene) to introduce nysN mutations CL346AS using
the oligonucleotides CL346AS-F: 50-TCGGCTACGGTGTCCACGCTAGCCT
GGGCCAGAAC CTGG-30 and CL346AS-R: 50-CCAGGTTCTGGCCCAGGC
TAGCGTGGACACCGTAG CCGA-30. Altered nucleotides are indicated in
bold while the new NheI restriction site introduced is underlined. Mutation
was ﬁrst conﬁrmed by restriction analysis and then veriﬁed by DNA sequenc-
ing. The mutated 1.3 kb FspAI/Bpu1102I fragment from the resulting plasmid
was cloned back into the corresponding sites of pGM11nysN4.1, yielding
pGM11nysN4.1-CL346AS. From the latter construct, the 4.1 kb insert contain-
ing mutated nysN genes was excised with EcoRI/HindIII and ligated with the
3.1 kb EcoRI/HindIII fragment of pSOK201, yielding plasmid pKOnysN-
CL346AS, which was used for nysN replacement in S. noursei.
Inactivation of NysJ KR17
The 4.0 kb PmlI/BamHI fragment from the recombinant phage N98 (Table S1)
wasexcisedand ligated into theHincII/BamHI sitesof vector pGEM3-zf+, yield-
ing plasmid pBB4.0. A 1.5 kb DNA fragment, including the KR17 active site
region, was PCR ampliﬁed from pBB4.0 using primers KR17-F: 50-TTTT
CTGCAGGCCGCGGTGCGCGC-30 and KR17-R: 50-TCCGGC ATGGTCCGTG
AAACC-30. The PCR product was digested with PstI (site underlined) and SacI
(recognition site in the ampliﬁed DNA fragment), and the 1.4 kb fragment was
ligated into the corresponding sites of pLITMUS28. The resulting plasmid,
pLIT1.4, was used as a template for site-directedmutagenesis with oligonucle-
otides KR17-mut1: 50-GCCCCGGCCAGGGCA ACTTCGAAGCCGGCAACAC
GTTCC-30 and KR17-mut2: 50-GGAACGTGTTGCCGGCTTCGAAGTTGCCCT
GGCCGGGGC-30. Altered nucleotides are indicated in bold while new
BstBI restriction site introduced is underlined. Correct mutation was veriﬁed
with BstBI digestion, and the entire insert of the mutated plasmid was veriﬁed
by DNA sequencing. From the resulting plasmid, pLIT1.4 m, the 1072 bp BclI/
AccIII fragment, was excised and used to replace the corresponding fragment
in pBB4.0, yielding plasmid pBB4.0 m. The entire 4.0 insert of pBB4.0 m
was excised with EcoRI and HindIII and ligated together with the 3.1 kb
EcoRI/HindIII fragment of pSOK201, yielding the KR17 inactivation vector
pKR17m.
Inactivation of NysJ KR16
The 14 kb XbaI insert of the recombinant phage N20 (Table S1) was ligated into
plasmid pGEM-3zf, and from the resulting plasmid, pL20X, the 3.7 kb BamHI
fragment was excised and ligated into pGEM-3zf+, yielding plasmid
pGEMB3.7. A 0.8 kb DNA fragment (encompassing the codon for the KR16
active site residue Y3404) was PCR-ampliﬁed from pGEMB3.7 with primers
KR16-F1: 50-ttttctgCAGCCGACCGGCACCGTCC-30, and KR16-1R: 50-tttt
aaGCTTCCTGGAC CGCGCGGG-30. The PCR product was digested with
PstI and HindIII (recognition sites underlined in the two PCR primers) and
ligated into the corresponding sites of pLITMUS28, yielding pLITPH0.8. The
latter plasmid served as a template for site-directed mutagenesis to introduce
the KR16 double mutation YA3404FE using the mutagenic oligonucleotides
mutKR16-1F: 50-CCCCGGCCAGGCCGGCTTCGAAGCCG CCAACGCGGTC
C-30 (sense) andmutKR16-1R: 50-GGACCGCGTTGGCGGCTTCGAAGCCGG
CCTGGCCGGGG-30 (antisense). Mutated nucleotides are shown in bold, and
the new BstBI recognition site introduced is underlined. The correct mutation
was identiﬁed by BstBI digestion and veriﬁed by DNA sequencing. From the
plasmid containing desired mutation, the 627 bp Bpu102I/Bpu10I fragment
was excised and used to replace the corresponding fragment in pGEMB3.7,
yielding plasmid pGEMB3.7 m. From the latter plasmid, the entire 3.7 kb insert
was excised with EcoRI/HindIII and ligated together with the 3.1 kb EcoRI/
HindIII fragment of pSOK201, yielding KR16 inactivation vector pKR16m.
The latter vector was introduced into the nysA-deﬁcient S. noursei mutant
GG5073SP (Borgos et al., 2006a) by double homologous recombination.
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Gene Replacements in S. noursei Strains
The constructed gene replacement vectors (see above) were introduced to the
S. noursei strains by conjugation, and gene replacements were selected after
double homologous recombination, as described elsewhere (Sekurova et al.,
1999). The correct chromosomal mutations were veriﬁed by PCR, DNA
sequencing of PCR products, and Southern blot analyses. Polyene macrolide
production was restored in the recombinant strains by introducing the nysA
gene as described elsewhere (Brautaset et al., 2003).
Preparative LC-MS Puriﬁcation of Genetically Modiﬁed Polyenes,
MS/MS, and NMR Experiments
The LC-MS-guided puriﬁcation was performed essentially as described else-
where (Bruheim et al., 2004; Borgos et al., 2006b), but with methanol instead of
acetonitrile as the mobile phase organic constituent (from 70% up to 80%
methanol, depending on the polyene to be puriﬁed). Purity and concentration
of the engineered polyenes was determined by reference to USP standards of
nystatin and AmB for tetraenes and heptaenes, respectively, assuming that
molar extinction coefﬁcients in the spectral regions of interest were unaltered.
Peak UV absorption at 309 nm and 386 nm, arising from the polyene region,
was used for tetraenes and heptaenes, respectively. Samples for MS/MS
analyses were prepared by dissolving puriﬁed compounds in DMSO to a ﬁnal
concentration of 5 mg/ml. The MS/MS analysis was performed using the
Agilent 1200 series LC/Qtof system. The eluent was 30% acetonitrile in water
at a ﬂow rate of 0.4 ml/min. An Agilent Zorbax Bonus-RP 2.13 50 mm column
was used. The Qtof mass spectrometer was operated with the electrospray
ionization source in positive ionization mode. Drying gas ﬂow was 11 l/min,
and nebulizer pressure was 45 psi. Drying gas temperature was 350C and
the fragmentor voltage was 175 V. During MS/MS spectra acquisition, a ﬁxed
collision energy of 25 V was used. Samples for NMR spectroscopy were
prepared by dissolving freeze-dried compounds puriﬁed by preparative
HPLC in d6-DMSO at 1 mM ﬁnal concentration. To be able to perform direct
comparison of NMR assignments reported previously (Bruheim et al., 2004)
and obtained in the present study, both sample and further NMR experimental
conditions were maintained analogous to those already described. All NMR
experiments were recorded at 298 K on a Bruker DRX600 spectrometer
equipped with a 5-mm z-gradient TXI (H/C/N) cryogenic probe. Proton and
carbon chemical shifts were referenced to TMS signal. To monitor the chem-
ical structure of the investigated compounds, both one-dimensional 1H and
two-dimensional COSY and 1H-13C HSQC spectra were recorded. Detailed
description and analysis of the results are given in the Supplemental Material.
Determination of In Vitro Antifungal and Hemolytic Activity
Determination of in vitro antifungal activity was done by cultivating C. albicans
in 96-well plates and monitoring cell growth in the presence of 24 different
concentrations of antibiotics, as described elsewhere (Borgos et al., 2006b;
Nedal et al., 2007). MIC50 and MIC90 values, representing minimum inhibitory
concentrations causing 50% and 90% inhibition of cell growth, respectively,
were calculated from at least 3 parallel experiments. Hemolytic assays for
the genetically modiﬁed polyene macrolides were performed by monitoring
their ability to cause lysis of deﬁbrinated horse blood erythrocytes washed
from plasma proteins with PBS buffer, as described elsewhere (Borgos et al.,
2006b; Nedal et al., 2007). Antibiotic solutions were prepared in DMSO to
achieve ﬁnal concentrations between 0 and 200 mg/ml, and the mixtures
were incubated at 37C for 1 hr before the optical densities of supernatants
at 545 nmwere measured. The results presented are mean values from 3 inde-
pendent measurements. Hemolytic concentrations causing 50% hemolysis,
HC50 values, were determined from the generated plots (Figure S12).
In Vivo Testing of Acute Toxicity and Antifungal Activity
All animal experiments were performed in accordance with the Guidelines for
Drugs Toxicity Testing on Animals approved by the Russian Academy of Med-
ical Sciences (RAMS). Prior to initiation of experiments, the protocols were re-
viewed and approved by the Ethical Committee of the Gause Institute of New
Antibiotics (RAMS). Male mice (weight, 19–22 g) of ﬁrst generation hybrids
BDF1 (S57Bl 3 DBA2) received from the Central Nursery of RAMS were
used in the experiments. The animals were kept on a standard diet consisting
of briquette forages with easy access to potable water in the animal nursery of
the Gause Institute of New Antibiotics. After the fortnight quarantine, healthy
animals were divided into groups with six individuals in each and were entered
into the experiments.
Nystatin, AmB, S44HP, BSG002, BSG005, and BSG020 (5 mg) were each
mixed with dry sodium deoxycholate (4.1 mg) in a sterile glass vial. Ten millili-
ters of phosphate buffer (NaH2PO4, 1.59 g; Na2HPO4, 0.96 g; and H2O, to
100 ml) was added and immediately subjected to vigorous shaking for
10 min until homogeneous suspensions were formed. The obtained suspen-
sions were placed into the new sterile glass vials, 5% neutral sterile glucose
solution was added, and the resulting solutions (up to 0.8 mg/ml) were used
for intravenous administration.
Acute Toxicity
Freshly prepared antibiotic solutions were individually injected into the
mouse’s tail vein at <0.5 ml per minute. Each antibiotic was used in a range
of doses resulting in 0% to 100% lethality and aminimum of three intermediate
doses. Toxicity-characterizing doses MTD and LD50 were calculated with the
method of ‘‘probit’’ analysis, according to Litchﬁeld andWilcoxon (1949), using
the statistical analysis program StatPlus (version 3.5.0., 2005).
Antifungal Activity
Mice were infected intravenously with 106 CFU of C. albicans ATCC 14053 per
mouse (0.1 ml). Thirty minutes after infection, antibiotics (six doses, ranging
from 1% to 95% MTD, three mice per dose per antibiotic) were administered
through the lateral tail vein. Each dose was administered once a day for four
days, including the day of infection (0, 1, 2, and 3 days). As a control, a group
of untreated infected mice and a placebo group of noninfected animals, which
were intravenously administered 0.2 ml of the solvent (phosphate buffer + 5%
glucose [1:1]), were used. On the ﬁfth day of the experiment, mice were
weighed and sacriﬁced. The C. albicans kidney burden for each mouse was
determined by counting CFUs in homogenates from the kidneys. The kidneys
were removed aseptically, weighed, and pounded in porcelain mortars with
sterile corundum; dilutions of the resulting suspensions were prepared and
plated on Sabouraud dextrose agar. The plates were incubated for up to
72 hr at 35C, colonies of C. albicans were counted, and the load was esti-
mated per 1 g of kidney tissue. Statistical analysis was performed with Micro-
soft Ofﬁce Excel 2003. Signiﬁcant distinctions had a p% 0.05 at comparison
by Student T-criterion.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, and twelve ﬁgures and can be found with this article online at http://
www.chembiol.com/cgi/content/full/15/11/1198/DC1/.
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